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1. Introduction 
1.1.  The Immune System 
The immune system is composed of a variety of cells and molecular mechanisms to defend the 
organism against a plethora of pathogens and transformed cells of the organism itself. It can be 
classified into two subgroups: the innate immune system and the adaptive immune system.  
The innate immune system is composed of several cellular components, such as dendritic cells (DCs), 
macrophages, mast cells, granulocytes and natural killer cells (NK cells) and non-cellular (humoral) 
components such as the complement system [Figure 1]. Defense mechanisms of the innate immunity 
are phagocytosis, recruitment of further immune cells, direct killing and opsonization of pathogens.  
Figure 1: Components of the 
innate and adaptive immune 
system. Left) Cellular and 
humoral components of the 
innate immune system. Right) 
Cellular and humoral 
components of the adaptive 
immune system.
1
 
 
 
 
DCs, macrophages and neutrophilic granulocytes are specialized in phagocytosis through binding of 
common foreign structures, the so called pathogen-associated patterns (PAMPs) or cell compounds 
which are released during cell damage and death, named damage-associated molecular patterns 
(DAMPs) with their pattern recognition receptors (PRRs).2,3 Apart from endocytosis, phagocytes may 
act as antigen presenting cells (APCs) presenting protein fragments of digested pathogens on their 
cell surface on major histocompatibility complex (MHC) molecules and thereby bridging the innate 
with the adaptive immune system. Depending on the presentation ability one may distinguish 
between professional and atypical APCs.4 Yet, DCs are the most specialized APCs. Recruitment and 
activation of further immune cells is a second mechanism achieved by cytokines, such as interferons, 
interleukins and chemokines, produced by cells of the innate immune system. NK cells are able to 
directly kill infected or malignant transformed host cells through MHC-depe de t o -self  a d 
issi g-self 5, antibody-dependent (antibody-dependent cellular cytotoxicity, ADCC)6 or 
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death-receptor-dependent mechanisms7. The first two mechanisms conduct killing through secretion 
of cytotoxic molecules, such as perforin and granzymes, whereas the third mechanism induces 
directly the apoptosis pathway. The complement system opsonizes pathogens for phagocytes, 
recruits immune cells through the chemokine function of some complement proteins and may 
directly kill via membrane perforation.8 In general, the innate immune system is limited in diversity 
and specificity of the immune response and is focused on fast distinction between harmful and 
harmless antigens.9 
The adaptive immune system emerged in jawed vertebrates (fishes) and was accompanied by the 
development of lymphocytes, MHC molecules, immunoglobulins (Ig), T-cell receptors (TCRs) and 
recombinase activating genes (RAG).10 An adaptive immune system is often required for an effective 
defense due to its specific reaction against antigens. The cellular components are lymphocytes, 
namely T cells and B cells. T cells can be subdivided into the main subsets CD8+ cytotoxic T 
lymphocytes (CTLs), CD4+ T helper cells (TH cells) and regulatory T cells (Treg cells). T cells are 
antigen-specific and are preselected in the thymus to avoid reactivity against self-antigens (central 
tolerance).11 Activation of naïve T cells take place through interaction with APCs presenting their 
antigen of choice.12 Three signals are required for an activation of T cells [Figure 2]. First, binding of 
the TCR to the appropriate MHC-peptide complex (pMHC), which is stabilized by the co-receptors 
CD8 on CTLs, i di g o to the α3-domain of the MHC class I molecules, or CD4 on TH cells, binding to 
the β2-domain of MHC class II molecules. Second, a costimulatory signal between T cell and APC, such 
as the interaction of the T-cell costimulatory protein CD28 and the CD80/CD86 (B7.1/B7.2) complex 
on APCs. Lack of the costimulatory signal leads to T cell anergy and/or tolerance (peripheral 
tolerance) and functions as a second mechanism in preventing an immune response against 
self-peptides. Last, cytokines produced by the APC and the T cell itself have to bind to their 
respective cell surface receptors.12-14 The cytokine milieu decides the polarization of the T cell 
towards an effector phenotype. B cells produce antigen-specific antibodies. Antibodies are able to 
neutralize antigenic structures, activate the complement system and subsequently induce the 
complement dependent cytolysis (CDC) or opsonize pathogens for phagocytosis or direct killing by 
cells of the innate immunity.15 While T cells recognize linear antigens, B cells may direct antibodies 
against non-linear antigenic structures. Antibodies therefore act in back-bridging the adaptive to the 
innate immunity. In addition, the interplay of innate and adaptive immunity is tightly regulated by 
cytokines produced by either cells of the innate or adaptive immune system. The response of the 
adaptive immune system is highly antigen-specific and diverse. The specific response against 
antigens has to be acquired by recombining and specifying TCRs16 or immunoglobulins17 and starts 
with a delay of a few days. A further distinction is the ability of the adaptive immune system to 
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memorize antigens which were already combated by the generation of memory B and T cells which 
can be quickly reactivated.18,19 
Figure 2: T cell activation by APC involves three kinds of signals. Naïve T 
cells get their first activation signal by recognition of foreign pMHC 
complexes. A costimulatory signal received from the same APC is 
required for T cell survival and for the proliferation ability. The lack of 
signal 2 leads to T cell anergy and/or tolerance. The cytokines produced 
by the APC determine the differentiation of the naïve T cell into an 
effector T cell subtype.
20
 
 
 
 
 
 
 
1.2. Human leukocyte antigen 
MHC molecules provide the junction for the activation of the adaptive immune system. In humans 
they are also referred to as human leukocyte antigen (HLA) molecules. Two classes of HLA molecules 
can be distinguished: HLA class I and HLA class II. Both classes are glycosylated membrane proteins 
with differences existing in their respective structure, their source of proteins and their cell 
type-dependent expression.21  
HLA class I molecules are expressed on all nucleated cells and present mainly peptides of intracellular 
antigens to CD8+ T cells. They a e o stituted of a  app o i atel   kDa hea  α-chain with their 
do ai s α1-α3 and the invariant 12 kDa light β2- i oglo uli  β2m) which is non-covalently linked to 
the heavy chain [Figure 3]. The α-do ai s α1 a d α2 constitute the peptide binding groove formed by 
t o α-heli es a d a  a tipa allel β-strand.22 Peptides loaded onto the HLA class I are 8 to 12 amino 
acids (aa) i  le gth. The e ded α-helices and large aromatic residues enclose the binding groove 
constraining the length of ligands.23 Peptides with 9 aa are usually preferred while longer sequences 
bulge out of the groove. The HLA molecule interacts with the peptide through sequence-independent 
interactions with the peptide termini and sequence-dependent interactions with amino acid residues 
located in the groove.24-26 Six pockets A-F can be refined contacting specific residues of the located 
peptide. The accommodation of a peptide is especially restricted by two pockets, usually pocket B 
(interacts with the peptide residue at position 2) and F (interacts with the C-terminal peptide 
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residue), which allows only particular residues to bind. Peptide positions which are especially 
restricted by the binding pockets are defined as anchor positions.27 Additionally, residues binding to 
less restricted pockets can be referred to as auxiliary anchors. In total, about 50 amino acid positions 
within the binding groove may interact with the peptide, many of which are highly polymorphic and 
therefore individualize the peptide repertoire of each MHC molecule.28,29 
HLA class II molecules are expressed in particular on APCs and present mainly peptides from 
extracellular antigens to CD4+ T cells. They are constituted of two chains, the α- a d the β-chain with 
t o do ai s ea h α1 a d α2, a d β1 a d β2, respectively) [Figure 3]. The α1- a d β1-domains form 
the binding groove which is opened on both ends rendering binding of longer peptides feasible. 
Peptides are usually 12-20 aa in length. Due to the ability to bind peptides with extended ends, 
length variants of the same core sequence (anchors usually at position 1, 4, 6, 9) can be presented 
without bulging out of the peptide (which is required for presentation of length variants in 
HLA class I). In addition, the same peptide may bind to different HLA class II molecules by shifting the 
core. Finally, anchor positions are less defined compared to HLA class I leading to a high promiscuity 
between allotypes. 
 
 
 
 
 
 
 
Figure 3: Schematic structure of HLA class I and HLA class II molecules. The ligand is bound in the binding groove. Pockets 
A-F of HLA class I molecules are illustrated on the right for an exemplary HLA-A*02 peptide.
30,31
 
The HLA molecules are encoded in the HLA region on the short arm of chromosome 6.32 Besides HLA 
molecules, the HLA gene complex comprises several genes with immunological relevance like 
complement factors, cytokines and proteins of the antigen processing pathway.33 Three classical HLA 
class I molecules (HLA-A, -B and -C) and three classical HLA class II molecules (HLA-DP, -DQ, -DR) are 
encoded in the HLA gene complex. The classical HLA alleles are highly polymorphic and codominantly 
expressed. Further, non-classical HLA molecules like the class I HLA-E, -F, and -G and the class II 
MHC class I molecule MHC class II molecule 
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HLA-DM and HLA-DO are encoded in this gene region. The number of known alleles is 12,351 for HLA 
class I and 4,404 for HLA class II (www.ebi.ac.uk/ipd/imgt/hla/stats.html, 2017-04).  
 
1.3. HLA class I antigen processing 
HLA molecules present linear fragments of antigens which are prior degraded within the cell. 
Cytosolic proteins originating from self or non-self antigens are the source of HLA class I molecules 
[Figure 4]. In addition, extracellular antigens can be presented on HLA class I by cross 
presentation.34,35 Apart from proper folded and functional proteins, substantial amounts of peptides 
arise from misfolded proteins, the so called defective ribosomal products (DRiPs). DRiPs represent 
about 30% of all proteasome degraded proteins.36,37 
The first step in antigen processing is the tagging of proteins for proteasomal degradation by the 
addition of three to four ubiquitin molecules.38 The degradation is carried out in the 26S proteasome, 
a macromolecular assembly of one 20S subunit (core) and two 19S subunits (caps). Four rings with 
se e  su u its ea h α7β7β7α7) provide a cavity in which the unfolded protein is proteolytically 
degraded. The su u its β1, β2 a d β5 (contained in both ring structures of the core) possess 
proteolytic activity with different cleavage specificity each. C-terminal acidic residues are preferred 
 the su u it β1. Tryptic-like specificity, cleaving sequences after basic residues, is displayed by the 
β2-subunit and cleavage after C-terminal hydrophobic residues is exhibited by subunit β5 with their 
chymotryptic-like specificity. The average length of emerging protein fragments is 7 to 9 aa with a 
range from 4 to 25 aa.39 The caps have two major roles which are accomplished by two protein 
groups. The Rpn proteins recognize ubiquitin-tagged proteins which are subsequently unfolding 
ATP-dependent by Rpt proteins.40 The o stituti el  e p essed p oteol ti  su u its β1, β2 a d β5 can 
e e ha ged  the su u its β1i also alled LMP , β2i also alled MECL  a d β5i (also called 
LMP7) forming the immunoproteasome.40 All three subunits are induced by interferon-γ IFN-γ) 
which is mainly produced by NK cells, NKT cells, effector CTLs and TH1 cells.
41 The substitution of one 
up to all six subunits leads to a change in the proteolytic activity with structural rearrangements of 
the proteasome. Enhanced tryptic-like and chymotryptic-like activity of the immunoproteasome 
facilitates the generation of HLA ligands with hydrophobic and basic C-terminal residues.42,43 
Additionally, the IFN-γ-induced PA28 subunit enhances the peptide production.44,45 Produced 
peptides can be further cleaved by peptidases in the cytosol or the endoplasmic reticulum (ER). This 
is in particular important for the N-terminal trimming of peptides.21 The N-terminal trimming can be 
prevented by the binding to the chaperonin TRiC.46  
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Loading of peptides onto HLA molecules takes place in the ER. The heterodimeric TAP1/TAP2 
complex (transporter associated with antigen processing) transports cytosolic peptides, preferentially 
with hydrophobic or basic C-terminal residues and a length of 9 to 12 aa, ATP-dependent into the ER. 
The ER contains additional proteases for further trimming of peptides.21 Peptides are loaded onto 
HLA molecules assisted by the peptide loading complex (PLC) consisting of HLA class I-stabilizing 
proteins calreticulin, Erp57 and tapasin. The HLA class I molecule is assembled in the ER aided by the 
chaperon calnexin which is then replaced by the PLC. pHLA complexes are subsequently transported 
via the secretory pathway onto the plasma membrane. 
The production of too short peptides by the proteasome, proteases in the cytosol and ER, TAP 
complex constraints in peptide C-terminal amino acids and length, and sequence restrictions of the 
expressed HLA lead to a rate of about one presented peptide out of 1000 produced peptides.47-49 
Figure 4: Antigen processing pathways 
for HLA class I and HLA class II. a) 
Intracellular antigens are processed by 
the proteasome and proteases into 
peptides which are transported into the 
ER by TAP and loaded onto chaperone-
stabilized HLA class I molecules. pHLA 
complexes are transported onto the cell 
surface via the secretory pathway. b) 
Extracellular antigens are processed by 
endosomal enzymes and loaded onto 
HLA class II molecules in the MIIC 
compartment. Prior, HLA class II is 
stabilized by the invariant chain which 
is degraded to the CLIP fragment by 
proteases. HLA-DM and HLA-DO 
catalyze the exchange of the CLIP 
fragment against the peptide.
50
 
 
1.4. HLA class II antigen processing 
Peptides descending from endocytosed antigens as well as endogenous proteins entering lysosomal 
degradation, e.g. via autophagy51,52, are presented by HLA class II molecules [Figure 4]. HLA class II 
molecules are folded in the ER like HLA class I. However, HLA class II molecules enter the secretory 
pathway without loaded peptide, but stabilized with the invariant chain. The proteolysis of antigens 
by proteases and cathepsins and the subsequent peptide loading takes place in the acidic MHC class 
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II compartment (MIIC).21 The Ii is degraded to a short leftover called CLIP fragment (class II invariant 
chain-associated peptide) which remains in the binding groove. The CLIP fragment is replaced by an 
appropriate peptide with the aid of the chaperones HLA-DM and HLA-DO.53 HLA-DM facilitates the 
dissociation of peptides binding with low affinity enabling the replacement against peptides with 
high affinity.54  
 
1.5. The HLA ligandome 
The HLA ligandome, also referred to as the immunopeptidome, is the collection of peptides 
presented by HLA molecules at the cell surface and is in perpetual communication with T cells. The 
HLA ligand repertoire of a cell depends on the expressed HLA allotypes as well as different 
physiological, intrinsic as well as pathogenic factors which may influence HLA expression or the 
ligand repertoire itself.55 Around 100,000 HLA molecules are presented on a cell presenting peptides 
with copy numbers varying from one to up to 10,000 copies per cell.47 Especially in tumor cells the 
HLA ligandome undergoes substantial changes following mutations in one or several oncogenes 
which affect cellular transcription, pathways or the metabolism. 
Figure 5: Factors influencing the HLA 
ligandome. Each HLA allotype has its 
specific binding repertoire which is 
further influenced by physiological, 
intrinsic and pathological factors.
55
  
 
 
 
 
 
 
1.6. Peptide motifs and binding prediction 
The high polymorphism of HLA molecules, especially of residues within the peptide binding groove, 
leads to unique peptide binding specificities which in turn mean unique ligand repertoires. Peptide 
binding specificities can be illustrated in so called peptide motifs providing information about the 
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importance of a position (bits) as well as the amino acid preferences at a specific position (size of 
amino acid). 
Three main approaches are commonly used to disclose binding specificities of HLA class I allotypes. 
The first approach is based on in vitro binding experiments using extended libraries of synthetic 
peptides or already known ligands from publically available databases such as SYFPEITHI or IEDB. The 
second approach is the liquid chromatographic tandem mass spectrometry (LC-MS/MS)-based 
identification of naturally presented ligands from tissue or cell lines. Therefore, the monoallelic 
transfection of HLA-negative (or low-expressing) cells, used in the definition of HLA-C and HLA-G 
peptide motifs in the results and discussion part II of this thesis, is a convenient approach.56-60 The 
third approach is based on the in silico prediction of the structural surrounding within the binding 
pocket.  
The information can be used to establish binding prediction tools. Commonly used tools are NetMHC, 
NetMHCpan and SYFPEITHI. The methods differ in the strategy used to establish binding prediction 
(described in section 3.3.8). NetMHCpan is the only method integrating binding specificities from 
related and uncovered HLA class I allotypes for the prediction of unknown HLA. Yet, all methods are 
suited for in silico binding prediction of peptides to HLA class I alleles. However, for HLA class II no 
tool meets the need. 
 
1.7. Interplay of cancer and the immune system 
The first part of the thesis examines the HLA ligandome of clear cell renal cell carcinoma (ccRCC). 
Therefore, the interplay of cancer with the immune system as well as generally applied 
immunotherapeutic approaches will be highlighted in the following sections before a more detailed 
focus will be placed onto ccRCC in the introductory section of the results and discussion part. 
Tumor cell development is caused by genetic alterations sequentially acquired over time. The 
transformation of a normal cell into a tumor cell is a gradual processing including critical mutations in 
suppressor genes, oncogenes and genes involved in DNA repair. Consequences of these mutations 
are the unregulated proliferation of tumor cells losing the ability to appropriately respond to signals 
which control normal cell behavior. Benign tumors, such as skin warts, remain confined, whereas 
malignant tumors (cancer) are capable to invade the surrounding tissue and to spread into distant 
locations using the circulatory or lymphatic system and thereby generating metastasis.61,62 Besides 
the above mentioned hallmarks, further characteristics of cancer cells are known.63 Genetic 
alterations usually come along with the immortality of these cells preventing telomere loss by 
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upregulating the telomerase as well as telomere-interacting proteins.64 Cancer cells are further 
resistant to apoptosis, a controlled suicide-mechanism induced by other cells like immune cells 
(extrinsic pathway) or by intracellular processes which sense cellular stress (intrinsic pathway).65-67 
The induction of angiogenesis, the mechanism to form new blood vessels, is particularly important 
for tumor growth in that nutrients as well as oxygen can be delivered to the tumor.68-70 In addition, 
tumor cells may reprogram their energy metabolism to persist, a hallmark already described by 
Warburg in 1930.71,72  
The transformation of cancerous cells engenders changes in the peptide repertoire presented at the 
cell surface with the appearance of tumor-specific antigens (TSAs) and tumor-associated antigens 
(TAAs). Mutated antigens, also referred to as neoantigens, are tumor-specific. TAAs can be 
categorized into cancer-testis antigens, oncofetal antigens, viral antigens, differentiation antigens, 
differential post-translational modified antigens73-75 or overexpressed self-antigens76. The 
presentation of TSAs or TAAs implicates the recruitment of the immune system which eliminates 
transformed cells [Figure 6].  
Figure 6: The Cancer-Immunity cycle. The death of cancer cells leads to the release of antigens. APCs ingest, process and 
present the antigen to T cells. The priming of T cells in nearby lymph nodes lead to the activation and subsequent trafficking 
to the tumor site. T cells infiltrate into the tumor and recognize cancer cells presenting the antigen for which T cells were 
primed. The recognition of the antigen leads to the subsequent killing of the cancer cells.
77
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The first step in the so called cancer-immunity cycle is the release of antigens by dying cells. For the 
activation of T cells, which takes place in nearby lymph nodes, antigens have to be ingested by APCs. 
Additional signals which are necessary for APC activation and trafficking to the lymph nodes include 
pro-inflammatory cytokines such as IFN-α o  TNF-α, TLR ago ists o  p odu ts f o  d i g tu o  ells 
[Table 1].77,78 APC activation is inhibited by cytokines such as interleukin-4 (IL-4), IL-10 or IL-13. 
Costimulatory receptors and cytokines (see section 1.1) are necessary for successful T-cell activation 
and differentiation. T-cell migration from the lymph node to the tumor site across the blood vessels 
is directed by chemokines binding to their corresponding chemokine receptor such as CXCR3 (ligands 
CXCL9/10/11) or CCR5 (ligands CCL3/4/5/8).79-81 Subsequent infiltration into the tissue is dependent 
on integrins, such as the LFA-1 receptor (Lymphocyte function-associated antigen 1) on leukocytes 
binding to ICAM-1 (intercellular adhesion molecule 1) on endothelial cells, and selectins (L-selectin 
on lymphocytes and E- or P-selectins on endothelial cells).82-84 Effector T cells recognize and kill tumor 
cells which present the antigen.  
Table 1: Overview of regulatory mechanism for each step of the cancer-immunity cycle.
77
 
 
 
Tolerogenic or apoptotic 
cell death 
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The theory that the immune system may interplay with cancerous cells was formulated in 1957 by 
Burnet and Thomas, nowadays known as the cancer immunosurveillance theory.85,86 Cancer 
immunosurveillance comprises the first phase of the extended theory of immunoediting, the process 
of immunogenic changes of the tumor. Immunoediting can be divided into three phases: elimination 
(known as immunosurveillance), equilibrium and escape.87 Cancer cells attempt to avoid elimination 
by the immune system generating poorly immunogenic tumor-cell variants, a mechanism called 
immunoselection.88 This state of equilibrium between the immune system and cancer cells may 
extend over many years in which the immune system has to perpetually adjust their defense 
mechanisms to the new selected tumor cell variants [Figure 7]. At the time cancer cells breach the 
immune defense (immunosubversion), immunoediting enters the third phase: escape of the tumor.  
Figure 7: Relationship 
between the tumor and the 
immune system. The steps 
of carcinogenesis are 
depicted in blue. The steps 
of overcoming the immune 
system are depicted in blue. 
The three phases of this 
immunoediting are 
represented in the middle.
88
 
 
Tumor escape occurs through loss of immunogenicity or resistance to suppressive or cytotoxic 
mechanisms of the immune cells within the tumor microenvironment.87,89,90 Loss of immunogenicity 
can be achieved by reduced immune recognition (such as HLA loss/downregulation or dysregulation 
of antigen processing91). A mechanism for increased resistance to cytotoxic immune cell reaction is 
the induction of anti-apoptotic mechanisms. Immunosuppression of the microenvironment includes 
the production of immunosuppressive molecules, such as transforming growth factor-β TGF-β , 
indoleamine-2,3-dioxygenase (IDO), vascular endothelial growth factor (VEGF) or galectin and the 
recruiting of regulatory immune cells, such as Treg cells and myeloid-derived suppressor cells 
(MDSCs).92 Treg cells produce the immunosuppressive cytokines IL-10 and TGF-β, e p ess the egati e 
costimulatory molecules CTLA-4, PD-1 and PD-L1 and consume IL-2 which is important for 
proliferation and differentiation of tumor-infiltrating lymphocytes (TILs). Immunosuppressive 
mechanisms of MDSCs include the induction of Treg cells, the production of immunosuppressive 
molecules such as TGF-β, the o su ptio  of a i o a ids su h as arginine and tryptophan or 
disabling TCR or chemokine receptors by nitration.87  
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1.8. Immunotherapy in cancer 
Immunotherapy is the treatment of a disease which takes advantage of the immune system. The 
immunotherapy may either focus on the activation or enhancement of an immune response (such as 
reinforcing the immune activity in anti-cancer treatment) or focus on the suppression of the immune 
system (such as dampening the immune activity against autoimmune diseases or to prevent organ 
rejection in transplanted patients). The following section gives a short history and overview on 
treatment of cancer by immunotherapies. 
The history of cancer immunotherapy started in the 1890s with the observation of William Coley that 
tumors may spontaneously regress after acute bacterial infections.93 In the following time he started 
to i je t a te ial p epa atio s, o ada s k o  as Cole ’s to i , i to a e  patie ts ith se e al 
types of tumors, including sarcomas and lymphomas, with remarkable responses and a cure rate of 
10%.94 However, the unknown mechanism of action and the upcoming success of radiotherapy 
passed his approach into oblivion. Even the hypothesis of Paul Ehrlich in 1909 that the immune 
system may control cancers had no implications.95 It took half a century until immunotherapy 
attracts attention with the cancer immunosurveillance theory (see section 1.7).85 However, the 
cancer immunosurveillance theory remained under debate until the 1990s. Several discoveries, such 
as the escape of auto-reactive T cells from thymic deletion96,97, the genetic instability of tumor cells98, 
the identification of TAAs99,100 and the higher incidence of tumors in immunodeficient mice101,102, 
changed the point of view.  
The variety of immunotherapies nowadays can be grouped in active and passive immunotherapies. 
A ti e i u othe apies el  o  a ti atio  of the od ’s o  i u e response, whereas passive 
approaches rely on intrinsic anti-cancer activity of administered drugs. Furthermore, a classification 
into specific or non-specific immunotherapies can be drawn dependent on direct targeting of cancer 
cells (specific) or a general activation of the immune system (non-specific). An overview of 
immunotherapeutic approaches is illustrated in Table 2. 
Table 2: Overview of immunotherapeutic approaches. Modified from
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 Active Immunotherapy Passive Immunotherapy 
Specific Vaccines 
- Prophylactic (HPV, HBV) 
- Therapeutic (peptide vaccines, peptide-
loaded DCs, RNA vaccines, tumor lysates, 
whole cancer cells) 
Adoptive T cell transfer (Tumor-infiltrating 
lymphocytes, TCR gene-modified lymphocytes, 
chimeric antigen receptors [CARs]) 
Monoclonal antibodies 
Non-specific I u e he kpoi t i hi ito s α-CTLA- , α-PD- , α-
PD-L1) 
Cytokines (IL-2, IFNs, etc.) 
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Specific immunotherapeutic approaches are antigen-dependent, whereas non-specific approaches 
are antigen-independent. An antibody-based specific immunotherapy targets TAAs presented at the 
cell surface of tumor cells such as differentiation antigens (like CD20, CD30 or CD52), glycoproteins 
(like Mucins, CA9 or PSMA), or growth receptors (like EGFR or ERBB2). Furthermore, monoclonal 
antibodies may target TAAs which are not expressed by the tumor cell itself, such as the tumor 
vasculature antigen VEGF. The antibody application in cancer treatment was reviewed among others 
in 104,105. Vaccines and adoptive T cell transfer (ACT) are based on antigen recognition in form of pHLA 
complexes presented by APCs and cancer cells. The presentation of antigens in form of pHLA 
complexes enhances the variety of targetable antigens and renders a personalized therapy feasible. 
Since the first part of this thesis deals with the identification of T-cell epitopes, ACT and therapeutic 
vaccination will be further explained. 
ACT employs autologous T cells which are cultured and selected for high-avidity antigen recognition 
ex vivo [Figure 8]. Moreover, the antigen specificity can be genetically engineered in vitro modifying 
the TCR or including a chimeric antigen receptor (CAR) which may also provide non-HLA-restricted 
antigen recognition. Large numbers of T cells (>1010) are expanded ex vivo using high amounts of IL-2 
(6000 U/ml) and reinfused into the patient about five to six weeks after tumor resection.106 
Administered cells are able to proliferate and to maintain their effector function.107 Their persistence 
in vivo correlates with tumor regression.108 A lymphodepletion before ACT is applied to eliminate 
lymphocytes which would compete with the transferred T cells for cytokines such as IL-7 and IL-15109 
or would inhibit their function such as regulatory T cells110. The ex vivo expansion of antigen-specific 
T cells has the advantage of the missing inhibitory tumor microenvironment and the subsequent 
injection of high amounts of antigen-specific T-cells. However, the incorrect selection of the target 
antigen can lead to severe auto-reactivity of the reinfused cells.  
Figure 8: Adoptive T cell transfer 
using autologous antigen-
specific tumor-infiltrating cells 
(TILs). The resected tumor is 
digested into a single-cell 
suspension following culture with 
high-dose IL-2. Cells are screened 
for antigen-specific T cell which 
are further expanded and 
reinfused into the patient after a 
lymphodepletion.
107
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Peptide vaccination approaches are based on in vivo stimulation of T cells by intradermal or 
subcutaneous injection of peptide formulations or autologous in vitro peptide-pulsed DCs. The basis 
of an effective vaccine is the appropriate activation of DCs. In general, the identification of TSAs or 
TAAs is based on mass spectrometry analysis of tumor samples and/or the prediction of HLA ligands 
from sequencing data (see section 1.6). A subsequent in vitro immunogenicity screen reveals the 
recognition ability of T cells.111  
Figure 9: Peptide vaccination. Peptide formulation is injected intradermally or 
subcutaneously into the patients. Peptides are taken up by APCs and presented to T 
cells.
112
 
 
 
 
 
 
 
 
Peptide formulations may include one to several peptides as well as short (minimal CTL epitope) to 
extended (CTL and TH lymphocyte epitopes) peptides.
113 A proper selection of the peptides is 
mandatory to avoid immunological tolerance towards these peptides.114,115 Short peptides are more 
prone to induce immunological tolerance because of the ability to directly replace peptides of cell 
surface-expressed HLA molecules of any cell.116 On the other side, long peptides have to be 
endocytosed and processed by APCs overcoming the risk of tolerance induction by direct 
replacement at the cell surface. In addition, long peptides may be presented by HLA class II enabling 
the activation of TH cells delivering additional activation signals to DCs through the CD40-CD40L 
signaling pathway.117,118 However, short peptide are easier to produce and can be better screened for 
antigen-dependent immunogenicity. Cocktail formulations with several peptides (up to 12-15) may 
be superior compared to single peptide approaches in that the tumor can be attacked on various 
presented antigens hampering further immune escape. In addition, targeting of several antigens 
which are required for tumor cell survival may further restrict the adaption of the tumor. However, 
the typical poor immunogenicity of peptides alone requires an additional adjuvant with 
immunostimulatory effects.  
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Adjuvants act in several ways including depot formation for a slow and continuous release of 
peptides and/or activation of APCs by binding to pattern recognition receptors. Emulsions such as 
MF59 (oil-in-water)119, incomplete F eu d’s adju a t ate -in-oil)120 or Montanide ISA 51 or ISA720 
(both water-in-oil emulsions)121 are some examples of adjuvants with depot formation ability. Recent 
research focuses on vaccine adjuvants which specifically activate APCs. Examples are the Toll-like 
receptor 4 (TLR4) agonist monophosphoryl lipid A (MPLA), the TLR7 agonist imiquimod, TLR9 agonists 
in form of CpG-containing oligonucleotides, the TLR3 agonist Poly(I:C) or the TLR1/2 agonist 
Pam3Cys.
122 Up to date, 60 active clinical trials (plus many more in the pipeline) with peptide vaccines 
for several malignancies a e listed o  the li i alt ials.go  e site “ea h te : Peptide a i e , 
Re uit e t status: A ti e , Date: 05.06.2017) displaying the upcoming era of immunotherapeutic 
strategies in disease combat. 
 
1.9.  Objectives 
The objectives of this thesis were the identification of suitable T-cell epitopes for the immunotherapy 
of ccRCC and the unveiling of HLA-C, HLA-E and HLA-G peptide motifs. The results and discussion part 
I addresses the identification of T-cell epitopes for the immunotherapy of ccRCC. In the second part 
of the results and discussion the peptide presentation specificities of HLA-C, HLA-E and HLA-G will be 
addressed. 
Renal cell carcinoma (RCC) is considered to be one of the most immunogenic tumors which is 
substantiated by spontaneous tumor rejections and high T cell infiltration.123,124 Besides resection of 
the malignant kidney, current therapies focus on targeting the tumor or the tumor environment with 
small inhibitory molecules. However, frequent resistance against those drugs limits their 
applicability.125 On the other side, non-specific immunotherapeutic approaches with either cytokines 
IL-2 or IFN-α or the lately approved checkpoint ab nivolumab demonstrates the potential of 
immunotherapies.126,127 Specific or personalized approaches, such as peptide vaccination or ACT, as 
well as combinatorial strategies hold the potential in enhancing the frequency and specificity of 
anti-cancer T-cell responses. To that end a comprehensive analysis of the HLA ligandome of the most 
frequent subtype ccRCC should be conducted and compared to the HLA ligandome of the 
corresponding adjacent benign counterparts as well as to a benign in-house database. 
Immunopeptidomics should be performed by liquid chromatography (LC)-coupled mass 
spectrometry (MS). Finally, the immunogenicity of selected HLA ligands had to be addressed by 
priming of naïve CD8+ T cells from healthy blood donors. 
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Classical HLA-C as well as the non-classical HLA-E and HLA-G molecules possess critical functions in 
both the innate and adaptive immunity. Compared to the well-defined immune activating functions 
of HLA-A and HLA-B molecules, the functions of HLA-C, HLA-E and HLA-G are diverse, ranging from 
immune activation, regulation and suppression depending on the receptor they interact with. This is 
mainly attributable to the interaction with NK cells. However, the characterization of peptide motifs 
has been lacking behind the more abundant HLA-A and HLA-B. For this purpose, peptide motifs of 
frequent HLA-C alleles as well as HLA-E and HLA-G should be analyzed. HLA ligands from monoallelic 
transfected lymphoblastoid C1R cells had to be analyzed by LC-MS/MS and employed for the 
definition of peptide motifs. The data should be utilized to establish SYFPEITHI matrices applicable 
for in silico binding prediction and for peptide assignment to the correct HLA. 
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2. Results and discussion, Part I: The immunopeptidomic landscape of 
clear cell renal cell carcinoma: identification and characterization of 
T-cell epitopes for immunotherapeutic approaches 
2.1.  Renal cell carcinoma 
Renal cell carcinoma (RCC) arises from the glandular epithelium (adenocarcinoma) of the renal cortex 
and represents about 85% of all renal malignancies.128 The other renal malignancies are the urothelial 
carcinoma, Non-Hodgkin lymphoma, sarcomas and Wilms tumor. It constitutes about 3% of all newly 
diagnosed cancers and is therefore among the ten most common cancers and the third common 
tumor of the urogenital tract after prostate and bladder carcinoma (US statistics illustrated in [Figure 
10]). The average age at the time of diagnosis is between 65 and 70 years. The incidence of RCC is 
higher in men compared to women (2:1) and higher in more developed countries.129 Worldwide 
about 295,000 people are annually diagnosed with RCC and about 134,000 deaths are related to the 
disease.130  
Depending on the morphology of the tumor and their molecular characteristics over 10 subtypes can 
be distinguished.131 The three main types with the highest incidence are clear cell RCC (ccRCC, with 
75-85% the most frequent type), papillary RCC (pRCC, 10-15%) and chromophobe RCC (chRCC, 
3-5%).132,133 The other subtypes represent less than 1% of RCCs.  
Hereditary predispositions, accounting for 2-3% of all RCC, are for instance the Von-Hippel Lindau 
disease (VHL) which is caused by mutations in the VHL tumor suppressor gene on chromosome 3 
(predisposition for ccRCC)134 and the Birt-Hogg-Dubé syndrome135 caused by a mutation in the FLCN 
gene on chromosome 17 encoding for folliculin which is suggested to act as a tumor suppressor 
(predisposition for chRCC)136. An overview of further genetic predispositions was reviewed by 
Schmidt et al.137 Further risk factors include smoking138, obesity139, hypertension and 
antihypertensive medication140,141 and the acquired renal cystic disease142 (reviewed in 143). 
RCC develops usually symptom-free over a longer time period and is often discovered accidently 
during screenings owing to another indication. Symptoms manifesting in an advanced stage are 
abdominal pain, palpable mass and haematuria. Therefore, it is not striking that at the time of 
diagnosis 30% of patients exhibit metastasis, whereas 25% display locally advanced disease and 45% 
localized RCC.144 A suspected RCC is investigated through anamnesis, physical examination, 
laboratory tests of the blood and the urine, the medical imaging by ultrasonography or computed 
tomography and a possible biopsie.145 
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Figure 10: Ten most frequent cancer types with estimated new cases and deaths in the US, 2014.
146
 *Rounded values to 
the nearest 10. Basal cell and squamous cell skin cancers and in situ carcinoma except urinary bladder are excluded. 
The standard classification of the disease progression into different tumor stages follows the TNM 
classification introduced by the Union for International Cancer Control [Table 3]. The TNM 
classification describes the disease progression based on three categories. The T refers to the size of 
the tumor and the spread into the kidney, the N indicates the infestation of regional lymph nodes, 
and the M indicates the presence of distal metastasis. The 5-year survival rate is dependent on the 
tumor stage. Observed survival rates published by the American Cancer Society are 81% for stage I, 
74% for stage II, 53% for stage III and 8% for stage IV patients. Note, that these percentages include 
also people deceasing due to other diseases. 
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Table 3: TNM classification of RCC.
147
 Schematic illustration of tumor staging, adapted from
148
. Illustration) A schematic 
stage I tumor localization is depicted in pink, a stage II tumor localization in blue, a stage III tumor localization in yellow and 
a stage IV tumor localization in red. 
 
2.2.  Therapy of renal cell carcinoma 
The first intervention in the treatment of localized tumors is a partial or radical nephrectomy 
(surgical excision) of the affected kidney. The partial nephrectomy is used to preserve healthy kidney 
tissue in patients with stage I disease, one functional kidney, bilateral manifestation of RCC, VHL 
syndrome or other diseases impairing kidney function.149 For metastatic RCC (mRCC) the additional 
treatment with targeted therapies or the checkpoint inhibitor nivolumab is exerted. These therapies 
Primary tumor (T) 
TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor in the kidneys 
T1  Tu o     i  g eatest di e sio , li ited to the kid e s 
 T1a Tu o     i  g eatest di e sio , li ited to the kid e s 
 T1b Tumor > 4 cm but not > 7 cm in greatest dimension, limited to the kidneys 
T2  Tumor > 7 cm in greatest dimension, limited to the kidneys 
 T2a Tumor > 7 cm but not > 10 cm in greatest dimension, limited to the kidneys 
 T2b Tumor > 10 cm in greatest dimension, limited to the kidneys 
T3  Tumor extends into major veins or perinephric issues, but does not invade the adrenal gland or 
sp ead e o d Ge ota’s fas ia 
 T3a Tumor spreads into renal vein or its muscles or perirenal and/or renal sinus fat, but not beyond 
Ge ota’s fas ia 
 T3b Tumor grossly extends into vena cava below the diaphragm 
 T3c Tumor grossly extends into vena cava above the diaphragm or invades the wall of the vena cava 
T4  Tu o  i ades e o d Ge ota’s fas ia a d e te ds i to the o tiguous ad e al gla d 
Regional lymph nodes (N) 
NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 
N1  Metastasis to regional lymph nodes 
Distant metastasis (M) 
M0  No distant metastasis 
M1  Distant metastasis 
Stage grouping 
Stage I  T1, N0, M0 (pink) 
Stage II  T2, N0, M0 (blue) 
Stage III  T1-T2, N1, M0 or T3a-T3c, N0-N1, M0 (yellow) 
Stage IV  T4, NX-N1, M0 or TX-T4, NX-N1, M1 (red) 
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can be also applied for inoperable tumors. Alternative strategies are the active surveillance or 
ablative therapies such as radiofrequency ablation or cryotherapy.150,151  
In former times, therapy of mRCC included single-agent or combinatorial chemotherapies and 
radiotherapy. However, due to high resistance against chemotherapy and radiotherapy the 
applicability was limited. In 1992, the first immunotherapeutic approach with high-dose IL-2 was 
approved. Until 2005, high-dose IL-2 and IFN-α e e the state-of-the-art treatment for mRCC. 
Despite response rates of about 15%, these therapies implicate frequent adverse side effects on the 
cardiovascular, gastrointestinal, neurological, pulmonary, hepatic, renal and hematological 
systems.152 Since 2005 nine therapeutic agents were approved belonging to the group of tyrosine 
kinase inhibitors targeting VEGFR and some other growth factor receptors, namely sorafenib, 
sunitinib, pazopanib, axitinib, lenvatinib and cabozantinib, the α-VEGF ab bevacizumab and the 
mammalian target of rapamycin (mTOR) inhibitors temsirolimus and everolimus [Figure 11]. The 
higher specificity of those drugs entails lower cytotoxicity and fewer side effects.153  
Figure 11: The evolution of the therapeutic treatment of mRCC. High-dose IL-2 and IFN-α e e used u til  da k 
age  he  the t osi e ki ase i hi ito  so afe i  as i t odu ed. I  the following years several other tyrosine kinase 
inhibitors, a monoclonal ab and drugs inhibiting TOR e e de eloped ode  age . The e  golde  e a  as i itiated 
by the checkpoint inhibitor nivolumab. The development of specific immunotherapeutic agents, such as vaccines or the 
adoptive T cell transfer, as well as drug combinations will lead to the dia o d age .149 
The latest recommendations for the systematic treatment of patients with metastatic disease are 
illustrated in Table 4 with sunitinib as standard of care for first-line therapy of most mRCC.154 The 
clinical benefits of administered drugs in RCC in terms of overall response rate, progression-free 
survival and overall survival were highlighted among others by Tsao et al.155 However, all targeted 
therapies have low response rates and a considerable risk of resistance development125, rendering 
new approaches necessary. 
The lately approved checkpoint ab nivolumab for treatment of mRCC is the first drug in the upcoming 
era of immunotherapy [Figure 11]. Nivolumab targets the checkpoint receptor programmed cell 
death protein 1 (PD-1) expressed on activated T cells, B cells and myeloid cells.156,157 PD-1 interacts 
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with PD-L1 and PD-L2, which are preferentially expressed on DCs and cancer cells upon IFN-γ 
stimulation and exhibit immunoinhibitory signals.157,158 For patients with prior failed sunitinib or 
pazopanib treatment the response rate of nivolumab was 25% compared to 5% for everolismus.127 
The progression-free survival was not improved. However, the overall survival was enhanced with 
25.0 vs 19.6 months compared to everolimus.127 
Table 4: Latest recommendations of the European Association of Urology for the treatment of mRCC patients.
159
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Several studies are currently investigating the application of further immune checkpoint inhibitors 
such as the anti-cytotoxic T lymphocyte-asso iated p otei   α-CTLA-4) antibodies ipilimumab and 
t e eli u a , the α-PD-1 antibodies nivolumab and pembrolizumab, and the anti-programmed cell 
death 1 ligand 1 (α-PD-L1) antibodies avelumab, atezolizumab and durvalumab.160 Several 
immunotherapeutic approaches, such as the DC-based vaccine AGS-003 loaded with RNA161, are 
currently in clinical trials (www.clinicaltrials.gov).  
MSKCC = Memorial Sloan-Kettering Cancer Center; LE = level of evidence 
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Moreover, the first therapeutic vaccine IMA901162 demonstrated the potential of specific 
immunotherapies in a clinical phase 2 study, but ultimately failed to improve overall survival in 
phase 3 in combination with sunitinib compared to sunitinib monotherapy.163 Because of significantly 
reduced CD8+ T cell responses in the phase 3 study compared to prior studies, one may speculate an 
immunosuppressive effect of sunitinib. However, sunitinib treatment is so far suggested to possess 
an immune activating function by increasing the percentage of IFN-γ p odu i g T ells a d de easi g 
the percentage of IL-4 producing T cells as well as downregulating Treg cells.
164 MDSC levels are 
reduced and myeloid DC levels are restored upon sunitinib treatment in RCC.165-167 In mice, numbers 
of CD8+ and CD4+ T cells were elevated with reduced expression of immunosuppressive costimulatory 
molecules such as PD-1 and CTLA-4 as well as reduced levels of Treg cells, MDSC and the 
immunosuppressive cytokine IL-10.168 In addition, changes in the vaccination timeline with reduced 
vaccination cycles as well as focusing on patients with low and intermediate risk, which might be 
accounting for the overall exceptional good outcome in both treatment arms, are further 
explanations of the study fail.163 Nonetheless, the phase 2 results emphasize the potential of specific 
immunotherapies. 
 
2.3. Cellular aberrations of ccRCC 
ccRCC is characterized by some recurring genetic alterations and a tremendous metabolic 
dysregulation.169-171 The mutation rate of ccRCC is rather low with about four to five mutations per 
megabase.172 However, there are some distinctive mutations recurring among patients. Frequent 
genetic aberrations involve the short arm of chromosome 3 which is lost in most of the ccRCC 
samples contained in The Cancer Genome Atlas (TCGA) database.173  
Besides the common loss, the short arm of chromosome 3 encompasses the most frequent mutated 
genes, namely VHL, PBRM1, SETD2 and BAP1.173 The most frequent mutations are found in VHL174 
which is part of the E3 ubiquitin ligase complex transferring ubiquitin molecules to targets for 
subsequent proteasomal degradation.175 The main targets of VHL are the hypoxia-inducible factors 
HIF- α a d HIF- α recognized subsequent to oxygen-dependent hydroxylation at specific proline 
residues by prolyl hydroxylases (PHD).176,177 HIFs act as transcription factors in a heterodimeric 
complex with HIF-β, also called the aryl hydrocarbon receptor nuclear translocator (ARNT). Under 
normoxic conditions HIF proteins are hydroxylated and degraded. However, non-functional or 
missing VHL as well as a usually hypoxic (oxygen-deprived) environment result in unregulated activity 
of HIF transcription factors. The heterodimeric complex binds to hypoxia-response elements (HRE) 
activating several genes with functions in cell proliferation and differentiation (e.g. CCDN1, 
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IGFBP1/2), apoptosis (e.g. BNIP, Bax), angiogenesis (e.g. VEGF), cell invasion (e.g. GAS6/AXL, CDCP1, 
FYN), energy metabolism (e.g. GLUT1/3, ALDOA/C, PLIN2), matrix metabolism (P4H) or pH regulation 
(CA9).178-181 Target genes of HIF- α a d HIF- α a e ot o pletel  o e lappi g a d a e ell-type 
dependent.182 In ccRCC, both isoforms may possess opposing effects with a shift towards the tumor 
promoting HIF- α.181,183 Moreover, the gene for HIF- α is ofte  deleted due to a f e ue t % of 
ccRCC TCGA dataset173) loss of the long arm of chromosome 14 where the HIF1A gene is located. 
Beside chromosome loss and VHL mutations, gene silencing by methylation of the VHL gene is a 
further mechanism for the impaired or missing VHL activity.184  
The other common mutated genes PBRM1, SETD2 and BAP1 are involved in histone remodeling or 
modification. The PBRM1 gene encodes for protein polybromo-1, a subunit of the SWI/SNF 
chromatin remodeling complex.185 SETD2 encodes for a histone methyltransferase activating gene 
expression through the generation of H3K36me3.186 BAP1 encodes for a histone deubiquitinase 
which acts as a tumor suppressor.187  
Additionally to the VHL/HIF pathway and the chromatin remodeling, the PI(3)K/AKT/MTOR pathway 
plays a particular role in tumor progression. Genes encoding for proteins of the PI(3)K/AKT/MTOR 
pathway, in particular PTEN and MTOR, are often mutated. Moreover, PI(3)K signaling is often 
activated by a gain of copy numbers of the long arm of chromosome 5 comprising GNB2L1 and 
SQSTM1 which are associated with the activation of the PI(3)K signaling pathway.173,188,189 The 
correlation of DNA methylation, RNA expression or protein expression of pathway involved genes, 
t a s ipts o  p otei s, espe ti el , ith patie t’s su i al de o st ates the i po ta e of the 
PI(3)K/AKT/MTOR pathway.173  
Overall, the genetic and epigenetic aberrations of ccRCC lead to a denoting metabolic shift including 
enhanced consumption of glucose along with downregulation of the tricarboxylic cycle and 
upregulation of the pentose phosphate pathway (NADPH production for lipid anabolism) and 
glutamine/glucose transporters.169,173 AMPK, which senses cellular ATP levels protecting the cell 
against energy deprivation, is downregulated as well as the tumor suppressor PTEN which inhibits 
PI(3)K/AKT/MTOR pathway signaling.173 Another apparent characteristic is the enhanced lipid storage 
of ccRCC which is the reason for the clear morphologic appearance of these cells.190 Based on these 
metabolic shifts, ccRCC as well as other subtypes of RCC are considered as metabolic diseases.191 The 
current therapeutic approaches focus on the metabolic shift of RCC. These approaches include the 
targets VEGF, produced by tumor cells in consequence of the disabled VHL pathway, VEGFR, 
presented by endothelial cells surrounding the tumor and leading to angiogenesis, and mTOR, 
activated by the PI(3)K/AKT/MTOR pathway subsequently leading to HIF transcription.  
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2.4. Tumor microenvironment of ccRCC 
Besides the metabolic aberrations, ccRCC is characterized by enhanced infiltration of immune cells in 
the tumor microenvironment123,192 considering ccRCC as immunogenic tumor. This is further 
emphasized by spontaneous regressions of the tumor even at metastatic stages124 and sporadic 
responses to non-specific immunotherapies with IL-2 and IFN-α126.  
Immune cell populations infiltrating the tumor site of ccRCC include T cells representing half of the 
immune cell infiltrate, myeloid cells, NK cells and B cells, whereas granulocytes are only present at 
low levels.193 Senbabaoglu et al.192 found out that the CD8+ T cell/Treg ratio as well as the amount of 
Th17 cells is positively correlated to patie t’s survival in ccRCC, whereas Th2 and Treg amounts are 
negatively correlated.192,194 The study by Geissler et al.195 displays an increase in T cell numbers with a 
higher tumor grade which indicates the dedifferentiation level of tumors. T cells on RCC lesions of 
higher grade had enhanced CD69 and CTLA-4 expression, both immune regulatory receptors of 
activated T cells.195 Mo eo e , patie t’s su i al as positi el  o elated to NK ell a d Th1 
infiltration, whereas a poor outcome was detected for patients with high T cell numbers, especially 
CD69 expressing cells.195 The immune inhibitory molecule of activated immune cells PD-1 is also 
associated to high-risk RCC tumors.196 The expression of effector T cell markers as well as the positive 
correlation to patie t’s survival supports the immunogenicity of RCC. However, there are many 
immune suppressive mechanisms of RCC preventing ultimately its defeat.  
A general overview of immune escape mechanisms was highlighted in section 1.7. Evidenced 
immune escape mechanisms for RCC were reviewed by Seliger197 and Frankenberger et al.198 RCC is 
able to evade or to suppress the immune system by several mechanisms. A reduction of immune 
recognition by downregulation of HLA molecules, however, is no mechanism to evade the immune 
system. Data show rather enhanced HLA expression in RCC.199,200 The expression of inhibitory 
molecules, such as PD-L1 and B7-H4, is a mechanism to suppress T cell function and to induce 
apoptosis in T cells.201-203 The non-classical HLA-G, usually restricted to immune-privileged organs 
(see section 3.1), is expressed by RCC inhibiting NK cells as well as T cells.204,205 In addition, RCC 
induces apoptosis in TILs by the expression of Fas ligand or CD70.206,207 Overexpression of 
gangliosides, glycosphingolipids at the outer part of the cell membrane, may function in T cell 
inhibition or promotion of T cell dysfunctionality by the induction of the cytokines IFN-γ and IL-4.208 
Moreover, gangliosides may inhibit antigen processing and presentation.208 The 
ganglioside-dependent induction of apoptosis by the activation of the transcription factor NF-κB as 
also demonstrated in vitro.209 Several by RCC secreted soluble factors, such as VEGF, TGF-β a d IDO, 
are also contributing to the immunosuppressive environment. VEGF inhibits DC maturation210, while 
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TGF-β a ts i  se e al a s i ludi g the supp essio  of CTL and NK cell functionality.211 IDO which 
degrades tryptophan leads to the inhibition of TIL proliferation and may recruit Treg cells.
212,213  
Besides these direct mechanisms of immune suppression, RCC indirectly promotes an 
immunosuppressive microenvironment by the attraction of immunosuppressive MDSCs, Tregs and 
tumor-associated macrophages (TAMs).214,215 Mechanisms of MDSCs and Tregs in immunosuppression 
were highlighted in section 1.7. TAMs are attracted by chemokines produced among others by tumor 
cells such as monocyte chemotactic protein-1 (MCP-1), macrophage colony stimulating factor 
(M-CSF) or VEGF.216 Attracted TAMs support tumor growth by the production of growth factors, such 
as EGF, FGF or TGF-β, and tumor spreading by the secretion of angiogenic factors, such as cytokines 
and matrix metalloproteinases (MMPs) -1, -3 and -10.217,218 On the other side, secreted IL-10 
suppresses the immune reaction.219 Furthermore, low levels of Th1 cells which provide IL-2 for CTLs 
and consumption of IL-2 by Tregs expressing the IL-2 receptor, lead to impeded CTL and NK 
functionality.198,220 Defect TCR sig ali g aused  the do egulatio  of the CD  ζ-chain is 
frequently found in RCC and may be induced by arginase I or nitric oxygen species produced by 
MDSCs.221,222 
The immunosuppressive microenvironment of tumors is far more complex than presented here. 
Overcoming general mechanisms with appropriate drugs will improve immunotherapies. The first 
step was performed by the development of checkpoint inhibitors. Further strategies to overcome the 
immunosuppressive microenvironment were reviewed by Joyce and Fearon.90 The reactivation of 
TILs impeding inhibitory signals through checkpoint inhibitors demonstrates the potential in 
intervening immune suppression.  
Peptide vaccinations, by contrast, try to boost specific reactions against TAAs by the activation of 
APCs (through an adequate adjuvant) and the specific activation of TAA-specific T cells. On the other 
side, immunosuppressive effects can be simply overcome in a first step by the in vitro expansion of 
tumor-specific T cells for ACT. Priming and boosting a specific anti-cancer response with the 
prevention of immune suppressive mechanisms will revolutionize therapies against cancer. This part 
of the thesis addresses the identification of suitable T-cell epitopes for ccRCC which can be applied 
for specific immunotherapeutic approaches, such as vaccines or ACT. 
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2.5. Materials and methods 
2.5.1. Samples 
A cohort of 58 snap-frozen patient samples (tumors as well as adjacent benign tissues) was collected 
for HLA ligandome analysis. The histological clear-cell subtype was attested by the Institute of 
Pathology, Tübingen, Germany. Informed consent following the Helsinki protocol was obtained for all 
patients. The study was performed according to the guidelines of the local ethics committee 
(446/2008BO2). HLA typing was carried out by the Department of Hematology and Oncology, 
University of Tübingen, Germany. A list of the patient cohort for HLA ligandome analysis is illustrated 
in Supplementary Table 1. Whole blood for the isolation of peripheral blood mononuclear cells 
(PBMCs) and CD8+ T cells for T cell assays was obtained from healthy volunteers by the blood 
transfusion unit of the University Hospital of Tübingen, Tübingen, Germany. A list of whole blood 
samples is illustrated in Supplementary Table 4. 
2.5.2. Isolation of HLA ligands from tissue 
HLA class I and II molecules were isolated by immunoaffinity purification223,224 employing pan-HLA 
class I-specific mAb W6/32 as well as pan-HLA class II-specific mAb Tü39 and HLA-DR-specific mAb 
L243. Sample preparation and immunoaffinity purification were performed at 4°C or on ice. In a first 
step, tissue was covered with 10 mM CHAPS/PBS (AppliChem, Darmstadt, Germany/Lonza, Basel, 
Switzerland) containing protease inhibitor (Complete; Roche, Basel, Switzerland) and sliced into small 
pieces. Subsequent homogenization (Homogenizer: Rotwerk, München, Germany, Potter glass: 
Novodirect, Kehl, Germany) and sonification (Branson, Danbury, CT, USA) fostered cell lysis. Cell 
lysate was centrifuged at 4000 rpm for 45 min, supernatant was filtered and coupled to serially 
connected columns with HLA class I or HLA class II mAb, respectively, covalently linked to CNBr-
activated sepharose (GE Healthcare, Little Chalfont, UK; pumps: Rotarus smart 30, Hirschmann, 
Eberstadt, Germany). Immunoaffinity purification was carried out overnight. On the following day, 
columns were washed for 30 min with ddH2O and 1 h with PBS. HLA molecules and HLA ligands were 
eluted into a low-binding sample tube (Eppendorf, Hamburg, Germany) following a 15 min 
incubation step with 100 µl 0.2% trifluoroacetic acid (Merck, Darmstadt, Germany) on a shaker. 
Elution procedure was repeated eight times. In the first elution round, 10 µl of 10% trifluoroacetic 
acid was additionally added. HLA ligands were separated from HLA molecules (and further large 
contaminants) by ultrafiltration using 3 kDa or 10 kDa centrifugal filter units (Amicon; Merck 
Millipore) for HLA class I or HLA class II, respectively. Filters were subsequently washed by 500 µl 
32.5% acetonitrile (Merck)/0.1% trifluoroacetic acid (ABE) to recover hydrophobic peptides. The 
following steps were performed at room temperature (RT). Filtrates were concentrated by vacuum 
centrifugation (Bachofer, Reutligen, Germany) to a volume of about 50 µl. HLA ligands were 
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extracted and desalted using ZipTip C18 pipette tips (Merck Millipore) and eluted in 35 µl ABE. 
Samples were vacuum-centrifuged to a volume of less than 5 µl and 1% acetonitrile/0.05% 
trifluoroacetic acid was added to a volume of 25 or 40 µl. Samples were stored at -80°C until 
LC-MS/MS analysis. 
2.5.3. Analysis of HLA ligands by LC-MS/MS 
Peptides were analyzed by reversed phase liquid chromatography (UltiMate 3000 RSLCnano, Dionex, 
Sunnyvale, CA, USA) coupled mass spectrometry (LTQ Orbitrap XL or Orbitrap Fusion Lumos, Thermo 
Fisher Scientific, Waltham, MA, USA). Overall, five technical replicates per sample with 5 µl each 
were measured. In a first step, sample was loaded onto a 75 µm x 2 cm C18 trap column (Acclaim 
PepMap RSLC, Thermo Fisher Scientific) for further purification and desalting at 4 µl/min for 
5.75 min. Subsequent peptide separation took place at 50°C on a 50 µm x 25 cm separation column 
(Acclaim PepMap RSLC, Thermo Fisher Scientific) applying a gradient from 2.4 to 32.0% acetonitrile 
over a time course of 90 min. Eluting peptides were ionized by nanospray ionization and accelerated 
into the mass spectrometer. For samples measured in the LTQ Orbitrap XL, survey scans were 
recorded in the orbitrap with a resolution of 60,000. The top 5 peaks with the highest intensity were 
selected for fragmentation if they fulfill the following criteria: within a mass range of 400-650 m/z 
and a charge state of 2+ or 3+ for HLA class I or within a mass range of 300-1500 m/z and a charge 
state higher 2+ for HLA class II. Precursor ions were isolated in the ion trap and fragmented by 
collision induced dissociation. Fragment ions were recorded in the ion trap. 
For samples measured in the Orbitrap Fusion Lumos [Supplementary Table 2, Supplementary Table 
3] instrumentation-adapted changes were applied. The TopSpeed method was implemented and 
survey scans were generated in the Orbitrap at a resolution of 120,000. Precursor ions were isolated 
in the quadrupole, fragmented by collision induced dissociation (HLA class I) or higher-energy 
collisional dissociation (HLA class II) and fragment ions were recorded in the Orbitrap. For HLA class II 
the charge state of precursor selection was limited to 5+. 
2.5.4. Spectral Annotation and data analysis 
Data was processed against the human proteome as comprised in the Swiss-Prot database 
(www.uniprot.org, release: September 27th 2013; 20,279 reviewed protein sequences contained). 
The Mascot algorithm (Mascot 2.2.04, Matrix Science, London, UK)225 was utilized for LTQ Orbitrap XL 
measured samples and the SequestHT algorithm226 for Orbitrap Fusion Lumos measured samples 
within the Proteome Discoverer (v1.3, Thermo Fisher Scientific) software. Mass tolerance filters were 
set to 5 ppm for precursor ions and 0.5 Da (LTQ Orbitrap XL) or 0.02 Da (Orbitrap Fusion Lumos) for 
fragment ions. Search was not restricted to an enzymatic specificity. Oxidized methionine was 
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enabled as a dynamic modification. Percolator227 assisted false discovery rate (FDR) calculation was 
set at a ta get alue of   .  % FDR . Results were restricted to rank 1 (best matches for each 
spectra) and a length of 8-12 aa for HLA class I or 9-25 aa for HLA class II, respectively. Replicates 
were processed independently to obtain consistent results for qualitative and quantitative analysis. 
2.5.5. Peptide synthesis 
Peptides used for immunogenicity tests were synthesized using the peptide synthesizers 433A 
(Applied Biosystems, Foster City, CA, USA) or LibertyBlue (CEM corporation, Matthews, NC, USA) 
applying the 9-fluorenylmethyloxycarbonyl/tert-butyl (Fmoc/tBu) strategy described in 228. Purity and 
identity of synthesized peptides were determined by HPLC or MS, respectively. 
2.5.6. Refolding and biotinylation of HLA-peptide complexes 
HLA-peptide complexes were generated  i u atio  of HLA hea  hai , β2m and the respective 
peptide under continuous and gentle stirring in 250 ml refolding buffer (pH 7.76) containing 6.97% 
L-arginine (Sigma-Aldrich, St. Louis, MO, USA)/2.4% HEPES (Roth, Karlsruhe, Germany)/0.4% 0.5 M 
EDTA, pH 8 (Sigma-Aldrich) in ddH2O. Refolding was carried out for HLA-B*40 (HLA-B*40:02 heavy 
chain used). For the other HLA allotypes refolding was performed with an UV-sensitive peptide which 
was subsequently replaced by UV (see section 2.5.7). All steps were performed at 4°C or on ice if not 
mentioned otherwise.  
On day 1, following components were injected subsequently into the refolding buffer under 
continuous and fast stirring: 385 mg reduced gluthatione (Sigma-Aldrich), 77.5 mg oxidized 
gluthatione (Sigma-Aldrich), 250 µl 200 mM phenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich) in 
methanol (Merck), 7 mg peptide resolved in DMSO (Merck) to a concentration of 10 mg/ml, 8 mg 
HLA heavy chain resuspended in 700 µl 3 M guanidine HCl (Sigma-Aldrich)/10 mM sodium acetate 
(Sigma-Aldrich)/10 mM EDTA in ddH2O, pH .  i je tio  uffe  a d  g β2m in 780 µl injection 
buffer. Reaction was performed overnight under gently stirring of the solution. On the next day, 8 mg 
HLA heavy chain resolved in 700 µl injection buffer was added under fast stirring once in the morning 
and once in the evening. On day 3, reaction was filtered through a 0.22 µm Stericup Express vacuum 
filter (Merck-Millipore) and concentrated to a volume of 20-25 ml in an Amicon stirring cell with a 
PBTK membrane, NMWL 30,000 (Merck-Millipore) at 60 psi. Retentate was collected in a 50 ml 
collection tube, while permeate was applied to a second round of refolding. Steps of day 1 to 3 were 
repeated with the following exception: only 250 µl 200 mM PMSF, 8 mg HLA heavy chain 
resuspended in 700 µl inje tio  uffe  a d  g β2m in 780 µl injection buffer were injected into the 
permeate. Retentates were centrifuged for 5 min at 4000 rpm and concentrated to a volume of 5 ml 
using 10 kDa centrifugal filter units (Amicon Ultra-15; Merck-Millipore). On the following day (d6), a 
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size exclusion chromatography on a Superdex 75 column was conducted after centrifugation and 
filtration of the retentate. Tris-buffered saline (TBS; 20 mM Tris (Sigma-Aldrich) pH 8 at 4°C and 
150 mM NaCl (Merck) in ddH2O) was used as running buffer. Monomer fractions were collected and 
mixed with 200 µM PMSF, 1 µg/ml Leupeptin (Roche) and 0.7 µg/ml Pepstatin (Roche). Fractions 
were concentrated to a volume of 5 ml using 10 kDa centrifugal filter units. Biotinylation was carried 
out overnight at 27°C by subsequent addition of following components to the retentate: 80 mM Tris, 
pH 8 at 25°C, 5 mM MgCl2 (Merck), 5 mM ATP (Sigma-Aldrich), 10-20 µg BirA ligase (in-house 
production) and 5.7 mM biotin (Sigma-Aldrich). Following biotinylation, a size exclusion 
chromatography was performed. Monomer fractions were collected, concentrated to 250-350 µl and 
protein concentration was determined by a Bradford assay. Aliquots of 50 µg monomer with a 
concentration of 2 mg/ml were frozen at -80°C until use. Successful refolding was additionally 
confirmed by MS. 
2.5.7. UV-mediated peptide exchange in monomers 
Monomers with UV-sensitive peptide and replacing peptide were exposed to UV for exchange. 
Therefore, 65 µl of monomer, diluted to 200 µg/ml in 2 mM EDTA in PBS, and 65 µl peptide, diluted 
to 400 µM in PBS-EDTA, were mixed in a 96-well polypropylene plate with V-bottom (Ref. 651201; 
Greiner Bio-One, Kremsmünster, Austria) and exposed to 366 nm UV light for 1 h. Plate was 
centrifuged at 4000 rpm for 5 min at RT and 100 µl of supernatant was collected in a 1.5 ml collection 
tube. For each monomer six wells were exchanged which was enough to perform the following 
experiments twice. A final concentration of 50 µg/ml was assumed (50% exchange rate). Aliquots of 
115 µl for priming, 135 µl for tetramer staining and a leftover aliquot were frozen at -80°C. 
2.5.8. Quality control of UV-exchanged monomers 
Proper UV-exchange was proven employing pan-HLA class I mAb W6/32 and antibodies recognizing 
non-linear epitopes (HCA2, HC10) exposed by denaturated HLA molecules as described in229. The 
mAb GAP-A3 was used as control. All steps were conducted at 4°C or on ice. Streptavidin-coated 
microspheres (bead concentration 100,000/µl; Bangs Laboratories, Indiana, IN, USA) were washed 
twice in PBS (2500 rpm, 5 min) and resuspended in 100 µl FACS buffer (2 mM EDTA/2% FBS (Thermo 
Fisher Scientific, Gibco) in PBS) per 100,000 beads. 100 µl bead and 100 µl monomer solution, prior 
diluted in PBS to 0.1 µg/ml, were mixed in a 96 U-bottom well plate (Corning, New York, NY, USA) 
and incubated for 30 min. For each monomer four wells were used. Plate was washed twice with 
FACS buffer and wells were incubated with 50 µl of either 1 µg/ml W6/32, 0.5 µg/ml HCA2, 0.6 µg/ml 
HC10 or 1 µg/ml GAP-A3 for 30 min (all antibodies are in-house produced). After two washing steps, 
wells were incubated with 50 µl of 1:100 polyclonal goat anti-mouse FITC-labelled secondary Ab 
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(Agilent Technologies, Santa Clara, CA, USA, Dako) for 30 min. Following two washing steps, 
monomers were analyzed by flow cytometry (FACS Canto II analyzer; BD Biosciences, San Jose, CA, 
USA). Data analysis was conducted by FlowJo 10.0.7. (FlowJo, LLC, Ashland, OR, USA). 
2.5.9. Tetramerization of monomers 
Tetramerization of refolded monomers was performed by the addition of 6.28 µl strepavidin-
phycoerythrin (Strep-PE, Thermo Fisher Scientific) in 20 µl 2 mg/ml monomer solution and 
subsequent rotation for 30 min in the dark. Step was repeated ten times. Tetramers were mixed with 
3x glycerol solution (20 mM Tris, pH 8 at 4°C/48% glycerol (Roth)/1.5% human serum albumin 
(Biotest, Dreieich, Germany) and 3x protease inhibitor (Roche)) in a ratio of 1:3. For UV-exchanged 
monomers tetramerization was carried out by ten time addition of 1.06 µl Strep-PE in 135 µl 
50 µg/ml monomer solution. Tetramers were mixed with 6x glycerol solution in a ratio of 1:6. 
2.5.10. Isolation of PBMCs 
PBMCs were isolated from whole blood of healthy donors using Ficoll (Merck-Millipore) separation 
solution. Blood was transferred into 50 ml collection tubes and centrifuged at 2000 rpm for 20 min at 
RT without break. The upper plasma layer was transferred into new 50 ml collection tubes. PBMC 
layer was generously collected and transferred into a 175 cm2 cell culture flask (Greiner Bio-One), 
diluted 1:1 with PBS-EDTA (2mM) and carefully layered onto 15 ml Ficoll solution. After 
centrifugation at 2000 rpm for 20 min at RT without break, upper plasma layer was discarded and the 
middle PBMC layer was generously collected into new 50 ml collection tubes. PBMCs were diluted 
1:1 with PBS-EDTA and centrifuged at 1500 rpm for 20 min at RT. Cells were washed twice with 
PBS-EDTA (10 min centrifugation steps at 1300 and 1100 rpm, respectively), resuspended in TCM 
(IMDM (Lonza) + 1x penicillin/streptomycin (Sigma-Aldrich) +  µM β-mercaptoethanol (Roth) + 
25 µg/ml gentamycin (Thermo Fisher Scientific) + 10% autologous plasma), transferred into two 
175 cm2 cell culture flasks and incubated overnight at 37°C, 7.5% CO2. 2x10
7 PBMCs were frozen for 
recall ELISpot (see section 2.5.15). Plasma was heat-inactivated at 56°C for 30 min and centrifuged at 
2500 rpm for 20 min at RT. Supernatant was transferred into a new 50 ml collection tube. After 
another centrifugation step, supernatant was used for TCM preparation or frozen at -20°C. 
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2.5.11. Isolation of CD8+ T cells 
CD8+ T cells were isolated from overnight culture of PBMCs by magnetic cell separation (MACS) using 
α-CD8 beads (Miltenyi Biotech, Bergisch Gladbach, Germany). PBMCs were transferred into 50 ml 
collection tubes and centrifuged at 1300 rpm for 10 min at RT. Cell pellet was resuspended in MACS 
buffer (0.5% BSA (Sigma-Aldrich)/2 mM EDTA in PBS), centrifuged at 1300 rpm for 10 min at 4°C, 
esuspe ded i   µl α-CD8 beads/1*107 cells and 50 µl MACS buffer/1*107 cells and incubated for 
15 min at 4°C. Following incubation, cells were centrifuged, filtered and CD8+ T cells were separated 
a o di g to the a ufa tu e ’s i st u tio s usi g L“ olu s Miltenyi Biotech). Cells were washed 
once with MACS buffer and cultured in 75cm2 flasks with 15 ml TCM + 10 U/ml IL-2 (R&D systems, 
Minneapolis, MN, USA) and 2.5 ng/ml IL-7 (Promokine, Heidelberg, Germany) overnight at 37°C and 
7.5% CO2. 
2.5.12. Priming of CD8+ T cells 
CD8+ T cells were harvest, washed twice with PBS (1300 rpm, 10 min, RT) and resuspended in TCM at 
a concentration of 1*106/100 µl. 1*106 cells were distributed into wells of 96-well plates, U-bottom 
(Costar; Corning) and incubated at 37°C and 7.5% CO2 (hereafter referred to as T-cell plates). 
Meanwhile, beads were prepared. 800,000 beads/well (bead stock: 100,000 beads/well) were 
washed twice with 20 ml MACS buffer (2500 rpm, 10 min 4°C) and resuspended to 8*106 beads/ml. 
96-well plates were prepared with 100 µl bead solution as well as 50 µl monomer solution, prior 
diluted to 4 µg/ml with MACS buffer, and incubated for 30 min at RT while shaking. In total, 20 wells 
were prepared for one monomer. 50 µl of biotinylated CD28 (in-house production) was added into 
the wells at a concentration of 12 µg/ml and plates were incubated for additional 30 min. Plates 
were washed five times with MACS buffer (2500 rpm, 2 min, 4°C) and beads were diluted in 200 µl 
MACS buffer/well (hereafter referred to as bead plates). Plates were stored at 4°C until use. 
CD8+ T cells were primed weekly for four times with streptavidin-coated microspheres coupled to 
biotinylated monomers and CD28. Therefore, 50 µl of bead stock was transferred from the bead 
plates into new 96-well plates and washed twice with TCM without plasma. Wells were resuspended 
in 100 µl TCM + 5 ng/ml IL-12 (Promokine) and beads were transferred to the T-cell plates. For 
stimulation rounds 2-4 100 µl medium was prior removed from the T-cell plate before adding the 
bead solution. Medium was changed when necessary. Two or three days after primings, 100 µl 
medium was removed and CD8+ T cells were fed with 100 µl TCM + 40 U/ml IL-2 and 5 ng/ml IL-7 
(final concentration in culture). 
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2.5.13. Tetramer staining 
Recognition of pHLA complexes by in vitro primed CD8+ T cells was ascertained by tetramer staining. 
All steps were performed at 4°C or on ice if not otherwise mentioned. Staining steps were performed 
for 20 min in the dark if not otherwise mentioned. Between staining steps, cells were washed with 
150 µl PBS-EDTA or FACS buffer (after tetramer staining), respectively, by centrifugation at 1800 rpm 
for 2 min and removing the supernatant by flicking.  
One third of cultured CD8+ T cells were transferred into new 96-well plates and washed four times. 
Cells were stained with 50 µl Aqua live/dead solution (Thermo Fisher Scientific/Invitrogen) prior 
diluted 1:400 (if stored solution reconstituted within last 2 weeks) or 1:200 (if reconstituted 2-4 
weeks before use) in PBS-EDTA. Subsequently, primed cells were stained with 50 µl of the 
corresponding tetramer solution (PE-labelled) which were prior diluted to 5 µg/ml in 50:50 PBS:FBS 
and 2 mM EDTA for 30 min at RT. After tetramer staining, cells were stained with 50 µl 1:100 diluted 
α-CD8-PerCP Ab (BioLegend, San Diego, CA, USA). Finally, fixation of the cells was performed with 
100 µl FACS buffer/ 1% formaldehyde (Sigma-Aldrich). Cells were washed twice and resuspended in 
200 µl FACS buffer. Samples were analyzed on a FACS Canto II analyzer. Data analysis was performed 
by FlowJo 10.0.7. Conditions for positive priming were a three-fold larger and distinct 
tetramer-positive population compared to the negative control. 
For cells which were primed with UV-exchanged pHLA complexes, positive wells were additionally 
stained with the corresponding tetramer containing the UV-sensible peptide. 
2.5.14. Intracellular IFN-γ a d TNF-α staining of primed CD8+ T cells 
Functionality of in vitro primed CD8+ T cells was determined by intracellular cytokine staining (ICS) of 
IFN-γ a d TNF-α. One third of cultured cells of different tetramer positive wells were combined, 
centrifuged at 1800 rpm for 2 min at 4°C and split into three to five wells of a new 96-well plate (1x 
positive control, 1-2x peptide of interest, 1-2x negative control) with a volume of 50 µl each. 50 µl 
150 ng/ml phorbol 12-myristate 13-acetate (PMA) + 3 µM ionomycin (Positive control; Company) or 
10 µg/ml peptide diluted in TCM were added to the cells as well as 50 µl 10 µg/ml Brefeldin A (Sigma-
Aldrich) + 10 µg/ml Golgi-Stop solution (BD Bioscience). Cells were cultured for 12-16 h at 37°C, 7.5% 
CO2. On the following day, cells were washed and stained with Aqua Live/dead and α-CD8 Ab as 
described in 2.5.13. Thereafter, cell membranes were permeabilized by incubation with 100 µl 
Cytoperm/Cytofix (BD Bioscience) for 20 min at 4°C in the dark and washed with Permwash buffer 
(0.1% saponine (AppliChem, St Louis, MO, USA)/0.5% BSA (Roth) in PBS). After permeabilization, 
intracellular IFN-γ a d TNF-α were stained with 1:200 IFN-γ-PE (BD Bioscience) and 1:120 TNF-α-
PacificBlue (BD Bioscience) diluted in Permwash buffer. Following two washing steps with Permwash 
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buffer, cells were diluted in 200 µl FACS buffer. Samples were analyzed on a FACS Canto II analyzer. 
Data analysis was performed by FlowJo 10.0.7. Conditions for positive ICS were a three-fold increase 
in IFN-γ a d TNF-α staining compared to the negative control. 
2.5.15. Recall IFN-γ ELISpot 
To exclude memory responses of the positive tested peptides in priming experiments, ELISpot assay 
was conducted after 12-day stimulation of PBMCs from respective healthy donors. 2*107 cells were 
thawed and ashed t i e ith  l IMDM +  pe i illi /st epto i  +  µM β-mercaptoethanol 
+ 25 µg/ml gentamycin + 3 µg/ml DNase (1400 rpm, 7 min). Subsequently, pellet was resuspended in 
2 ml of TCM (5% pooled serum, instead of 10% used in TCM for priming experiments), distributed 
into four wells of a 24-well plate and incubated over night at 37°C, 7.5% CO2. The following day, cells 
were stimulated with a 500 µl peptide mix containing 1 µg/ml of each peptide tested in the 
respective donor. On day 3, 6 and 8 cells were stimulated with a final concentration of 20 U/ml IL-2 
prior diluted in 500 µl TCM. On day 10, medium was exchanged and ELISpot plate was coated with 
100 µl of 2 µg/ml human 1-D1K IFN-γ Ab (MabTech, Stockholm, Sweden; 1:250 dilution with PBS) and 
incubated bubble-free at 4°C. On day 13, plate was washed twice with cold IMDM and incubated 
with 50 µl TCM for 2 h at 37°C to block unspecific binding sites. In the meantime cells were collected, 
washed twice with TCM and resuspended to 1*107 cells/ml. 500,000 cells were distributed into the 
wells of the pre-coated plate and 50 µl of peptide diluted in TCM with a final concentration of 
1 µg/ml was added. As positive control phytohaemagglutinin (PHA; Sigma-Aldrich) in a final 
concentration of 10 µg/ml was added to one additional well. Plate was incubated for 24 h at 37°C, 
7.5% CO2. On the following day, plate was washed twice with 200 µl PBS/0.05% Tween 20 (Merck), 
twice with 200 µl ddH2O and again three times with 200 µl PBS/0.05% Tween 20 and subsequently 
incubated with 100 µl biotinylated secondary anti-IFN-γ Ab 7-B6-1 (1:3000 dilution in PBS/0.5% BSA; 
MabTech) bubble-free for 2 h at RT. Following six washing steps with 200 µl PBS/0.05% Tween 20, 
plate was incubated with 100 µl of avidin-conjugated alkaline phosphatase (1:1000 dilution in 
PBS/0.5% BSA; Sigma-Aldrich) for 1 h at RT. Finally, plate was washed three times with PBS/0.05% 
Tween 20 and three times with PBS and incubated with 50 µl of BCIP/NBT solution (one tablet 
dissolved in 10 ml ddH2O; Sigma-Aldrich) for 7 min in the dark. Reaction was stopped washing the 
plate with water and plate was completely dried for one day and evaluated using the C.T.L 
ImmunoSPOT reader (Cellular Technology Inc., Kennesaw, GA, USA). Conditions for a positive 
response were a spot count of at least 10 and a three-fold higher spot count compared to the 
negative control. 
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2.6.  Results 
2.6.1. MS-based disclosure of the HLA ligandome 
HLA class I ligandome analysis was performed for 58 ccRCC samples and corresponding adjacent 
benign tissue using mass spectrometry-based analysis of peptides after immunoprecipitation of HLA 
molecules. In total, 41,448 HLA ligands could be identified deriving from 11,521 antigens. HLA ligands 
were defined employing NetMHCpan-3.4 (Rank < 2 or 500 nM) and SYFPEITHI (  60% of maximal 
score) [Supplementary Table 1]. The mean number of HLA ligands was 1573, ranging from 121 to 
4934, for the tumor samples and 947, ranging from 42 to 2843, for the adjacent benign samples 
[Figure 12, Supplementary Table 2]. Sample purity, defined by the frequency of HLA ligands 
compared to the total number of identified peptides, was on average 90.1% for tumors and 86.7% 
for benign samples with a range of 77.9% to 96.7% and 60.3% to 95.0%, respectively. Overall, a broad 
range of HLA alleles could be covered gaining a comprehensive analysis of the immunopeptidome. 
Investigation of the HLA class II ligandome was performed for 52 ccRCC samples and corresponding 
adjacent benign tissue with a total number of 32,158 peptides identified deriving from 6099 
antigens. The mean number of peptides was 965 (range 240 to 5103) for the tumor samples and 860 
(range 131 to 5414) for the adjacent benign samples [Figure 13, Supplementary Table 3]. Samples 
analyzed on the Orbitrap Fusion Lumos exhibited 5.22 times more peptides compared to LTQ 
Orbitrap XL analyzed samples (means: 3388 vs 649). 
Figure 12: HLA class I peptide yields, ligand 
yields and sample purity. Yields are assigned to 
the left y-axis (black). Sample purity, which is 
defined by the frequency of ligands compared 
to the total number of identified peptides, is 
assigned to the right y-axis (red). Box & 
whiskers plot with 5-95% whiskers are 
displayed. 
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Figure 13: HLA class II peptide yields. Yields are plotted 
for all 52 samples (left), for the five samples analyzed 
on the Orbitrap Fusion Lumos (middle) and for the 47 
samples analyzed on the LTQ Orbitrap XL (right). Box & 
whiskers plot with 5-95% whiskers are displayed. 
 
 
 
 
 
2.6.2. Identification of HLA class I tumor-associated peptides using comparative profiling 
Comparative profiling of HLA ligands of ccRCC and adjacent benign tissue was employed to identify 
tumor-exclusive peptides. Peptides unique to the tumor were defined as tumor-associated peptides 
(TUMAPs). A large in-house database containing 95,177 HLA ligands of 158 benign tissues from 
different organs (including blood, kidney, liver, lung, small intestine, heart, brain, and many more) 
was additionally included for HLA class I ligand comparison to ensure tumor-exclusivity of TUMAPs 
not only compared to the adjacent benign kidney, but also in relation to many other organs. 
In total, 1591 TUMAPs could be identified which were presented in at least two ccRCC samples 
[Figure 14]. Restricting the dataset to TUMAPs with a representation frequency of at least three and 
a unique source protein origin the number of TUMAPs decreased to 433 deriving from 351 antigens. 
This set of TUMAPs was further analyzed for their HLA restriction and the gene expression (data from 
the TCGA database with 453 ccRCC samples and 68 benign kidney samples; kindly provided by the 
Institute for Clinical Pharmacology in Stuttgart) of the corresponding antigen. 
Considering a fold change gene expression of the antigen of > 2 in ccRCC compared to the benign 
kidney cohort, the set of 433 TUMAPs originating from 351 antigens was further reduced to 170 
TUMAPs from 112 antigens. Overexpressed antigens with one (or more) TUMAP represented in at 
least three samples are illustrated in Supplementary Table 5 (in the appendix) and Figure 15.  
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Figure 14: Comparative profiling of 58 ccRCC vs. corresponding adjacent benign tissues and 158 benign tissues. The 
frequency of HLA ligands in the tumor is illustrated in red (positive y-axis) and for the benign tissue in green (negative 
x-axis). Each bar represents one HLA class I ligand. 
The antigen representing the highest diversity is PLIN2 (Perilipin-2) with 29 different HLA class I 
TUMAPs. PLIN2 is involved in the transport of long fatty acids and in the storage of lipids and is 
mainly expressed in fat tissue. It is upregulated upon VHL inactivation and is a main factor for the 
clear cell morphology (lipid droplets) of ccRCC.230 The most frequently presented TUMAPs are 
GAVTGSVEK (5x, A*11), SINTVLGSR (5x, A*03), SVFRNAASF (4x, B*15) and TSSKGQLQK (4x, A*03). 
 However, several other antigens give rise to more frequently presented TUMAPs which would be 
more advantageous for so called off-the-shelf approaches.163,231 The most frequent TUMAP is 
ILWREVVTL (15x, A*02) from the transcription factor HSF4 (heat shock factor protein 4). 
Interestingly, even the antigen is tumor-exclusive among the HLA ligandomes of ccRCC since no 
peptide was found in other benign tissues. Further examples of tumor-exclusive antigens are the 
NADH dehydrogenase subunit NDUFA4L2 (most frequent TUMAP: GSAALYLLR, 9x, A*11/A*68:01), 
the ion channel KCNN1 (RVFLISLEL, 8x, A*02), the metastasis suppressor KISS1R (RPAPADSAL, 6x, 
B*07/B*35), the growth factor PGF (YPSEVEHMF, 5x, B*35), and the angiogenesis modulator 
ANGPTL4 (two length variants: AQNSRIQQL[F], 7x, both B*15).  
Other frequent TUMAPs are FLLSLIDRL (9x, A*02, EGLN3), HPIETLVDIF (9x, B*35, VEGFA), SEINTTHNL 
(9x, B*40/B*44, PRUNE2), ALIVSLPYL (8x, A*02, SLC17A3), GLVDIMVHL (8x, A*02, DNAH11) and 
SEAEALARTW (8x, B*44, DIRAS2). TUMAPs presented on more than two HLA allotypes are 
MPLGHIMRL (8x, B*07/B*35/B*51/B*53, EGLN3), AEKELVQSL (5x, B*40/B*41/B*44, P4HA2) or 
FPTEQINEI (5x, B*35/B*51/B*53, ADSSL1). These peptides are applicable for a larger population 
compared to peptides presented only on one of these HLA alloypes. An extended list of TUMAPs for 
the 112 target candidates is depicted in Supplementary Table 5. 
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Figure 15: Antigens with at least one frequent 
TUMAP (n ≥ 3) and > 2-fold higher expression 
in tumor compared to benign kidney within the 
TCGA cohort. The size of the letters is 
proportional to the frequency of the top TUMAP 
of the respective antigen. Range: The letters of 
the most frequent antigen HSF4 have a size of 
15, whereas the letters from several antigens 
with a frequency of their top TUMAP of n = 3 
have a size of 3. 
 
2.6.3. Hypoxia-induced genes within the selected candidates 
One characteristic of ccRCC is its hypoxic-like state which is the consequence of VHL mutations. The 
subsequent activation of hypoxia-induced antigens by HIFs renders these targets a promising 
approach for ccRCC treatment. Ortiz-Barahona et al.182 used a computational strategy to specify the 
binding site of HIFs. Besides the o e se ue e „RCGTG , R = G or A [purine]) of HRE, several other 
nucleotides within position -1 to +17 displayed some particular variances. Overall, 216 genes could 
be identified to be probable targets of HIFs of which 61 were already known.  
12 of the 112 overexpressed antigens with at least one frequent TUMAP are targets of HIFs. All of 
them were already known as HIF targets: CA9232, EGLN3233, IGFBP3234, VEGFA235, LOX236, ADM237, 
DDIT4238, PFKP239, P4HA2240, BNIP3241, PLOD1240 and PLOD2240. The well characterized ccRCC tumor 
antigen CA9 is normally expressed in the stomach and is involved in the cellular pH regulation.242 It is 
upregulated in many tumors. EGLN3 is a cellular oxygen sensor which hydroxylates substrates, such 
as the HIF proteins in a negative feedback, for proteasomal degradation.243 IGFBP3 is an insulin 
growth factor (IGF) binding protein altering the interaction of IGF to their receptors. In pancreatic 
cancers IGFBP3 overexpression is correlated with the metastatic ability of the tumor.244 The growth 
factor VEGFA promotes angiogenesis and cell migration.245 LOX catalyzes the post-translational 
deamination of lysine residues and is correlated to the invasive potential of tumor cells.246 ADM is 
involved in vasodilatation, whereas DDIT4 regulates cell survival and proliferation via the inhibition of 
mTORC1. PFKP is a key regulator of glycolysis. P4HA2 catalyzes the post-translational hydroxylation 
of proline residues, while BNIP3 is a cell death protein which may rather lead to necrosis instead of 
apoptosis.247 PLOD1 and PLOD2 regulate the hydroxylation of lysine residues in procollagens. 
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2.6.4. Identification of HLA class I tumor-associated peptides from cancer-testis antigens 
For the identification of TUMAPs from cancer-testis antigens (CTA) the CT database 
(www.cta.lncc.br/) was utilized. Moreover, the GTEx database (www.gtexportal.org/home/), 
containing RNA-Seq data of a plethora of tissues, was used to verify the cancer-testis specification.  
Six TUMAPs derived from CTAs were presented on at least two ccRCC samples [Table 5]. The CTA 
PRAME (Melanoma antigen preferentially expressed in tumors) gives rise to the TUMAPs 
SLLQHLIGL248 and GQHLHLETF. Additional peptides found in one ccRCC sample were MPMQDIKMIL, 
QLLALLPSL and SPSVSQLSVL. Other antigens with a TUMAP in at least two ccRCC samples were 
IGF2BP3, SYCP1, KDM5B and ODF2. 
Table 5: TUMAPs derived from cancer-testis antigens. HLA restriction, number and frequency of positive samples are 
illustrated for each TUMAP. 
TUMAP Gene HLA 
Found on 
n allotype positive 
ccRCC samples 
Allotype 
positive 
samples 
% of respective 
allotype positive 
samples 
SLLQHLIGL PRAME A*02 5 25 20 
KIQEILTQV IGF2BP3 A*02 3 25 12 
AITTSEQYY SYCP1 A*01 3 18 17 
GQHLHLETF PRAME B*15 3 7 43 
MPVMEQSVL KDM5B B*35 2 14 14 
RDSLVERL ODF2 B*37 2 2 100 
 
2.6.5. Search for frequent tumor mutations 
For the identification of mutated peptides arising from frequently mutated antigens the 600 most 
frequent mutations throughout all tumors contained in the COSMIC (Catalogue of somatic mutations 
in cancer) database were downloaded. The processing of the data including the 600 most frequent 
mutations exhibits no HLA ligand from frequently mutated antigens which is consistent with the low 
mutational burden of ccRCC.172  
2.6.6. Biological involvement of target candidates 
The biological involvements of the 112 antigens were analyzed for general tumor characteristics such 
as enhanced cell proliferation or angiogenesis, as well as for some ccRCC-specific characteristics such 
as hypoxic conditions and distorted lipid and glucose metabolism. For this purpose, the Uniprot 
database was screened with follo i g ke o ds: Respo se to h po ia , Cell p olife atio , 
A gioge esis , Lipid  and Glu ose , to identify those antigens within the 112 targets involved in 
the respective biological process.  
46 
 
Genes induced under hypoxic conditions (see section 2.6.3) are highlighted in magenta [Figure 16]. 
Antigens involved in cell proliferation are transcription factors, such as HSF4, PRAME or CEBPA, 
histone-modifying proteins (SAP30), cell cycle regulators (CCND1) or growth factors (VEGFA, PGF) 
and their regulators (IGFBP3). Antigens involved in blood vessel formation are growth factors 
(VEGFA, PGF) and their receptors (MET) and other regulators, such as ANGPTL4 or extracellular 
matrix components (COL4A2, CSPG4) and modulators (LOXL2). The lipid metabolism involved 
antigens include transporters (SLC17A3, ABCA1), intracellular lipid transporting proteins (FABP7, 
PLIN2), lipid-modifying enzymes (CYP3A5, CYP2J2, LPCAT1), lipid storage proteins (PLIN2, HILPDA), 
homeostasis regulators (ANGPTL4, C3) or transcription factors (CEBPA). The glucose metabolism 
involved antigens include transporters (SLC17A3, C3), transport regulators (TRIB3), enzymes of the 
glucose metabolism (ALDOA, PFKP, ACLY, ACS) or transcription factors (CEBPA). 
Figure 16: Biological involvement of target antigens. Antigens induced in response to hypoxia are highlighted in magenta; 
antigens important for cell proliferation are highlighted in blue; antigens relevant for angiogenesis are indicated in red; 
antigens involved in the lipid metabolism are marked in green and antigens involved in the glucose metabolism are 
indicated in orange. 
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2.6.7. Identification of HLA class I tumor-associated peptides using quantitative analysis 
Quantitative analysis was exerted to identify HLA ligands which are overrepresented in ccRCC. For 
that purpose, 46 ccRCC samples were compared to each other [Supplementary Table 2]. Areas of 
peptides were picked from unfiltered peptide lists (without FDR and rank filter to include peptides 
which might miss the 5% FDR cut-off in a replicate but have been identified with statistical 
significance in another replicate of the same sample). Criterion for the inclusion of a peptide is its 
representation in at least two replicates. In replicates were the peptide is not detected the detection 
limit (area of the lowest detectable peptide) was applied. Only peptides which were predicted to be 
HLA ligands were included. 
In total, 27,768 of 41,488 HLA class I ligands (66.9%) could be integrated into the analysis. The log2 
fold change presentation was calculated for each peptide. 6,145 HLA class I ligands (22.1%) were 
overrepresented in ccRCC with a log2 fold change expression  2 (4-fold overrepresentation) [Figure 
17]. Constraining the dataset to peptides emerging from unique antigens and a presentation 
frequency of n  3, 952 HLA class I ligands from 677 antigens remained [Supplementary Table 6]. 
Figure 17: Quantitative analysis of 46 
adjusted ccRCC and adjacent benign 
tissues. Log2 fold change presentation of 
27,768 HLA class I ligands is plotted. 
 
 
 
 
Overlap analysis of the 677 antigens with overrepresented HLA class I ligands with the 112 antigens 
from comparative and expression-based analysis reveals 59 overlapping antigens [Figure 18, left] and 
58 overlapping HLA class I ligands [Figure 18, right]. An overview of overlapping antigens is illustrated 
in Table 6. 
Figure 18: Overlap of the HLA class I ligand 
source antigens (left) and HLA class I 
ligands (right) from comparative and 
quantitative analysis. Green: comparative 
profiling, blue: quantitative analysis.
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Table 6: Overlap of HLA class I ligands from comparative and quantitative analysis. 
Sequence UniprotID Gene HLA Sequence UniprotID Gene HLA 
ILWREVVTL Q9ULV5 HSF4 A*02 AESQILKHLL P40261 NNMT B*40/B*44 
GSAALYLLR Q9NRX3 NDUFA4L2 A*11/A*68 SPRAAEPVQL Q16790 CA9 B*07 
HPIETLVDIF P15692 VEGFA B*35 DEGKLSITL Q8WUY3 PRUNE2 B*18 
SEINTTHNL Q8WUY3 PRUNE2 B*40/B*44 DEINLHQL Q8WUY3 PRUNE2 B*18 
ALIVSLPYL O00476 SLC17A3 A*02 DPIDEISVIEY Q86TB3 ALPK2 B*35 
MPLGHIMRL Q9H6Z9 EGLN3 B*07/B*35/B*51/B*53 FPWEKPTTL Q86TB3 ALPK2 B*35 
SEAEALARTW Q96HU8 DIRAS2 B*44 GVIIAKKYFFK Q96D42 HAVCR1 A*11 
EIKIKLGI O15539 RGS5 B*08 KIAQKALDL P09601 HMOX1 G*01 
IAYPRAVTL P48029 SLC6A8 C*03/C*12 KIIAPLVTR O00469 PLOD2 A*11 
SVSPVKATQK Q86XJ1 GAS2L3 A*03/A*11 KLLDATHVY O15427 SLC16A3 A*03/A*02/B*15 
VEKVVLVSL P01024 C3 B*40/B*41 MPVDERDLQA P55042 RRAD B*35 
AELPIFPQL P78415 IRX3 B*40/B*41 RTVPPAVTGITF P04075 ALDOA B*57/B*58 
FPIDKPPSF P51805 PLXNA3 B*35/B*53 SEEEASINL P04075 ALDOA B*40 
IAFSATRTI P02746 C1QB B*51 SLLHLGALY O00767 SCD A*29 
RPAPADSAL Q969F8 KISS1R B*07/B*35 SPSPGKDPTL Q9ULV5 HSF4 B*35 
TPHDFIEHF P24385 CCND1 B*35/B*53 TESETRILL P01024 C3 B*40/B*44 
AEKELVQSL O15460 P4HA2 B*40/B*41/B*44 TSSKGQLQK Q99541 PLIN2 A*03 
LLAASVALA P47972 NPTX2 A*02 DQYKFLAV Q9NRX3 NDUFA4L2 B*08 
REVTVDTTL P51589 CYP2J2 B*40 AEVGDTIRVTF P00450 CP B*44 
ALFEGVVRQI P55042 RRAD A*02 DEISIAQSL A6NI28 ARHGAP42 B*18 
FPTEQINEI Q8N142 ADSSL1 B*35/B*51/B*53 GASLGARFY Q9NRX3 NDUFA4L2 C*16 
GAVTGSVEK Q99541 PLIN2 A*11 GIASSSIAAK P40305 IFI27 A*03/A*11 
HALMEKDSL O15539 RGS5 C*03/C*12 IQDAQDKLYL Q99541 PLIN2 B*38 
ILLQKPDSV O15539 RGS5 A*02 SELLVEQY Q99541 PLIN2 B*18 
IPVNEKDTL O75446 SAP30 B*35 SHVAPTETF P00450 CP B*38 
KLLQNNYGL O15539 RGS5 A*02 THEEVINLI Q9Y6N9 USH1C B*38 
SINTVLGSR Q99541 PLIN2 A*03 VPPVFVSVY Q12791 KCNMA1 B*35 
TTLRWALLY P51589 CYP2J2 A*29/A*26 VPPVFVVSY O15427 SLC16A3 B*35 
YPSEVEHMF P49763 PGF B*35 WPDWALPRL Q9UJY1 HSPB8 B*07/B*35 
WPDWALPRL Q9UJY1 HSPB8 B*07/B*35     
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2.6.8. Identification of HLA class II tumor-associated peptides using comparative profiling 
Comparative profiling of HLA class II presented peptides from 52 ccRCC and corresponding adjacent 
benign tissue was employed to identify tumor-exclusive peptides (see section 2.6.1). Due to lack of 
an appropriate tool, HLA binding prediction was not exerted. A large in-house database of 123 benign 
tissues containing 94,896 HLA class II presented peptides was included to ascertain tumor-exclusivity 
of TUMAPs [Figure 19]. 
Figure 19: Comparative profiling of 52 ccRCC vs. corresponding adjacent benign tissues and 123 benign tissues. The 
frequency of HLA ligands in the tumor is illustrated in red (positive y-axis) and for the benign tissue in green (negative 
x-axis).  Each bar represents one HLA class II ligand. 
Overall, 917 TUMAPs could be identified which were presented in at least two ccRCC samples. 
Constraining the dataset to peptides originating from unique antigens and a representation 
frequency of n  3, 213 peptides from 135 antigens remained [Supplementary Table 7]. However, 
due to the limited HLA restriction of peptides as well as the limitations in predicting the HLA 
restriction of a peptide a high representation frequency is essential to increase the population 
coverage. With a representation frequency of n  5 (about 10% of all ccRCC) 30 peptides from 25 
antigens remained [Figure 20]. 
Figure 20: Antigens with at least one frequent TUMAP 
(n ≥ 5). The size of the letters is proportional to the 
frequency of the top TUMAP of the respective antigen. 
Range: The letters of the most frequent antigen PXDN have 
a size of 11, whereas the letters from several antigens with 
a frequency of their top TUMAP of n = 5 have a size of 5. 
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108 4 21 
Overlap analysis of the top 25 HLA class II antigens with HLA class I antigens revealed four antigens, 
NDUFA4L2, ENPP3, IGFBP3 and VCAM1, which present peptides on both HLA class I and HLA class II 
molecules [Figure 21]. Extending the HLA class II antigen list to the top 135 (antigens with TUMAPs 
with a representation frequency of n  3), 7 additional antigens were overlapping: NPTX2, C3, 
DNAH11, PLIN2, FGG, COL6A2 and COL4A2. 
Figure 21: Overlap of HLA class I and HLA class II pathways. Green: 
HLA class I antigens, blue: HLA class II antigens. Four antigens provide 
ligands to both the class I and class II pathways. 
 
 
 
 
2.6.9. Immunogenicity screening of selected HLA class I ligands 
The immunological recognition of peptides was addressed by priming of CD8+ T cells of healthy 
donors with pHLA complexes and costimulatory CD28 prior coated onto microspheres.249,250 Outcome 
of CD8+ T cell priming was read out by tetramer staining. HLA class I ligands in immunogenicity 
screens covered the HLA allotypes HLA-A*02, HLA-B*07, HLA-B*08, HLA-B*15, HLA-B*40 and 
HLA-B*44. Except for HLA-B*40 (refolding), all monomers were generated by UV exchange.  
The success of UV-mediated peptide exchange was assessed by staining of monomers coated onto 
microspheres with the mAbs W6/32, HC10, HCA2 and GAP-A3 (control). Misfolded pHLA complexes 
can be detected by the mAbs HC10 and HCA2 which bind to linear structures usually not accessible in 
properly folded monomers. No staining with HCA2 and HC10 could be detected for all UV-exchanged 
monomers, but for monomers with UV-labile peptide exposed to UV without exchanging peptide 
[Supplementary Figure 1]. Some staining with HCA2 and HC10 was detected for the 
HLA-B*08/DQYKFLAV monomer. HLA-B*44 staining with HCA2 was detectable for some monomers. 
However, no staining with HC10 was detectable. Except for HLA-A*02, the mAb HC10 achieved 
higher fluorescence staining compared to HCA2 in the UV-sensitive monomer exposed to UV light. 
Still, HC10 staining of HLA-A*02 was substantial. Therefore, HC10 seems to be more appropriate for 
the quality control of UV-exchanged monomers. 
An overview of tested HLA class I ligands, their HLA restriction and the identification strategy is 
illustrated in Table 7. 
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Overall, 26 HLA class I ligands were screened for their recognition by CD8+ T cells. 19 of 26 HLA 
ligands (73%) were tested positive [Figure 22]. 3 of 26 HLA ligands displayed tetramer-positive 
populations, but as well exhibited positive populations in tetramer staining with the UV-sensitive 
tetramer. The populations of tetramer-positive cells ranged from 0.1% for YVKERSKAM (EGLN3, 
B*08) to 6.8% for KIQEILTQV (IGF2BP3, A*02). Furthermore, the amount of positive wells ranged 
from one to 18 (SQILKHLL, NNMT, B*08) out of 20 wells tested for one donor. 
To access the functionality of the cells ICS was performed for 9 of the 19 HLA ligands tested positive. 
After KIQEILTQV and VLITGLPLI (CYP2J2, A*02) stimulation CD8+ T cells displayed functionality 
producing IFN-γ a d TNF-α [Figure 23]. ILWREVVTL (HSF4, A*02), KLLDEVTYL (CYP2J2, A*02) and 
MPLGHIMRL (EGLN3, B*07) stimulated CD8+ T cells displayed IFN-γ a d TNF-α p odu tio  but the 
production was not significantly higher than the negative control. 
To exclude memory T cell responses towards the peptides a recall IFN-γ ELI“pot as pe fo ed afte  
a 12 day stimulation of donor PBMCs. No IFN-γ se etio  as dete ta le fo  all peptides [Figure 24]. 
However, memory T cells might recognize the peptide without IFN-γ se etio . The efo e, stimulated 
cells were additionally read out by tetramer staining. CD8+ T cells displayed no binding to tetramers 
(not shown). In conclusion, the positive priming results of each of the 19 peptides could be confirmed 
by negative ELISpot and tetramer staining experiments after 12 day stimulation of respective PBMCs. 
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Table 7: Immunogenicity analysis of selected HLA class I ligands. Strategy for HLA ligand selection: Qual = Comparative profiling, Quan = Quantitative analysis, CTA = cancer-testis antigen, 
Qual_Antigen = HLA ligands from selected antigens from comparative profiling which do not fulfill all criteria. Positive tested HLA ligands are marked in green, ambiguous results are marked in 
orange, negative tested HLA ligands are marked in red. ICS =intracellular cytokine staining. *Ambiguous results in tetramer staining with peptide of interest and UV-sensitive peptide. N.s. = not 
significant, n.t = not tested, + = positive, - = negative. 
Sequence 
Source 
Protein 
HLA 
Identification 
strategy 
Priming 
[Positive/Total] 
Donor 
Wells 
[Positve/Total] 
Largest Tetramer
+
 
population [%] 
ICS 
ILWREVVTL HSF4 A*02 Qual/Quan 1/1 J263 10/16 4.51 n.s. 
FLLSLIDRL EGLN3 A*02 Qual 1/2 J263/J267 2/36 0.11 n.t. 
KLLDEVTYL CYP2J2 A*02 Qual 0/1 J263 1/20* 0.72 n.s. 
ALIVSLPYL SLC17A3 A*02 Qual/Quan 1/1 J263 3/14 1.99 - 
LLAASVALA NPTX2 A*02 Qual/Quan 0/1 J265 0/20 0 n.t. 
KIQEILTQV IGF2BP3 A*02 Qual/CTA 1/1 J263 1/11 6.76 + 
VLITGLPLI CYP2J2 A*02 Qual_Antigen 1/1 J263 3/20 1.4 + 
RPPNNEKLSL CYP2J2 B*07 Qual_Antigen 1/1 J262 2/20 0.1 - 
VPREVTVDTTL CYP2J2 B*07 Qual_Antigen 1/1 J262 3/20 0.37 - 
MPLGHIMRL EGLN3 B*07/B*08/B*35/B*51/B*53 Qual/Quan 1/1 J262 9/20 0.61 n.s. 
EAKKKFRNL EGLN3 B*08 Qual_Antigen 1/2 J265/J269 3/40 0.13 n.t. 
YVKERSKAM EGLN3 B*08 Qual_Antigen 1/2 J265/J269 2/40 0.1 n.t. 
DQYKFLAV NDUFA4L2 B*08 Qual/Quan 0/2 J265/J269 0/20 0 n.t. 
SQILKHLL NNMT B*08 Qual 1/1 J265 18/20 0.49 - 
AQNSRIQQLF ANGPTL4 B*15 Qual 1/1 J268 5/20 0.75 n.t. 
RSFAGNLNTY PFKP B*15 Qual 0/1 J268 0/20 0 n.t. 
AQNSRIQQL ANGPTL4 B*15 Qual 1/1 J268 3/20 1.19 n.t. 
SLIDRLVLY EGLN3 B*15 Qual 1/1 J268 1/20 0.48 n.t. 
VQPSYATRY EGLN3 B*15 Qual 0/1 J268 0/20 0 n.t. 
GQHLHLETF PRAME B*15 Qual/CTA 1/1 J268 5/20 0.19 n.t. 
REVTVDTTL CYP2J2 B*40 Qual/Quan 1/1 J267 3/20 1.8 n.t. 
AEKELVQSL P4HA2 B*40/B*41/B*44 Qual/Quan 0/1 J267 1/20* 0.08 n.t. 
AESQILKHLL NNMT B*40/B*44 Qual/Quan 1/1 J267 2/20 0.41 n.t. 
TETTSTTLRW CYP2J2 B*44 Qual_Antigen 1/1 J267 1/20 1.34 n.t. 
AEVLPQHKF ACAD11 B*44 Qual 1/1 J267 3/20 0.46 n.t. 
AEAALSHSY CDK18 B*44/B*18 Qual 0/1 J267 1/20* 0.04 n.t. 
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Figure 22: Tetramer staining (beginning, page 1/5)
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Figure 22: Tetramer staining (continued, page 2/5)
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Figure 22: Tetramer staining (continued, page 3/5)
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Figure 22: Tetramer staining (continued, page 4/5)
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Figure 22: Tetramer staining. A) Gating strategy. Cells were gated for single and viable cells (Aqua Live/Dead staining), B) 
Tetramer staining of primed CD8
+
 T cells. 700,000 events were measured. Negative control: Tetramer staining of CD8
+
 T 
cells primed with a different tetramer. UV peptide: Positive wells were additionally stained with the tetramer comprising 
the respective UV-sensitive peptide used for UV-exchange. 
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Figure 23: Intracellular cytokine staining. A) Gating strategy and example for positive control. Cells were gated for single 
and viable cells (Aqua Live/Dead staining), B) IFN-γ a d TNF-α p odu tio  of p i ed CD + T cells. 700,000 events were 
measured. 
 
 
 
FSC-A FSC-A FSC-A TNF-α 
S
S
C
-A
 
F
S
C
-H
 
L
iv
e
/D
e
a
d
 
IF
N
-γ
 
A 
B 
IF
N
-γ
 
TNF-α 
Negative control Peptide Negative control Peptide 
YLLPAIVHI 
DDX5 
ILWREVVTL 
HSF4 
YLLPAIVHI 
DDX5 
VLITGLPLI 
CYP2J2 
YLLPAIVHI 
DDX5 
KLLDEVTYL 
CYP2J2 
YLLPAIVHI 
DDX5 
KIQEILTQV 
CYP2J2 
TPGPGVRYPL 
HIV-1 nef 
MPLGHIMRL 
EGLN3 
59 
 
  Figure 24: Recall ELISpot. PBMCs of healthy donors (same donors as for priming experiments) were stimulated for 12 days 
with peptides tested positive in respective priming experiments to exclude memory responses. 500,000 cells/well were 
stained. Irrelevant peptide for J262-J268 was YLLPAIVHI (A*02, DDX5), for J269 GSEELRSLY (A*01, POL_HV1H2). A mix of 
immunogenic viral HLA-A*02 peptides from Epstein-Barr virus (EBV) and cytomegalovirus (CMV) were used as positive 
control for J262-J268, for J269 a HLA-A*01 mix was employed. Additionally, PHA was employed as positive control. 
Numbers corresponds to spot count. Positive wells are marked with an asterisk. TNTC = too numerous to count. 
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2.7. Discussion 
The immunogenic property of ccRCC is substantiated by sporadic responses in IL-2- or IFN-α-treated 
patients as well as beneficial effects demonstrated for nivolumab. These non-specific approaches 
reveal the potential of immunotherapy of ccRCC. On the other side, application of targeted therapies 
with tyrosine kinase inhibitors, mTOR inhibitors and bevacizumab are limited due to frequently 
occurring resistance to these drugs.125 Specific immunotherapeutic approaches, like peptide 
vaccination or ACT, hold the potential to enhance and specify responses in patients. To that end, the 
identification of suitable T-cell epitopes is of major importance. 
To address the identification of T-cell epitopes several methods are feasible and were employed in 
this part of the thesis. The main analysis was the comparative profiling of the naturally presented 
HLA ligandome of tumors compared to the benign counterpart which is an appropriate procedure to 
identify candidate targets. Compared to other approaches which include the in silico prediction of 
HLA ligands from tumor-associated antigens described in the literature or identified by gene 
expression analysis, exome sequencing or other approaches, the HLA ligandome analysis directly 
focuses on the presented immunopeptidome.111,251 This includes the consideration of antigen 
processing which processes in antigen and peptide selection are thus far not well dissolved and 
cannot be predicted. Hence, in the immunopeptidomics approach peptides can be selected which are 
known to be presented by the tumor.  
The comprehensive analysis in this project focuses on the main subtype of RCC. The restriction to 
ccRCC is an important approach to define the immunopeptidome of this subtype, since different 
subtypes of RCC are characterized by different cellular aberrations leading to individual HLA 
ligandomes. 
Comparative profiling of HLA ligandomes is the major step in the selection of TUMAPs considering 
their tumor-exclusive presentation. Here, a cohort of 58 and 52 ccRCC and corresponding adjacent 
benign sample pairs were analyzed for HLA class I and HLA class II, respectively. The integration of an 
in-house database comprising 158 and 123 benign samples for HLA class I and HLA class II, 
respectively, provides crucial information of the immunopeptidomes of several other benign organs. 
In total, 1591 and 917 TUMAPs for HLA class I and HLA class II, respectively, could be identified which 
were presented in at least two ccRCC samples. The benign database acts as an important 
determinant for this preselection. However, some organs and less frequent HLA alleles lack with the 
risk of some remaining false TUMAPs. On the other hand, the comprehensive ccRCC cohort is 
appropriate for the identification of TUMAPs since HLA allotypes, especially for more common 
allotypes, are covered by several samples. Nevertheless, it is important to mention that this is a 
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preselection approach to identify targets which have to be further validated in immunogenicity 
screens. 
The peptide yields display high variances which are mainly caused by three factors. The first factor is 
the weight of the tissue. Correlation of tissue weight with peptide yields exhibits a linear correlation 
up to the weight of about 0.8 to 1 g (not shown). The second factor is the improvement of sample 
processing in the course of time. The main improvement was the additional application of 
acetonitrile for washing of the filter units. In that way, peptide yields and peptide concentration 
(which correlates to the area under the curve in the survey scan summation of the respective 
identified peptide) could be tremendously improved.252 In turn, sample sizes could be diminished. 
Third, five samples were measured on the Orbitrap Fusion Lumos which exhibits a 5-fold increase in 
peptide yields for HLA class II [Figure 13]. Peptide yields from JY cells exhibit a 4-fold increase for HLA 
class I ligands in the Orbitrap Fusion Lumos compared to the LTQ Orbitrap XL (not shown).  
The differences in sample purity might be caused by the composition of the sample, for example 
necrotic areas, blood vessel or fat tissue amounts. This leads to increased amounts of soluble 
peptides (e.g. from necrotic cells) and proteins (e.g. structure proteins, histones and ribosomes from 
necrotic cells or hemoglobin and albumin from the blood stream) which might unspecifically bind to 
the column. 
After the identification of TUMAPs by comparative profiling, the choice of the most promising 
candidates can be further addressed by several approaches. Here, approaches focusing on the HLA 
ligandome as well as the HLA ligand source antigens were applied. For HLA ligand selection the 
frequency of ligand presentation, the HLA restriction and the quantitative presentation were 
implemented. The selection of frequent HLA ligands is advantageous for the construction of a 
warehouse for an off-the-shelf approach.163,231 Furthermore, the focus on frequent HLA alleles is 
important to cover the majority of the population. The quantitative analysis provides additional 
information of the overrepresentation of an antigen. This is relevant since sample sizes were not 
adjusted prior to immunoaffinity purification subsequently leading to varying peptide amounts and 
varying concentrations when diluting to the same volume. For quantitative analysis only adjusted 
sample pairs (sample volumes were adjusted on the basis of the total area of identifications in the 
dose fi di g  u s  were used, whereas the comparative analysis comprises all samples including 
dose finding  runs for subsequent sample adjustment and samples which were not adjusted. 
Further analysis of the HLA ligand source antigens using gene expression and cancer-testis 
association databases as well as literature search were used to select the most promising candidates.  
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Overlap analysis of comparative and quantitative analysis reveals 59 overlapping antigens with 58 
overlapping HLA class I ligands [Figure 18]. The lower number of overlapping HLA class I ligands can 
be explained by the different focus of both methods. While comparative profiling focuses on all 
TUMAPs, the quantitative analysis does not consider TUMAPs which are only detected in one 
replicate. 
Gene expression data from the TCGA database were included to search for antigens which are 
overexpressed in ccRCC compared to benign kidneys. Overexpressed antigens may have a 
considerable role in pathogenesis or are induced by cellular or microenvironmental aberrations. 
Targeting antigens with relevant functions in the tumor hold the promise for more effective 
therapies. Gene expression in other organs was not considered. However, gene expression and HLA 
ligand presentation were shown to be not correlated.253 The integration of HLA ligandomes of several 
organs gives the essential information of HLA ligand presentation on these organs. 
The adaption to hypoxia is one of the characteristic features of ccRCC following VHL mutation and is 
involved in tumor development. Disrupting the adaption to hypoxia is already considered as target 
therapy for ccRCC.254 On the other side, genes induced via this commonly altered pathway may serve 
as suitable targets. Here, 12 hypoxia-induced antigens could be identified with enhanced gene 
expression and frequently presented TUMAPs. 
Further targets are CTAs and mutated antigens which are not expressed in normal tissue. Six TUMAPs 
from five CTAs were identified which were at least presented on two ccRCC samples [Table 5]. On the 
other hand, no mutated peptide could be found by searching for the 600 most frequent mutations 
throughout all tumors, which is consistent with the low mutational burden of ccRCC.172 However, the 
search was limited to the top 600 mutations, certainly missing some less frequent and ccRCC specific 
mutations. For the construction of a warehouse the search for infrequent and patient specific 
mutations is anyway inappropriate and the search for them should be only considered for 
personalized therapies. 
Overall, a set of 26 HLA class I ligands from six HLA allotypes were chosen for the immunogenicity 
screening with 19 HLA ligands tested positive [Table 7]. 
Priming of CD8+ T cells from healthy donors was applied to investigate the recognition ability of naïve 
T cells. This approach has several advantages compared to the ex vivo or short-term cytokine-
stimulated screening for memory T cells in PBMCs or TILs of the corresponding patient. First of all, 
the limited availability of autologous blood samples or fresh tissue for TIL isolation is restricting the 
feasibility of this approach. The second limitation is the difficulty to detect memory T cells against 
tumor antigens due to the immunosuppressive microenvironment which leads to anergic T cells.  
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For the quality control of pHLA complexes required for priming experiments, UV-exchanged 
monomers were validated by staining with antibodies recognizing epitopes in misfolded HLA 
molecules. This method was suited for all tested HLA allotypes although the applicability of this 
method was so far only shown for HLA-A*02, HLA-B*07 and HLA-B*08.229 Only for HLA-B*44 the 
applicability of the HCA2 ab might be inappropriate. Indications are the low binding capability to the 
UV-treated monomer without exchanging peptide and the inconsistent results of the UV-exchanged 
monomers compared to the corresponding staining with HC10 [Supplementary Figure 1]. The 
staining of the monomer exchanged with the DQYKFLAV peptide displayed binding of both HC10 and 
HCA2 abs implying an unsuccessful exchange. This could be the reason for the unsuccessful priming 
for this pHLA complex [Table 7]. Furthermore, only NetMHCpan-3.0 rank defines DQYKFLAV as 
HLA-B*08 ligand (NetMHC rank: 2, NetMHC affinity: 1623 nm, SYFPEITHI: 0%). 
The high frequency of peptides tested positive displays the suitability of the applied strategies in the 
selection of peptides. Interestingly, the source antigens of most of the immunogenic peptides are not 
tumor-exclusive, neither on the RNA level nor on the immunopeptidome. One example is the highly 
on liver tissue expressed antigen NNMT. Several peptides from NNMT are presented on HLA 
molecules in benign livers. However, the HLA ligands AESQILKHLL and SQILKHLL are presented tumor-
exclusive and display high immunogenicity with 2 of 20 and 18 of 20 positive tested wells, 
respectively [Table 7].  
6 of 7 negative HLA ligands were tested once. Further testing is needed to ascertain their 
immunogenicity. Three HLA ligands tested negative displayed a positive population, but tetramer 
staining with the corresponding UV-labile pHLA complex used for exchange displayed positive 
populations, too. Therefore, these peptides have to be retested. For HLA-B*15, tetramers with 
UV-sensitive peptide exposed a banana-like shift in the tetramer staining [Figure 22] indicating 
misfolded and unspecifically binding tetramers. The repetition of the tetramerization procedure and 
a subsequent tetramer staining displayed the same results indicating the instability of the monomer 
itself. For that reason and the fact that no distinct population was detected, these controls were not 
considered. 
ICS was performed for wells with primed CD8+ T cells. Except for KIQEILTQV (IGF2BP3, A*02) and 
VLITGLPLI (CYP2J2, A*02) stimulation, cells displayed no functionality. A reason could be the 
exhaustion of the cells after four rounds of priming and IL-2 stimulation over a time course of five 
weeks. For that matter, ICS results may not reflect the functionality of the cells. A prolonged 
cultivation of the cells without IL-2 may have settled a probable over reactivity. However, the 
successful priming of CD8+ T cells displays the immunogenicity of these targets. 
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The ability of the peptides to prime CD8+ T cells was confirmed by ELISpot and tetramer staining 
experiments after a 12 day stimulation of memory T cells. Neither recognition of the pHLA complex in 
terms of positive tetramer staining, nor functionality in terms of IFN-γ se etio  as dete ta le. 
Some spots were detected for the HLA-B*44 UV-sensitive peptide. However, this can be explained by 
carry over from the wells of the positive peptide mix to the wells of the UV-sensitive peptide which 
were directly located below. 
HLA class II TUMAPs are potential targets for a CD4+ T cell activation which may support CD8+ T cells. 
Another option is the use of elongated, immunogenic HLA class I ligands which have to be processed 
by APCs and might additionally be presented on HLA class II molecules. Due to the unfeasibility to 
test peptides in the context of HLA class II in priming experiments (refolding of pHLA class II 
complexes are challenging) as well as the lack of patient blood or TILs for ex vivo stimulation of 
memory T cells, HLA class II TUMAPs were not tested. 
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2.9. Supplementary data 
Supplementary Table 1: RCC patient cohort and HLA typing 
Samples HLA class I HLA class II 
RCC137 A*32:01; B*35:02; C*04:01 DRB1*11:04; DQA1*05:05; DQB1*03:01 
RCC160 A*01:01; A*03:01; B*27:05; B*35:01; C*02:02; C*04:01 DRB1*01:01; DRB1*04:01; DQB1*03:02; DQB1*05:01 
RCC168 A*01:01; A*26:01; B*15:17; B*38:01; C*07:01; C*12:03 DRB1*14:33; DRB1*16:02; DQB1*05:02; DQB1*06:03 
RCC171 A*01:01; B*08:01; C*07:01 DRB1*03:01; DQA1*05:01; DQB1*02:01 
RCC203 A*01:01; B*08:01; C*07:01 DRB1*03:01; DQA1*05:01; DQB1*02:01 
RCC224 A*03:01; B*38:01; C*12:03 DRB1*13:01; DQB1*06:03 
RCC225 A*01:01; A*02:01; B*35:02; B*40:01; C*03:04; C*04:01 DRB1*03:01; DRB1*09:01; DQB1*02:01; DQB1*03:03 
RCC243 A*02:01; A*11:01; B*44:02; C*05:01 DRB1*07:01; DRB1*12:01; DQA1*02:01; DQA1*05:05; DQB1*02:02; DQB1*03:01 
RCC245 A*24:01; B*37:01; B*44:03; C*06:02; C*16:01 DRB1*08:01; DQA1*04:02; DQB1*04:02 
RCC246 
A*26:01:01; A*29:02:01:01; B*07:02:01; B*44:03:01; 
C*07:02:01:03; C*16:01:01 
DRB1*07:01:01:01; DRB1*08:01:01; DQB1*02:02:01; DQB1*04:02:01 
RCC247 A*11; A*30; B*13; B*15 DRB1*01; DRB1*07; DRB4 
RCC296 A*03:01; A*24:02; B*35:03; B*55:01; C*07:02; C*12:03 DRB1*04:07; DRB1*04:08; DQA1*03:02; DQB1*03:01; DQB1*03:04 
RCC301 
A*23:01:01; A*33:01:01; B*14:02:01; B*44:03:01; 
C*04:01:01:01; C*08:02:01 
- 
RCC302 A*03; A*32; B*07; B*15 DRB1*04; DRB1*11; DRB3; DRB4 
RCC318 
A*02:01:01:01; A*24:02:01:01; B*08:01:01; B*51:01:01; 
C*02:02:02; C*07:01:01:01 
- 
RCC345 A*03:01; A*30:02; B*35:01; B*58:01; C*04:01; C*07:01 DRB1*01:01; DRB1*13:02; DQA1*01:01; DQA1*01:02; DQB1*05:01; DQB1*06:04 
RCC432 A*11:01; A*31:01; B*35:01; B*44:02; C*04:01; C*05:01 DRB1*01:01; DRB1*11:04; DQB1*03:01; DQB1*05:01 
RCC433 
A*02:01:01:01; B*07:02:01; B*44:02:01:01; 
C*07:02:01:03; C*05:01:01:02 
DRB1*04:01:01; DRB1*15:01:01:01 
RCC440 A*02:01; B*27:05; B*44:02; C*01:02; C*05:01 DRB1*01:03; DRB1*15:01; DQA1*01:01; DQA1*01:02; DQB1*05:01; DQB1*06:02 
RCC449 A*03:01; A*30:02; B*35:01; B*50:01; C*04:01 DRB1*03:01; DRB1*13:03; DQB1*02:01; DQB1*03:01 
RCC451 
A*24:02:01:01; A*31:01:02; B*07:02:01; B*40:01:02; 
C*07:02:01:03; C*03:04:01:01 
DRB1*03:01:01:01; DRB1*15:01:01:01; DQB1*02:01:01; DQB1*06:02:01 
RCC455 A*11:01; A*29:02; B*27:02; B*44:03; C*02:02; C*16:01 DRB1*07:01; DRB1*16:01; DQB1*02:02; DQB1*05:02 
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Supplementary Table 1 (continued) 
Samples HLA class I HLA class II 
RCC456 A*01:01; A*02:01; B*08:01; B*52:01; C*02:02; C*07:01 DRB1*15:02; DRB1*16:01; DQB1*05:02; DQB1*06:01 
RCC467 
A*01:01:01:01; A*02:01:01:01; B*18:01:01:02; 
B*37:01:01; C*06:02:01:01; C*07:01:01:01 
DRB1*11:04:01; DRB1*13:02:01; DQB1*03:01:01:02; DQB1*06:04:01 
RCC476 
A*02:01:01:01; A*31:01:02; B*35:03:01; B*40:01:01; 
C*02:02:02; C*03:04:01:01 
DRB1*11:02:01; DRB1*13:02:01; DRB3*02:02:01; DRB3*03:01:01; 
DQA1*01:02:01; DQA1*05:01:01; DQB1*03:19; DQB1*06:04:01; DPB1*04:01:01; 
DPB1*14:01 
RCC792 A*02; A*03; B*15; B*27 - 
RCC986 A*01:01; A*26:01; B*49:01; B*58:01; C*07:01 DRB1*01:01; DRB1*08:04; DQA1*01:01; DQA1*04:01; DQB1*04:02; DQB1*05:01 
RCC990 A*02:01; B*27:05; B*55:01; C*02:02; C*03:03 DRB1*04:01; DRB1*14:01; DQA1*01:01; DQA1*03:01; DQB1*03:02; DQB1*05:03 
RCC1005 A*02:01; B*51:01; B*57:01; C*06:02; C*15:02 DRB1*07:01; DRB1*13:01; DQA1*01:03; DQA1*02:01; DQB1*03:03; DQB1*06:03 
RCC1056 A*02:01; A*31:01; B*44:02; B*44:03; C*05:01; C*07:02 DRB1*07:01; DRB1*11:03; DQA1*02:01; DQA1*05:05; DQB1*02:02; DQB1*03:01 
RCC1060 A*03:01; B*13:02; B*51:01; C*01:02; C*06:02 DRB1*01:01; DRB1*07:01; DQA1*01:01; DQA1*02:01; DQB1*02:02; DQB1*05:01 
RCC1083 A*01:01; A*68:02; B*08:01; B*53:01; C*07:01; C*04:01 DRB1*03:01; DRB1*13:02; DQB1*02:01; DQB1*06:04; DQA1*01:02; DQA1*05:01 
RCC1086 A*01:01; A*03:01; B*07:02; B*08:01; C*07:02; C*07:01 DRB1*03:01; DRB1*15:01; DQB1*02:01; DQB1*06:02; DQA1*01:02; DQA1*05:01 
RCC1117 A*02:01; B*07:02; B*15:01; C*03:04; C*07:02 DRB1*13:01; DRB1*15:01; DQA1*01:01; DQA1*01:03; DQB1*06:02; DQB1*06:03 
RCC1148 
A*01:01:01:01; A*11:01:01; B*07:02:01; B*44:03:01; 
C*07:02:01:01; C*16:01:01 
DRB1*07:01:01:01; DRB1*13:02:01; DRB3*03:01:01; DRB4*01:01:01:01; 
DQB1*02:10; DQB1*06:04:01; DQA1*01:02:01; DQA1*02:01; DPB1*03:01:01; 
DPB1*11:01:01 
RCC1152 
A*29:01:01:01; A*25:01; B*44:02:01:01; B*07:05:01; 
C*05:01:01:01; C*15:05:01  
DRB1*04:01:01; DRB1*11:01:01; DRB3*02:02:01; DRB4*01:01:01:01; 
DQB1*03:02:01; DQB1*03:01:01; DQA1*05:01:01; DQA1*03:01:01; DPB1*04:01:01; 
DPB1*04:02 
RCC1154 
A*01:01:01:01; A*02:01:01:01 B*08:01:01; B*27:05:02; 
C*07:01:01; C*02:02:02 
DRB1*03:01:01:01; DRB1*01:01; DRB3*01:01:02:01; DQB1*02:01:01; 
DQB1*05:01:01; DQA1*05:01:01; DQA1*01:01:01; DPB1*03:01:01; DPB1*04:02 
RCC1157 A*02:01; A*24:02; B*07:02; B*51:01; C*02:02; C*07:02 DRB1*11:01; DRB1*15:01; DQA1*01:01; DQA1*05:05; DQB1*03:01; DQB1*06:02 
RCC1170 
A*24:02:01:01; A*68:02:01:01; B*35:02:01; B*53:01:01; 
C*04:01:01:01 
DRB1*13:02:01; DRB1*11:04:01; DRB3*03:01:01; DRB3*02:02:01; DQB1*03:01:01; 
DQB1*06:04:01; DQA1*01:02:01; DQA1*05:01:01; DPB1*04:01:01 
RCC1187 
 
A*24:02:01:01; A*68:01:02; B*51:01:01; B*18:01:01; 
C*07:01:01; C*14:02:01 
 
DRB1*13:01:01; DRB1*07:01:01:01; DRB3*01:01:02:01; DRB4*01:01:01:01; 
DQB1*02:02; DQB1*06:03:01; DQA1*01:03; DQA1*02:01; DPB1*02:01:02; 
DPB1*04:02 
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Supplementary Table 1 (continued) 
Samples HLA class I HLA class II 
RCC1188 
A*24:02:01:01; A*11:01:01; B*14:07N; B*18:01:01; 
C*07:01:01; C*08:02:01 
DRB1*11:01:01; DRB1*07:01:01:01; DRB3*02:02:01; DRB4*01:01:01:01; 
DQB1*02:02; DQB1*03:01:01; DQA1*05:01:01; DQA1*02:01; DPB1*03:01:01; 
DPB1*04:01:01 
RCC1192 
A*03:01:01:01; A*11:01:01; B*08:01:01; B*51:01:01; 
C*07:01:01; C*15:02:01 
DRB1*11:01:01; DRB1*03:01:01:01; DRB3*01:01:02:01; DRB3*02:02:01; 
DQB1*02:01:01; DQB1*03:01:01; DQA1*05:01:01; DPB1*02:01:02; DPB1*09:01 
RCC1203 A*02:01; A*68:02; B*40:01; B*53:01; C*04:01; C*03:04 
DRB1*13:02:01; DRB1*13:01:01; DRB3*01:01:02:01; DRB3*03:01:01; 
DQB1*06:04:01; DQB1*06:03:01; DQA1*01:02:01; DQA1*01:03; DPB1*13:01; 
DPB1*04:01:01 
RCC1223 
A*02:01:01:01; B*15:01:01:01; B*39:01:01:01; 
C*12:03:01:01; C*03:03:01 
DRB1*13:01:01; DRB1*01:01:01; DRB3*02:02:01; DQB1*06:03:01; DQB1*05:01:01; 
DQA1*01:01:01; DQA1*01:03; DPB1:04:02; DPB1*03:01:01 
RCC1238 
A*68:01:02; B*44:02:01:01; B*51:01:01; C*07:04:01; 
C*15:02:01 
DRB1*13:01:01; DRB1*01:01:01; DRB3*02:02:01; DQB1*06:03:01; DQB1*05:01:01; 
DQA1*01:02:01; DQA1*01:03; DPB1*06:01; DPB1*02:01:02 
RCC1355 A*03:01; A*11:01; B*08:01; B*18:01; C*07:01 DRB1*03:01; DRB1*13:01; DQA1*01:03; DQA1*05:01; DQB1*02:01; DQB1*06:03 
RCC1369 A*25:01; A*32:01; B*18:01; B*44:02; C*08:02; C*12:04 DRB1*04:01; DRB1*15:01; DQA1*01:02; DQA1*03:02; DQB1*03:02; DQB1*06:02 
RCC1397 A*01:01; A*02:01; B*44:05; B*52:01; C*02:02; C*12:02 DRB1*07:01; DRB1*16:01; DQA1*01:02; DQA1*02:01; DQB1*03:03; DQB1*05:02 
RCC1405 A*24:02; A*29:01; B*07:05; B*35:01; C*02:02; C*15:02 DRB1*11:01; DRB1*14:01; DQA1*01:01; DQA1*05:05; DQB1*03:01; DQB1*05:03 
RCC1409 A*02:01; A*68:01; B*15:01; B*40:01; C*03:03; C*03:04 DRB1*04:01; DRB1*11:03; DQB1*03:02; DQB1*03:01; DQA1*03:01; DQA1*05:05 
RCC1428 A*02:01; A*03:01; B*07:02; B*44:02; C*07:02; C*05:01 DRB1*07:01; DRB1*15:01; DQB1*02:02; DQB1*06:02; DQA1*01:02; DQA1*02:01 
RCC1438 A*02:01; A*24:02; B*39:01; B*51:01; C*02:02 DRB1*01:01; DRB1*07:01; DQB1*05:01; DQB1*03:03; DQA1*01:01; DQA1*02:01 
RCC1444 A*01:01; A*02:01; B*07:02; B*13:02; C*07:02; C*06:02 DRB1*07:01; DRB1*15:01; DQB1*02:02; DQB1*06:02; DQA1*01:02; DQA1*02:01 
RCC1479 A*03:01; A*11:01; B*35:01; B*51:01; C*04:01; C*01:02 DRB1*01:01; DRB1*14:01; DQB1*05:01; DQB1*05:03; DQA1*01:01 
RCC1483 A*01:01; A*24:02; B*40:01; B*57:01; C*03:04; C*06:02 DRB1*04:01; DRB1*07:01; DQA1*02:01; DQA1*03:01; DQB1*03:02; DQB1*03:03 
RCC1491 A*01:01; A*66:01; B*08:01; B*41:02; C*07:01; C*17:03 DRB1*03:01; DRB1*13:03; DQB1*02:01; DQB1*03:01; DQA1*05:01 
RCC1493 A*02:01; B*18:01; B*50:01; C*06:02; C*07:01 DRB1*07:01; DRB1*11:04; DQA1*02:01; DQA1*05:05; DQB1*02:02; DQB1*03:01 
RCC1502 A*01:01; A*26:01; B*08:01; B*38:01; C*07:01; C*12:03 DRB1*03:01; DRB1*14:01; DQA1*01:01; DQA1*05:01; DQB1*02:01; DQB1*05:03 
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Supplementary Table 2: HLA class I sample overview. Peptide and ligands yields as well as the sample purity and measuring details are illustrated. 
 
Malignant Benign 
   Samples Peptides Ligands Ligands [%] Peptides Ligands Ligands [%] Mass Spectrometer Search Algorithm Adjusted 
RCC137 2010 1822 90,65 1745 1561 89,46 LTQ Orbitrap XL Mascot Yes 
RCC160 1865 1791 96,03 1409 1329 94,32 LTQ Orbitrap XL Mascot Yes 
RCC168 1919 1798 93,69 1504 1331 88,50 LTQ Orbitrap XL Mascot Yes 
RCC171 2886 2506 86,83 1182 963 81,47 Orbitrap Fusion Lumos SequestHT Yes 
RCC203 1105 987 89,32 501 446 89,02 LTQ Orbitrap XL Mascot Yes 
RCC224 1771 1583 89,38 1257 1048 83,37 LTQ Orbitrap XL Mascot Yes 
RCC225 2474 2347 94,87 49 42 85,71 LTQ Orbitrap XL Mascot No 
RCC243 2134 2030 95,13 1683 1555 92,39 LTQ Orbitrap XL Mascot Yes 
RCC245 849 764 89,99 703 588 83,64 LTQ Orbitrap XL Mascot Yes 
RCC246 1192 961 80,62 1857 1724 92,84 LTQ Orbitrap XL Mascot Yes 
RCC247 1406 1143 81,29 373 298 79,89 LTQ Orbitrap XL Mascot No 
RCC296 1626 1457 89,61 1074 939 87,43 LTQ Orbitrap XL Mascot Yes 
RCC301 2150 1859 86,47 1159 1010 87,14 LTQ Orbitrap XL Mascot No 
RCC302 2027 1730 85,35 559 418 74,78 LTQ Orbitrap XL Mascot No 
RCC318 2145 1721 80,23 195 164 84,10 LTQ Orbitrap XL Mascot No 
RCC345 2498 2246 89,91 2227 1970 88,46 LTQ Orbitrap XL Mascot Yes 
RCC432 1189 1112 93,52 1179 1074 91,09 LTQ Orbitrap XL Mascot Yes 
RCC433 2450 2309 94,24 2255 2137 94,77 LTQ Orbitrap XL Mascot Yes 
RCC440 5191 4934 95,05 3269 2826 86,45 Orbitrap Fusion Lumos SequestHT Yes 
RCC449 2364 2155 91,16 1227 1114 90,79 LTQ Orbitrap XL Mascot Yes 
RCC451 1188 1130 95,12 738 550 74,53 LTQ Orbitrap XL Mascot Yes 
RCC455 1979 1856 93,78 839 750 89,39 LTQ Orbitrap XL Mascot Yes 
RCC456 1681 1536 91,37 233 210 90,13 LTQ Orbitrap XL Mascot No 
RCC467 2074 1991 96,00 881 828 93,98 LTQ Orbitrap XL Mascot Yes 
RCC476 2146 1980 92,26 1408 1076 76,42 LTQ Orbitrap XL Mascot Yes 
RCC792 910 761 83,63 117 99 84,62 LTQ Orbitrap XL Mascot No 
RCC986 1589 1437 90,43 1162 1020 87,78 LTQ Orbitrap XL Mascot Yes 
RCC990 1119 987 88,20 556 442 79,50 LTQ Orbitrap XL Mascot No 
RCC1005 862 813 94,32 533 497 93,25 LTQ Orbitrap XL Mascot No 
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Supplementary Table 2 (continued) 
 Malignant Benign    
Samples Peptides Ligands Ligands [%] Peptides Ligands Ligands [%] Mass Spectrometer Search Algorithm Adjusted 
RCC1056 1880 1763 93,78 1256 1148 91,40 LTQ Orbitrap XL Mascot Yes 
RCC1060 900 778 86,44 998 816 81,76 LTQ Orbitrap XL Mascot Yes 
RCC1083 1264 1129 89,32 307 185 60,26 LTQ Orbitrap XL Mascot No 
RCC1086 1004 879 87,55 829 588 70,93 LTQ Orbitrap XL Mascot Yes 
RCC1117 1346 1237 91,90 1267 1150 90,77 LTQ Orbitrap XL Mascot Yes 
RCC1148 2458 2261 91,99 1761 1638 93,02 LTQ Orbitrap XL Mascot Yes 
RCC1152 3113 2547 81,82 1596 1357 85,03 LTQ Orbitrap XL Mascot Yes 
RCC1154 946 772 81,61 553 474 85,71 LTQ Orbitrap XL Mascot Yes 
RCC1157 1165 1127 96,74 455 431 94,73 LTQ Orbitrap XL Mascot Yes 
RCC1170 2084 1796 86,18 1027 921 89,68 LTQ Orbitrap XL Mascot Yes 
RCC1187 1279 1179 92,18 940 840 89,36 LTQ Orbitrap XL Mascot Yes 
RCC1188 2113 1961 92,81 1302 1203 92,40 LTQ Orbitrap XL Mascot Yes 
RCC1192 1414 1102 77,93 1286 1180 91,76 LTQ Orbitrap XL Mascot Yes 
RCC1203 1382 1237 89,51 777 701 90,22 LTQ Orbitrap XL Mascot Yes 
RCC1223 3507 3147 89,73 608 453 74,51 LTQ Orbitrap XL Mascot Yes 
RCC1238 2073 1897 91,51 1900 1776 93,47 LTQ Orbitrap XL Mascot Yes 
RCC1355 965 906 93,89 717 669 93,31 LTQ Orbitrap XL Mascot Yes 
RCC1369 940 843 89,68 248 228 91,94 LTQ Orbitrap XL Mascot Yes 
RCC1397 705 660 93,62 459 311 67,76 LTQ Orbitrap XL Mascot Yes 
RCC1405 530 512 96,60 322 298 92,55 LTQ Orbitrap XL Mascot Yes 
RCC1409 3906 3600 92,17 2117 1914 90,41 Orbitrap Fusion Lumos SequestHT Yes 
RCC1428 2125 2041 96,05 510 451 88,43 Orbitrap Fusion Lumos SequestHT No 
RCC1438 141 121 85,82 2992 2843 95,02 Orbitrap Fusion Lumos SequestHT No 
RCC1444 1354 1139 84,12 1121 850 75,83 LTQ Orbitrap XL Mascot Yes 
RCC1479 1949 1788 91,74 820 763 93,05 LTQ Orbitrap XL Mascot Yes 
RCC1483 1583 1502 94,88 1402 1254 89,44 LTQ Orbitrap XL Mascot Yes 
RCC1491 1383 1255 90,74 932 810 86,91 LTQ Orbitrap XL Mascot Yes 
RCC1493 1154 1021 88,47 830 747 90,00 LTQ Orbitrap XL Mascot Yes 
RCC1502 1417 1282 90,47 1063 907 85,32 LTQ Orbitrap XL Mascot Yes 
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Supplementary Table 3: HLA class II sample overview. Peptide yields as well as measuring details are illustrated. 
Samples Peptides Malignant Peptides Benign Mass Spectrometer Search Algorithm 
RCC137 1059 1019 LTQ Orbitrap XL Mascot 
RCC160 1165 1138 LTQ Orbitrap XL Mascot 
RCC168 993 785 LTQ Orbitrap XL Mascot 
RCC171 3420 1884 Orbitrap Fusion Lumos SequestHT 
RCC203 1128 382 LTQ Orbitrap XL Mascot 
RCC224 640 444 LTQ Orbitrap XL Mascot 
RCC225 979 485 LTQ Orbitrap XL Mascot 
RCC243 774 1165 LTQ Orbitrap XL Mascot 
RCC245 434 395 LTQ Orbitrap XL Mascot 
RCC246 240 280 LTQ Orbitrap XL Mascot 
RCC247 539 131 LTQ Orbitrap XL Mascot 
RCC296 773 742 LTQ Orbitrap XL Mascot 
RCC302 443 421 LTQ Orbitrap XL Mascot 
RCC345 1344 831 LTQ Orbitrap XL Mascot 
RCC432 474 696 LTQ Orbitrap XL Mascot 
RCC433 905 1030 LTQ Orbitrap XL Mascot 
RCC440 5103 5414 Orbitrap Fusion Lumos SequestHT 
RCC449 1029 594 LTQ Orbitrap XL Mascot 
RCC451 505 361 LTQ Orbitrap XL Mascot 
RCC456 856 458 LTQ Orbitrap XL Mascot 
RCC467 270 468 LTQ Orbitrap XL Mascot 
RCC476 609 463 LTQ Orbitrap XL Mascot 
RCC792 246 291 LTQ Orbitrap XL Mascot 
RCC986 1063 864 LTQ Orbitrap XL Mascot 
RCC990 890 789 LTQ Orbitrap XL Mascot 
RCC1005 503 275 LTQ Orbitrap XL Mascot 
RCC1056 1002 1025 LTQ Orbitrap XL Mascot 
RCC1060 485 879 LTQ Orbitrap XL Mascot 
RCC1083 791 591 LTQ Orbitrap XL Mascot 
RCC1086 516 1281 LTQ Orbitrap XL Mascot 
RCC1117 543 836 LTQ Orbitrap XL Mascot 
RCC1152 1151 641 LTQ Orbitrap XL Mascot 
RCC1157 503 515 LTQ Orbitrap XL Mascot 
RCC1170 490 433 LTQ Orbitrap XL Mascot 
RCC1188 490 274 LTQ Orbitrap XL Mascot 
RCC1192 431 511 LTQ Orbitrap XL Mascot 
RCC1203 727 256 LTQ Orbitrap XL Mascot 
RCC1223 391 432 LTQ Orbitrap XL Mascot 
RCC1238 415 448 LTQ Orbitrap XL Mascot 
RCC1355 605 456 LTQ Orbitrap XL Mascot 
RCC1369 676 478 LTQ Orbitrap XL Mascot 
RCC1397 697 909 LTQ Orbitrap XL Mascot 
RCC1405 425 380 LTQ Orbitrap XL Mascot 
RCC1409 4397 3366 Orbitrap Fusion Lumos SequestHT 
RCC1428 4305 2470 Orbitrap Fusion Lumos SequestHT 
RCC1438 1062 2454 Orbitrap Fusion Lumos SequestHT 
RCC1444 645 742 LTQ Orbitrap XL Mascot 
RCC1479 869 491 LTQ Orbitrap XL Mascot 
RCC1483 372 272 LTQ Orbitrap XL Mascot 
RCC1491 723 788 LTQ Orbitrap XL Mascot 
RCC1493 497 775 LTQ Orbitrap XL Mascot 
RCC1502 603 1199 LTQ Orbitrap XL Mascot 
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Supplementary Table 4: Whole blood donors and HLA typing. Tested HLA alleles are underlined 
 
 
Supplementary Table 5: HLA Class I TUMAPs of selected target candidates can be found in the 
Appendix. 
Supplementary Table 6: HLA Class I candidates from quantitative analysis can be found in the 
Appendix. 
Supplementary Table 7: HLA Class II TUMAPs of selected target candidates can be found in the 
Appendix. 
 
Donor HLA 
J262 A*01, A*02, B*07, B*44 
J263 A*02, A*03, B*15, B*51 
J265 A*01, A*02, B*08, B*41 
J267 A*02, A*29, B*40, B*44 
J268 A*02, A*03, B*15, B*51 
J269 A*01, B*08, B*35 
72 
 
Supplementary Figure 1: Quality control of UV exchanged tetramers. UV-/Pep-: Control, Tetramer with UV-sensitive 
peptide, UV+/Pep-: misfolded control, Tetramer with UV-sensitive peptide exposed to UV light. mAb HC10 and HCA2 bind 
to exposed linear structures of unfolded HLA class I molecules. Values were substracted from background staining with mAb 
GAP-A3. 
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3. Results and discussion, Part II: Unveiling the peptide motifs of HLA-C 
and HLA-G from naturally presented peptides and generation of 
binding prediction matrices 
The following part has been accepted for publication in the Journal of Immunology headed 
Unveiling the peptide motifs of HLA-C and HLA-G from naturally presented peptides and generation 
of binding prediction matrices . Autho s o t i uti g to this o k a e listed elo . All e pe i e ts 
(exceptions are stated in the following lines), data analysis and manuscript writing was performed by 
the author of this thesis. Heiko Schuster did the cell sorting, aided to the draft of the project layout 
and proofread the manuscript. Linus Backert gave bioinformatics support in data analysis and 
proofread the manuscript. Michael Ghosh supported the cell culture and proofread the manuscript.  
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3.1.  Introduction 
The HLA is a polygenic and polymorphic segment on human chromosome 6 which encodes 
histocompatibility antigens including the classical (or class Ia) and non-classical (or class Ib) HLA 
molecules (see section 1.2). HLA-A, HLA-B and HLA-C belong to the classical HLA molecules which 
display a high degree of polymorphism. In contrary, HLA-E and HLA-G are considered non-classical 
HLA molecules showing limited polymorphism [Table 8]. Similar to classical HLA molecules, HLA-E 
and HLA-G a e hete odi e s o sisti g of a hea  α- hai  a d β2m and take part in the peptide 
presentation pathway. HLA-C, -E and -G share the ability to interact with NK cell receptors as well as 
TCRs thereby bridging between innate and adaptive immunity. 
Table 8: Characteristics of classical and non-classical HLA class I molecules. *Physiological expression on fetal derived 
placental cells and immune-privileged organs. Expression is induced in various diseases, such as autoimmune/inflammatory 
diseases, viral infections, transplantation, cancer, as an immune escape mechanism. 
 
HLA-A/B HLA-C HLA-E HLA-G(*01) 
MHC class Ia = classical Ia = classical Ib = non-classical Ib = non-classical 
Polymorphism High High 
Limited 
(non-polymorphic) 
Limited 
(non-polymorphic) 
Ligand Peptide Peptide Peptide Peptide 
Binds β2m? Yes Yes Yes Yes 
Binds TCR? Yes Yes Yes Yes 
Binds NK-cell 
receptors? 
Few Yes Yes Yes 
Immune activity Activating Activating Inhibiting > activating Inhibiting > activating 
Expression In most tissues In most tissues In most tissues 
Tissue-specific 
expression* 
Ligand repertoire High High Low High 
Within the classical HLA molecules, HLA-C plays a special role in the interaction with NK cells. This 
feature manifests itself in the u usuall  o se ed α  do ai 255 which in combination with a 
ge e all  less pol o phi  egio  i  the α  do ai  shape the i di g site of kille  ell 
immunoglobulin-like receptors (KIRs). Compared to HLA-A and HLA-B, HLA-C show a lower expression 
level at the cell surface representing only about 10% of classical HLA molecules. HLA-C allotypes have 
been implicated in many diseases, including viral infections, cancer or autoimmune disorders with 
HLA-C restricted epitopes recognized by either CTLs or NK cells. One of the most frequent cancer 
mutations, KRAS G12D, has been recently shown to be presented by HLA-C*08:02. Moreover, the 
corresponding epitope is able to induce T cell responses in cancer patients which can be harnessed 
for adoptive transfer immunotherapy.256 
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Many genetic associations of HLA-C alleles with several diseases have been reported which range 
from increased protection to higher susceptibility for a certain disease.257 Last but not least, HLA-C 
expression on extravillous trophoblasts plays a central role in the development and tolerance of the 
fetus during pregnancy by interacting with maternal NK cells.258  
Peptide motifs of HLA-C were first based on pool sequencing and few individual sequences.259 The 
first high-throughput approach to determine the binding specificities of a larger set of HLA-C alleles 
was conducted by Rasmussen et al.260 applying an in vitro peptide-HLA class I dissociation assay with 
synthetic peptides. By using this approach binding motifs for 16 HLA-C allotypes were uncovered, 
however with often less pronounced anchor residues. 
The non-classical HLA-E has been implicated in the presentation of HLA class I leader peptides.261,262 
Its expression level is dependent on the HLA class Ia expression level and previous reports suggest it 
to be around 5% of the HLA-C expression.263 The HLA-E-peptide complex acts as ligand for the family 
of CD94/NKG2 receptors expressed predominantly on NK cells but also on a subset of CD8+ T 
cells.264,265 Both, the KIR and CD94/NKG2 receptor family sense changes in HLA expression by 
interacting with HLA-C or HLA-E, respectively. While the conserved HLA-E-CD94/NKG2 system seems 
to be specialized in sensing HLA expression levels, polymorphic KIRs are able to detect early changes 
in the peptide repertoire presented on classical HLA, especially HLA-C.266-268 HLA-E-CD94/NKG2 
interaction has also been associated with fetal-maternal tolerance through inhibition of uterine NK 
cells by HLA-E expressing extravillous trophoblasts.269 In addition to the presentation of HLA class I 
leader peptides, HLA-E is able to present pathogenic epitopes to CTLs.270,271 However, the peptide 
binding pocket of HLA-E is highly hydrophobic and thus especially adapted for binding of HLA class I 
leader peptides. This unusual hydrophobicity within the binding pockets may further restrict the 
peptide repertoire. In fact, only few peptides could be shown to be presented in vivo by HLA-E. 
The non-classical HLA-G is mainly expressed on fetal tissue exerting a major tolerogenic function and 
promoting fetal development.272 In adults expression of HLA-G is found on immune-privileged 
organs, including cornea, thymus, pancreatic islets, endothelial, and erythroblasts. In addition, 
dendritic cells and macrophages may also express HLA-G.273 Moreover, expression can be induced 
during various diseases, including cancer, viral infections, inflammatory diseases or autoimmune 
disorders mainly as an escape strategy to avoid immune recognition. Due to the checkpoint function, 
HLA-G is considered as an attractive target for anti-cancer treatment using blocking antibodies.274 On 
the other hand, HLA-G expression in transplants is associated with better tolerance of the graft.275 
HLA-G interacts with different inhibitory receptors such as Immunoglobulin-like transcript 2 (ILT2) 
expressed by B cells, subsets of NK and T cells, monocytes and dendritic cells276, ILT4 which is solely 
expressed by monocytes and dendritic cells277 and KIR2DL4 which is expressed mainly on NK cells.278 
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Compared to HLA-E the peptide repertoire of HLA-G is larger but less complex than the peptide 
repertoire of HLA class Ia molecules.279 The peptide motif of HLA-G was first defined by Diehl et al. 
from a small set of naturally eluted and pool sequenced peptides exhibiting anchors at position 2 
(isoleucine or leucine), position 3 (proline) and position 9 (leucine).280 
Considering the high importance of HLA-C, -E and -G in many immunological processes the 
clarification of ligand characteristics of these HLA molecules is of great relevance. In this study, 
peptide motifs were unveiled via comprehensive analyses of naturally presented HLA ligands. HLA 
presented peptides were analyzed by LC-MS/MS after immunoprecipitation of HLA molecules from 
transfected C1R cells. The EBV-transformed lymphoblastoid C1R cell line is well suited for this 
approach due to a functional antigen presentation pathway and low endogenous HLA 
expression281,282 and we had applied this approach earlier for monoallelic motif determinations 56-
59,283-287, and more recently also by Abelin et al.60 We utilized this approach for the 15 most frequent 
HLA-C alleles (numbers according to www.allelefrequencies.net288) [Table 9]. Moreover, for the first 
time we comprehensively analyzed the peptide pool presented by the non-classical HLA molecules, 
HLA-E and HLA-G. For all analyzed HLA-C allotypes as well as HLA-G binding motifs were generated by 
Gibbs clustering.289 SYFPEITHI290 matrices were subsequently created for octa-, nona- and decamers 
and their predictive power has been analyzed in comparison to NetMHCpan-3.0.291 
Table 9: Most frequent HLA-C alleles withi  the Ger a y pop 8  cohort on allelefrequencies.net comprising data from 
39,689 individuals. These alleles were also the most frequent within several other examined populations from different 
ethnic groups. 
Rank HLA-C Allele Frequency in German population 
(n=39,689) 
 1 C*07:01 14.7% 
2 C*07:02 13.4% 
3 C*04:01 12.5% 
4 C*06:02 10.0% 
5 C*03:04 7.4% 
6 C*05:01 6.4% 
7 C*12:03 6.3% 
8 C*02:02 5.4% 
9 C*03:03 5.1% 
10 C*01:02 3.6% 
11 C*15:02 2.6% 
12 C*08:02 2.4% 
13 C*16:01 2.3% 
14 C*14:02 1.5% 
15 C*17:01 1.0% 
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3.2. Materials and methods 
3.2.1. DNA vectors 
DNA of HLA-C alleles, HLA-E and HLA-G were synthesized and integrated into the pcDNA3.1(+) 
plasmid utilizing the GeneArtTM gene synthesis service from Thermo Fisher Scientific. Nucleotide 
sequences were obtained from the IMGT/HLA database292 for C*01:02:01, C*02:02:01, C*03:03:01, 
C*03:04:01:01, C*04:01:01:01, C*05:01:01:01, C*06:02:01:01, C*07:01:01:01, C*07:02:01:01, 
C*08:02:01:01, C*12:03:01:01, C*14:02:01, C*15:02:01, C*16:01:01, C*17:01:01:01, E*01:01:01:01, 
G*01:01:01:01. Codon usage was adapted to the codon bias of Homo sapiens genes without 
changing the protein sequence. 
Vectors were linearized mixing 50 µg plasmid DNA with 50 µl CutSmart Buffer (NEB, MA, USA), 10 µl 
PvuI-HF (20,000 U/ml, NEB) and 390 µl ddH2O and incubating for 2 h at 37°C. Complete linearization 
was confirmed by agarose gel electrophoresis. DNA was extracted by phenol/chloroform/isoamyl 
alcohol (Sigma-Aldrich /Merck/Sigma-Aldrich) and precipitated by adding 1/10 volume of 3 M sodium 
acetate (Roth) and 2.5 volume 100% ethanol (VWR Chemicals, Radnor, PA, USA). The linearized 
vector was frozen for 2 h at -80°C and afterwards centrifuged at 13000 rpm for 30 min at 4°C. The 
supernatant was removed and the pellet was dried under sterile conditions. The DNA pellet was 
solved in 40 µl sterile Ampuwa water and the concentration was determined by Nanodrop at 260 nm 
(NanoDrop 1000 Spectralphotometer; Peqlab, Erlangen, Germany). 
3.2.2. Transfection and Selection 
Prior to transfection, C1R cells were washed 3x with cold RPMI1640 (Thermo Fisher Scientific) and 
resuspended to a final concentration of 40*106 cells/ml. For transfection, 500 µl mycoplasma-free 
cell suspension was mixed with 10 µg linearized plasmid DNA in a Gene Pulser® electroporation 
cuvette (0.4 cm gap, BioRad, Hercules, CA, USA). Electroporation was conducted using GenePulser II 
(BioRad) at 250 V and 975 µF. Afterwards, cells were incubated in 75 cm2 flasks with 12 ml pre-
warmed RPMI1640 + 10% FBS + 1x Penicillin/Streptomycin. Transfected cells were exposed to 
selection medium 24 h after electroporation by adding 1 mg/ml G418 (Merck) into the culture 
medium. Selection medium was exchanged twice a week. 
3.2.3. HLA expression and cell sorting 
HLA cell surface expression was verified by flow cytometry. For this purpose 1*106 cells were washed 
with FACS buffer and transferred into a 96-well plate (Greiner Bio-One). After an additional wash, 
cells were incubated with 100 µl of 20 µg/ml of pan-HLA class I-specific monoclonal W6/32 Ab (in 
house production)293 or the HLA-E specific monoclonal 3D-12 Ab (BioLegend, San Diego, CA, USA) on 
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ice for 20 min. Cells were washed twice and subsequently incubated with 100 µl 1:100 polyclonal 
α-mouse IG-FITC secondary Ab (Agilent Technologies) on ice for 20 min protected from light. After 
additional three washing steps cells were resuspended in 75 µl FACS buffer. Finally, 7.5 µl 
7-aminoactinomycin D (BioLegend) was added to each sample and the cells were analyzed on a FACS 
Canto II analyzer. Data analysis was performed by FlowJo 10.0.7. 
For intracellular staining of the C1R-E*01:01 transfectant, cells were fixed with 100 µl 
Cytoperm/Cytofix solution for 20 min prior to incubation with respective antibodies. For cell wash, 
2% FBS/2 mM EDTA/0.1% saponine/0.5% BSA in PBS was used. 
3.2.4. Cell sorting 
Cell populations showing high expression of HLA were sorted using a BD FACS Jazz cell sorter (BD 
Biosciences) following the HLA cell surface staining procedure. 
3.2.5. Cell harvest 
Cells were cultured up to an amount of 2.5*109 cells and harvested by centrifugation at 1500 rpm for 
15 min at 4°C. After two washing steps with cold PBS, cells were collected in a 50 ml centrifugation 
tube and frozen at -80°C. 
3.2.6. Isolation of HLA ligands by immunoaffinity purification 
HLA class I molecules were isolated utilizing standard immunoaffinity purification as described in 
section 2.5.2 employing pan-HLA class I-specific monoclonal W6/32 Ab. 
3.2.7. Analysis of HLA ligands by LC-MS/MS 
Samples were analyzed by LC-MS/MS on the Orbitrap Fusion Lumos as described in section 2.5.3. 
3.2.8. Database Search and Spectral Annotation  
Data was processed against the human proteome as comprised in the Swiss-Prot database 
(www.uniprot.org, release: September 27th 2013; 20,279 reviewed protein sequences contained) 
applying the SequestHT algorithm226 in the Proteome Discoverer (v1.3, ThermoFisher) software as 
described in section 2.5.4. 
3.2.9. HLA ligands annotation, length distribution, ligand and source proteome overlap  
Due to endogenous expression of HLA-B*35:03 and HLA-C*04:01 in C1R cells, isolated HLA ligands of 
these allotypes had to be excluded from further analysis in order to allow for identification of HLA 
ligands of the transfected allele. GibbsCluster 1.1289 is an unsupervised way to cluster peptides in 
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dependency of their sequence similarity. For each transfectant clustering of nonameric peptides, 
which represent the most abundant length variant in all analyzed alleles, were carried out. The 
number of clusters was set to 1- . A t ash luste  ith a th eshold of  as i o po ated to e o e 
outlie s. “e ue e eighti g t pe as set to Cluste i g . Fo  all othe  optio s default setti gs e e 
used. Peptide motifs of HLA-B*35:03 and HLA-C*04:01 were previously described294,295 and could be 
confirmed performing exemplarily Gibbs clustering of some HLA-B*35:03 or HLA-C*04:01 positive 
samples of our in-house database containing different samples and corresponding HLA typings. Thus, 
clusters of these two allotypes could be well distinguished from the previously undefined analysis 
cluster which was assigned to the transfected HLA. The transfected HLA cluster was visualized 
employing Seq2Logo 2.0296 and Kullback-Leibler logo type using default settings. Anchor and auxiliary 
anchor positions were defined based on respective nonamer clusters which were assigned to the 
transfected HLA and were subsequently adopted for octa- and decamers. This workaround was 
necessary since a clear distinction of all three expressed allotypes was not possible in all cases due to 
low peptide count and higher proportion of non-HLA peptides (Unsupervised clusters show 
combinations of transfected HLA, HLA-B*35:03 and HLA-C*04:01 motifs). With the exception of 
HLA-C*01:02 peptide anchor residues did not differ over the different length variants and clusters for 
octa- and decamers showed no obvious difference to the nonamer cluster. Peptides possessing 
anchor residues of the assigned transfected HLA cluster were selected from the initial peptide list for 
8-11mers and were defined as ligands. SYFPEITHI matrices were determined for 8-10mers using 
frequencies of amino acids at each position from defined ligands according to established 
procedures.290 The length distribution was calculated including 8-11mer ligands. Ligand overlap was 
determined using the 500 highest expressed ligands of each allele defined by the sum of all precursor 
areas in all five technical replicates. Source proteome overlap was determined using the source 
proteins of the respective top 500 presented ligands. 
3.2.10. Validation of SYFPEITHI matrices 
For SYFPEITHI matrix validation a k-fold (k = 5) cross-validation was used.297 For this purpose, peptide 
lists of each transfected allotype were randomly split into five equal folds, whereby four folds were 
used as training dataset to determine a SYFPEITHI matrix applying the GibbsCluster approach 
described above. The fifth fold was used for evaluation of the matrix. Clustering was performed on 
the fifth fold and peptides in the transfected HLA cluster were defined as true binders, whereas 
peptides in the other clusters and outliers were defined as false binders for the transfected HLA. 
Evaluation was performed exemplarily for one nonamer evaluation dataset. Receiver operating 
characteristic (ROC) curve analysis was conducted to visualize the performance. Area under the curve 
(AUC) was calculated for each ROC curve. For comparison to NetMHCpan-3.0 commonly used 
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thresholds were set to decide whether a peptide is defined as binder or not. For SYFPEITHI a 
threshold of  60% of the maximal score (defined by the sum of the highest possible scores in each 
position of the peptide) was set, for NetMHCpan-3.0 a threshold of rank < 2 was employed. 
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3.3.  Results 
3.3.1. HLA expression of transfected C1R cells 
HLA expression of transfected C1R cells was analyzed by flow cytometry using the 
pan-HLA class I-specific antibody W6/32. Untransfected C1R cells were included as a negative control 
to distinguish expression of the transfected HLA from endogenous HLA-B*35:03 and HLA-C*04:01 
expression. All transfectants, except C1R-HLA-E*01:01, demonstrated expression of the transfected 
HLA at the cell surface [Supplementary Figure 2]. C1R-HLA-E*01:01, stained by either W6/32 or 
HLA-E specific antibody 3D-12, exhibited no cell surface expression of transfected HLA-E*01:01. 
However, intracellular staining of C1R-HLA-E*01:01 with 3D-12 antibody revealed the presence of 
intracellular pools of HLA-E*01:01. Furthermore, PCR of isolated plasmid DNA and subsequent 
sequencing of the HLA-E*01:01 locus confirmed the persistence of the transfected gene as well as 
the correct sequence (data not shown). Since the C1R cell line is HLA-E*01:03+298, which has a higher 
affinity to HLA class Ia leader peptides299, this might explain missing expression of transfected 
HLA-E*01:01 due to a lack of sufficient leader peptides. However, neither HLA-E*01:01 nor 
HLA-E*01:03 could be detected on the cell surface by flow cytometry which in turn might be 
reasoned by the overall low expression of endogenous HLA [Supplementary Figure 2C]. For all 
remaining transfected HLA, cell surface expression was sufficient for subsequent characterization of 
naturally processed and presented HLA ligands. 
3.3.2. Peptide motifs of HLA-C 
Peptides were obtained after immunoaffinity chromatography of HLA molecules from cell lysates. 
After separation by reversed-phase liquid chromatography peptides were analyzed by mass 
spectrometry. GibbsCluster 1.1289 was used to separate ligands of the transfected HLA from those of 
endogenously expressed alleles in an unbiased manner [Supplementary Figure 3]. For HLA-C*05:01 
and HLA-C*08:02 clustering revealed a similar motif to the endogenously expressed HLA-C*04:01. To 
avoid cross-contamination within the groups, clustering was repeated after exclusion of all peptides 
extracted from the C1R-HLA-C*04:01 transfectant. 
In total, 392 to 3,463 ligands could be identified for respective HLA transfectants possessing the 
anchor amino acids defined by clustering of nonamers [Table 10]. Figure 25 displays the peptide 
motifs of the 15 analyzed HLA-C molecules. All HLA-C allotypes share a hydrophobic C-terminal 
anchor position with differences in the preferred amino acid residues. This varies from aliphatic 
residues such as valine or leucine in HLA-C*15:02 to aromatic residues phenylalanine and tyrosine in 
HLA-C*02:02. Most allotypes accept multiple hydrophobic or aromatic anchor residues at the 
C-terminus, while a few have a clear preference for a single amino acid (e.g. leucine in HLA-C*01:02,  
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Table 10: HLA ligand yields for each corresponding C1R transfectant and numbers of source proteins. Overlapping ligands 
and source proteins are removed from the sum of ligands and the sum of source proteins. 
 
 
 
 
 
 
 
 
 
 
 
-C*03:03/04 or -C*17:01). The frequency of aromatic residues correlates with the polymorphism at 
position 116 within the HLA molecules [Table 11].29 Allotypes with a serine at position 116 favor 
more often aromatic residues at the C-terminal position of the peptide, while phenylalanine, tyrosine 
or leucine at position 116 may interfere with the binding of aromatic residues. 11 of 15 HLA-C 
allotypes accept a second anchor shaped by peptide residues at position 2 (HLA-C*02:02, -C*03:03, -
C*03:04, -C*06:02, -C*07:01, -C*07:02, -C*12:03, -C*14:02, -C*15:02, -C*16:01 and -C*17:01), while 
residues at position 3 constitute the second anchor for 4 of 15 HLA-C alleles (HLA-C*01:02, -C*04:01, 
-C*05:01 and -C*08:02). In contrast to small variations with regard to the C-terminal anchor residues, 
preferred residues at position 2 or 3 display a high degree of variability. A unique preference of 
proline in position 3 is favored by HLA-C*01:02. Small aliphatic or hydrophilic residues at position 2 
constitute the anchor of HLA-C*02:02, -C*03:03, -C*03:04, -C*12:03, -C*15:02, -C*16:01 
and -C*17:01. All of these allotypes possess a tyrosine at position 9 which may inhibit binding of 
larger anchor residues.29 Of note, 6 of them favor large aromatic residues at position 1 which may 
support the interaction provided by the small anchor residue at position 2. Only HLA-C*15:02 
displays preferences for basic residues at position 1 which are also able to support the binding of the 
peptide.  
 
 8mers 9mers 10mers 11mers # ligands 
# source 
proteins 
# source 
proteins 
(cumulative) 
C*01:02  102 987 235 36 1360 1165 1165 
C*02:02  116 1533 214 100 1963 1589 2483 
C*03:03  91 852 99 38 1080 945 2963 
C*03:04  251 1601 176 91 2119 1716 3530 
C*04:01  467 1161 153 35 1816 1484 4243 
C*05:01  626 1563 249 64 2502 1898 4985 
C*06:02  47 870 32 4 953 846 5271 
C*07:01  55 310 19 8 392 366 5357 
C*07:02  116 589 53 19 777 700 5472 
C*08:02  792 2231 330 110 3463 2444 5981 
C*12:03  146 1160 53 29 1388 1158 6143 
C*14:02  484 1604 313 38 2439 1879 6590 
C*15:02  191 1639 56 22 1908 1522 6834 
C*16:01  685 1899 106 50 2740 2086 7133 
C*17:01  120 418 49 45 632 542 7184 
E*01:01  0 5 0 0 5 5 7184 
G*01:01  248 1725 204 81 2258 1816 7536 
     Sum 22,197 7,536  
83 
 
 
HLA-C*01:02 HLA-C*01:02 10mers HLA-C*02:02 
HLA-C*03:03 HLA-C*03:04 HLA-C*04:01 
HLA-C*05:01 HLA-C*06:02 HLA-C*07:01 
HLA-C*07:02 HLA-C*08:02 HLA-C*12:03 
HLA-C*14:02 HLA-C*15:02 HLA-C*16:01 
HLA-C*17:01 HLA-G*01:01 
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Figure 25: Sequence logos of the clusters corresponding to the transfected HLA allotype visualized using Seq2Logo 2.0.
296
 
The size of the letter indicates the impact of the corresponding amino acid presented by a given position in either positive 
or negative fashion. Black = aliphatic residues, gray = aromatic residues, green = hydrophilic residues, blue = basic residues, 
red = acidic residues. 
This may be feasible due to an asparagine at position 66 instead of a lysine which constitutes this 
position in most allotypes. Within the HLA-C*03 subtypes differences in peptide specificities are 
marginal. Acidic residues at position 3 form the anchor for HLA-C*04:01, -C*05:01 and -C*08:02. All 
three molecules combine an asparagine at position 114 and an arginine at position 156. The arginine 
may serve for electrostatic interaction, whereas the asparagine at position 114 instead of aspartic 
acid may enable the binding of an acidic residue. While HLA-C*04:01 has a clear preference for 
aromatic residues at position 2, HLA-C*05:01 and -C*08:02 accept only small residues at this 
position. An explanation may be the phenylalanine at position 9 of HLA-C*05:01 and -C*08:02 
reducing the space to accomodate larger resides.29 HLA-C*04:01 possesses a serine at this position 
which may enable the binding of large aromatic residues. Basic anchor residues at position 2 are 
preferred by HLA-C*06:02, -C*07:01 and -C*07:02. This may be explained by the aspartic acid at 
position 9 of HLA-C*06:02, -C*07:01 and -C*07:02. Major differences in the peptide specificities of 
the HLA-C*07 subtypes HLA-C*07:01 and -C*07:02 are revealed at position 1 and the anchor position 
2. Both subtypes prefer arginine as anchor residue whereas alternatively accepted anchor residues 
are threonine or asparagine for HLA-C*07:01 and tyrosine or lysine for HLA-C*07:02. The tyrosine in 
position 2 of HLA-C*07:02 ligands may be accepted due to a serine at position 99 where usually an 
aromatic residue is located. Further, HLA-C*07:01 favors basic residues at position 1 whereas 
HLA-C*07:02 does not have such a preference. As for HLA-C*15:02, the preference for basic residues 
at position 1 of HLA-C*07:01 ligands can be explained by an asparagine at position 66. Unique to 
HLA-C*14:02 is its preference for aromatic residues at anchor position 2. Again, a serine at position 9 
instead of an aromatic amino acid which is generally placed at this position may enable binding of 
large aromatic residues. Further allotypes favoring aromatic residues at anchor position 2 are 
HLA-A*23 and -A*24 which as well possess a serine at position 9. Auxiliary anchors (defined by a 
percentage share of > 50% of amino acids with similar features) are located at position 1 of 
HLA-C*03:03, -C*03:04 and -C*17:01 ligands and at position 2 of HLA-C*04:01 ligands with a 
preference for aromatic residues. Remarkable is the higher frequency of aromatic residues at 
position 5 and 7 of HLA-C*07:01 and -C*07:02 ligands and at position 8 of HLA-C*17:01 ligands which 
may be explained by a leucine at position 147 instead of a tryptophan situated in this position in the 
other allotypes. The preference for aromatic residues at position 5 and 7 of HLA-C*07:01 
and -C*07:02 ligands may also be explained by an alanine at position 152 which may provide a larger 
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Table 11: Polymorphic residues within HLA-C molecules and the position within the peptide interacting with respective residue.
27,29
 Boldface: Polymorphic residues which may explain 
differences in the peptide motifs. 
 
 
 Polymorphic residues within HLA-C molecules 
Allotype 9 24 66 73 77 80 95 97 99 114 116 143 147 152 156 163 
C*01:02 F S K T S N L W C D Y T W E R T 
C*02:02 Y A K T N K L R Y D S T W E W E 
C*03:03 Y A K T S N I R Y D Y T W E L L 
C*03:04 Y A K T S N I R Y D Y T W E L L 
C*04:01 S A K A N K L R F N F T W E R T 
C*05:01 Y A K T N K L R Y N F T W E R T 
C*06:02 D S K A N K L W Y D S T W E W T 
C*07:01 D S N A S N L R Y D S T L A L T 
C*07:02 D S K A S N L R S D S T L A L T 
C*08:02 Y A K T S N L R Y N F T W E R T 
C*12:03 Y A K A S N L W Y D S T W E W T 
C*14:02 S A K T S N L W F D S T W E R T 
C*15:02 Y A N T N K I R Y D L T W E L T 
C*16:01 Y A K T S N L W Y D S T W A Q T 
C*17:01 Y A K A N K I R Y N F S L E L E 
 2 2 1-4/6 5-8 7/8 8/9 9 3/5/6/9 2/3 3/5-7 5/7/9 9 5/7-9 3/5-7 3-7 1/2/4 
 Position in Peptide interacting with respective residue 
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pocket for residues at position 5 and 7 of the ligands, a feature not shared by HLA-C*17:01. 
Exceptional to HLA-C*01:02 is its change at the anchor position 3 with proline for octameric and 
nonameric HLA ligands to a shared anchor with aliphatic residues at position 2 and proline, serine or 
histidine at position 3 for longer ligands. In sum, peptide motifs of all analyzed HLA-C molecules could 
be identified and are in agreement with our knowledge of allotype specific pocket characteristics. All 
HLA allotypes that have been analyzed in this study prefer nonameric ligands with frequencies 
varying from 62.5% to 91.3% [Figure 26]. Octamer frequency ranges from 4.9% to 25.0%. Decamers 
and undecamers were less frequent with 2.9% to 17.3% or 0.4% to 7.1%, respectively. 
Figure 26: Length 
distribution of HLA-C 
and HLA-G alleles. 
 
 
 
 
 
 
3.3.3. HLA-C in the context of the supertype concept 
The concept of grouping HLA allotypes into supertypes depending on their main anchor specificities 
was introduced in 1995.287,300 In sum, nine supertypes could be defined covering most of the HLA-A 
and HLA-B alleles: HLA-A*01, -A*02, -A*03, -A*24, -B*07, -B*27, -B*44, -B*58, -B*62.301,302 In 2004, 
Doytchinova et al. applied a bioinformatics approach based on structural similarities between 
allotypes integrating also the HLA-C alleles.303 Using this strategy, two HLA-C supertypes could be 
defined, named C1 and C4. Supertype C1 was defined by a serine or glycine at position 77, whereas 
C4 supertypic allotypes possess an asparagine at this position. Allotypes from our study belonging to 
the C1 supertype are HLA-C*01:02, -C*03:03, -C*03:04, -C*07:02, -C*08:02, -C*12:03, -C*14:02 and -
C*16:01. Whereas HLA-C*02:02, -C*04:01, -C*05:01, -C*06:02, -C*07:01, -C*15:02 and -C*17:01 
belong to the C4 supertype. However, this definition is not in line with the peptide motifs of HLA-C 
allotypes unveiled here [Figure 25]. Considering the peptide motifs of HLA-C we propose now a new 
categorization into five groups. Three of these groups may be integrated into HLA-A and HLA-B 
supertypes (HLA-C*02:02, -C*03:03, -C*03:04, -C*12:03, -C*15:02, -C*16:01 and -C*17:01 into the 
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A*01, B*58 or B*62 supertype, and HLA-C*14:02 into the A*24 supertype, HLA-C*06:02, -C*07:01 
and -C*07:02 into the B*27 supertype). Allotypes with an anchor at position 3 may deserve 
additional supertype definitions. A C*01 supertype with proline at position 3 and aliphatic residues at 
the C-terminus may account for the uniqueness of HLA-C*01. A C*04 supertype would integrate HLA-
C*04:01, -C*05:01 and -C*08:02 into the supertype concept. 
3.3.4. Characteristics of HLA-E and HLA-G ligands 
HLA-E*01:01 transfected C1R cells present two HLA class I leader peptides, namely VMAPRTLIL 
derived from HLA-C*04:01 and VMAPRTLVL derived from HLA-A*02:01. The latter one is to some 
extent surprising because there is no evidence for surface expression of HLA-A*02:01 in C1R.281,304 
VMAPRTLVL was detected in every C1R transfectant (Note: C1R is HLA-E*01:03+) ensuring that it is 
not a false positive but most probably derived from a DRiP. Overall three additional HLA class I leader 
peptides VMAPRTLLL (HLA-C*02:02 and -C*15:02), VMAPRALLL (HLA-C*07:01 and -C*07:02) and 
VMAPRTLFL (HLA-G*01:01) were detected which are presented by HLA-E*01:03. MHC class I leader 
peptides of HLA-B*35:03 (VTAPRTVLL) and HLA-C*17:01 (VMAPQALLL) are not presented by 
HLA-E*01:01 (Note: only HLA-B*35:03 signal sequence could have been expressed on C1R-E*01:01) 
or the endogenously expressed HLA-E*01:03. This discrimination of peptides with one or two amino 
acid changes, mostly in positions contributing less to the interaction to HLA, illustrates the adaption 
of HLA-E in HLA leader peptide presentation and its restricted peptide repertoire.  
HLA-G*01:01 reveals a marked peptide motif with anchors at position 3, composed of proline, 
isoleucine and valine, and at the C-ter i al positio  Ω  fo ed  leu i e. A  au ilia  a ho  ith 
lysine and arginine is shaped at position 1. Hydrophobic residue preferences show up at position 2 
a d positio  Ω-2 [Figure 25]. Contrary to HLA-E, HLA-G*01:01 exhibits a large peptide binding 
repertoire with 2258 identified ligands eluted solely from HLA-G*01:01 transfected C1R cells. 
3.3.5. Ligand overlap 
In order to look for ligand overlap across the analyzed allotypes the top 500 most abundant ligands 
(defined by the sum of the area under the curve values of five technical replicates) of each HLA 
molecule were integrated. For HLA-C*07:01 only 392 ligands could be considered [Table 12]. The 
overlap in HLA presented peptides among allotypes with clearly distinguishable peptide motifs (one 
or both anchor residues are different) was marginal with a maximal overlap of 2.46% between 
HLA-C*03:04 and HLA-C*08:02. Allotypes with consistent anchor residue preferences display higher 
overlap within the presented peptides ranging from 3.20% between HLA-C*07:02 and HLA-C*14:02 
and up to 11.98% between HLA-C*02:02 and HLA-C*12:03. Notably HLA-C*05:01 and HLA-C*08:02 
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Table 12: Ligand overlap [%] of the top 500 HLA ligands of each allele. Ligand overlap was determined using the top 500 ligands of each allele defined by the sum of area in all five technical 
replicates. Crossed out numbers are not representative. 
 
 
C*01:02 0.10 0.10 0.10 0.00 0.00 0.10 0.11 0.10 0.00 0.20 0.60 0.10 0.00 0.20 0.70 
 
C*02:02 7.53 6.38 1.63 0.00 0.00 0.90 0.00 0.00 11.98 0.00 2.25 5.82 4.82 0.00 
  
C*03:03 42.86 1.01 1.52 0.00 1.02 0.00 1.73 5.26 0.00 3.41 6.38 8.70 0.30 
   
C*03:04 1.32 2.15 0.00 0.79 0.00 2.46 3.73 0.00 3.41 7.41 6.16 0.10 
    
C*04:01 0.00 0.00 1.13 0.00 0.00 0.60 0.00 0.50 1.01 1.63 0.00 
     
C*05:01* 0.00 0.00 0.00 27.39 0.00 0.00 0.30 0.00 0.50 0.00 
      
C*06:02 3.96 5.26 0.00 0.00 0.60 0.00 0.00 0.00 0.40 
       
C*07:01** 10.12 0.00 1.13 0.00 1.02 0.56 0.00 0.22 
        
C*07:02 0.00 0.00 3.20 0.00 0.00 0.00 0.30 
         
C*08:02* 0.00 0.00 0.40 0.00 0.20 0.00 
          
C*12:03 0.00 3.41 7.64 3.31 0.00 
           
C*14:02 0.00 0.00 0.00 1.42 
            
C*15:02 2.67 2.88 0.40 
             
C*16:01 2.56 0.00 
              
C*17:01 0.20 
               
G*01:01 
* C1R-C*04:01 peptides removed 
** only 392 ligands 
89 
 
show a high overlap, sharing 27.39% ligands. Comparison to HLA-C*04:01 is limited due to 
endogenous expression of the allotype on C1R and its similarity to HLA-C*05:01 and -C*08:02. Since 
peptides from C1R-C*04:01 had to be excluded for ligand definition of HLA-C*05:01 and -C*08:02 the 
overlap is consequently 0. Nevertheless, overlap of HLA-C*05:01 and HLA-C*08:02 to HLA-C*04:01 
should be markedly lower since HLA-C*04:01 favors large aromatic residues in position 2 whereas 
HLA-C*05:01 and HLA-C*08:02 prefer small residues. In fact, including intrinsic HLA-C*04:01 ligands 
(no exclusion of peptides of C1R-C*04:01 from C1R-C*05:01 and -C*08:02 peptide lists) the overlap is 
higher between HLA-C*05:01 and -C*08:02 with 40.45% compared to 26.26% between HLA-C*04:01 
and -C*05:01 or 25.31% between HLA-C*04:01 and -C*08:02, respectively. High overlap is seen 
between the HLA-C*03 subtypes HLA-C*03:03 and HLA-C*03:04 with 42.86% of shared ligands. The 
HLA-C*07 subtypes HLA-C*07:01 and HLA-C*07:02 display with 10.12% a rather small overlap within 
their ligands compared to the HLA-C*03 subtypes which can be explained by differences in the 
preferred residues in anchor position 2. In general, ligand overlap is marginal within HLA allotypes 
unless the same anchor residues are shared.305 
3.3.6. Source proteome overlap 
Theoretically all proteins within a cell may be used as source for peptide presentation. However, 
different factors such as source protein expression level, antigen processing and transport efficiency 
and affinity of the peptide to the HLA and their stability may select for a smaller set of source 
proteins which are presented by one allotype. The source proteins of the 500 most abundant ligands 
were selected for the overlap analysis of the source proteome [Table 13]. The source protein overlap 
was the highest for allotypes with a high ligand overlap which is obvious since the overlapping 
ligands derive from the same source protein. More interesting is the overlap of the source proteome 
added by non-overlapping ligands. In fact, the additional overlap contributed by non-overlapping 
ligands is comparable within all allotypes, independent of their peptide motifs, with a median 
increase of 5.42%. This allotype- and also subtype-independent low increase in the source proteome 
overlap displays the high diversification which is added by an additional HLA molecule. 
3.3.7. Performance of established SYFPEITHI matrices 
Identified peptides were used to establish SYFPEITHI matrices. Therefore peptides were clustered 
using GibbsCluster 1.1.289 Anchor positions and residues were defined from clusters of the 
transfected HLA. Peptides harboring predefined anchor residues were defined as ligands and were 
used to establish SYFPEITHI matrices [Supplementary Figure 3, Appendix 8.2]. In order to examine 
the performance of the established SYFPEITHI matrices 5-fold cross-validation was performed.297 
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Table 13: Source proteome overlap [%]. Source proteins of the top 500 expressed HLA ligands, defined by the sum of area in all five technical replicates, were included. 
 
 
 
C*01:02 4.73 4.79 5.95 4.59 5.63 5.26 3.95 5.36 7.33 5.47 5.80 5.37 7.09 4.98 5.59 
 
C*02:02 13.07 14.00 7.56 7.82 5.65 5.81 5.88 8.18 17.30 5.96 8.45 11.90 9.70 5.38 
  
C*03:03 41.70 7.33 6.83 4.86 4.93 4.03 7.95 10.67 7.75 10.18 11.20 13.76 6.39 
   
C*03:04 9.21 8.72 4.72 5.71 4.95 9.60 9.83 6.72 11.36 12.79 11.86 7.10 
    
C*04:01 7.65 5.37 5.91 5.12 8.52 6.83 5.56 7.76 7.25 7.65 5.23 
     
C*05:01 5.83 5.89 6.19 32.49 6.44 7.30 7.51 6.49 4.68 4.83 
      
C*06:02 9.21 10.45 6.56 5.43 6.99 5.82 5.13 4.81 6.51 
       
C*07:01 13.51 5.18 5.57 4.99 5.74 4.96 4.74 5.44 
        
C*07:02 5.31 3.86 7.10 5.44 4.88 5.05 5.66 
         
C*08:02 7.31 7.27 9.46 7.61 4.67 6.03 
          
C*12:03 7.12 9.29 13.36 7.86 5.16 
           
C*14:02 7.02 5.67 4.74 6.84 
            
C*15:02 9.44 8.71 6.91 
             
C*16:01 7.90 4.98 
              
C*17:01 5.04 
               
G*01:01 
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For that purpose, the initial peptide list of each analyzed transfectant was split into five parts. Four 
parts were used for clustering and subsequent definition of the SYFPEITHI matrix, while one part 
remained to validate the matrix. Peptides in the cluster corresponding to the transfected HLA were 
defined as true binders whereas peptides of the other clusters and peptides fitting to no cluster were 
defined as false binders. ROC points were calculated in 5% steps of the SYFPEITHI maximal score. 
AUC values extend from 0.88 for HLA-C*14:02 and HLA-C*17:01 to 0.97 for HLA-C*01:02 nonamer 
matrix. Only the HLA-C*16:01 matrix performed less good with an AUC = 0.78 [Supplementary Figure 
4]. In conclusion, the performance of the matrices is excellent for discrimination of true and false 
binders within the dataset. 
3.3.8. Comparing SYFPEITHI and NetMHCpan-3.0 binding predictions 
SYFPEITHI290 and NetMHC291,306 are commonly used tools for HLA binding predictions. However, both 
prediction tools are based on different strategies. SYFPEITHI uses a position based matrix scoring 
system depending on amino acid frequencies at each position and the definition of anchor and 
auxiliary anchor positions utilizing naturally eluted HLA ligands. In contrast, NetMHCpan-3.0 uses 
artificial neural networks which were trained on quantitative in vitro binding data of peptides-HLA 
class I complexes from IEDB.307 Thus, all ligands are also binders, but peptides identified to be binders 
in vitro are not necessarily natural ligands. To compare both prediction tools peptides of each 
transfectant were split into true or false binders for the transfected HLA by clustering (peptides of 
the transfected HLA luste  = t ue i de s , othe  peptides = false i de s . Co o l  used 
th esholds fo  i de  defi itio  e e used ith  % of the a i al score for SYFPEITHI and Rank 
< 2 for NetMHCpan-3.0. The rate of false positive (FP) and true positive (TP) predicted binders is 
illustrated in Figure 27 for all analyzed allotypes except for HLA-E*01:01. SYFPEITHI illustrates a 
powerful prediction with a high TP rate ranging from 0.66 to 0.91 and a low FP rate ranging from 0.00 
to 0.22. Only the nonameric matrix for HLA-C*14:02 with a FP rate of 0.54 performed poorly which 
can be explained by their motif similarities to HLA-C*04:01 (endogenously expressed by C1R) at 
position 2 (anchor and auxiliary anchor, respectively, preferring aromatic residues) and anchor 
position 9. NetMHCpan-3.0 exhibits higher TP rates between 0.71 and 0.97 but at the same time 
higher FP rates between 0.07 and 0.65. Similar to SYFPEITHI, NetMHCpan-3.0 prediction for 
HLA-C*14:02 performs with a FP rate of 0.72. The highest disparity is seen for HLA-G*01:01 with a TP 
rate of 0.91 and a FP rate of 0.05 for SYFPEITHI and a TP rate of 0.67 and a FP rate of 0.65 for 
NetMHCpan-3.0. Hence, NetMHCpan-3.0 displays a rather random prediction. In conclusion, the 
performance of the established SYFPEITHI matrices could be confirmed by comparison to 
NetMHCpan-3.0. SYFPEITHI outperformed with higher precision for all allotypes [Figure 28]. 
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Figure 27: Performance of SYFPEITHI 
matrices and NetMHCpan-3.0 
prediction. Dataset of each 
transfectant was divided into true 
and false binders to the respective 
HLA using unbiased clustering. 
Peptides in cluster of the 
corresponding transfected HLA were 
defined as true binders; peptides in 
clusters representing the 
endogenously expressed HLA 
molecules were defined as false 
binders of the transfected HLA. 
Peptides e e defi ed as liga ds ith a “YFPEITHI s o e of  % o  NetMHCpa -3.0 Rank < 2. TP = true positive, FP = false 
positive. 
 
Figure 28: Precision of SYFPEITHI 
and NetMHCpan-3.0. The precision 
is defined by the true positive rate 
divided by the sum of true and false 
positives (= TP/TP+FP) 
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3.4.  Discussion 
It is not only the definition of the binding specificities of classical but often underestimated HLA-C 
alleles and the non-classical HLA-E and HLA-G, which is of great importance. With regard to their 
roles in many diseases, like cancer, viral infections, inflammatory diseases, autoimmune disorders 
and transplantation, naturally processed and presented HLA ligands may contribute to our 
understanding of disease and foster approaches for intervention. 
3.4.1. HLA-C 
In this study, the peptide motifs of the 15 most frequently represented HLA-C alleles were 
comprehensively analyzed using mass spectrometry based characterization of naturally presented 
HLA ligands [Figure 25]. Due to the low expression of HLA-C308-312, it is hardly feasible to determine 
the peptide motifs in a system with simultaneous normal expression of HLA-A and -B in an 
unsupervised clustering approach. Hence, the lymphoblastoid C1R cell line with a low endogenous 
expression of HLA-B*35:03, which is strongly repressed due to a point mutation in the translation 
initiation codon281, and HLA-C*04:01 was utilized to uncover the peptide motifs of HLA-C alleles. 
The ligand yields encompass a wide range, which is owed to differences in the expression levels, but 
may also be caused by performance variances of mass spectrometric measurements. Nevertheless, 
yields of extracted HLA ligands were sufficient for all alleles to determine the binding motif of 
predominating nonamers in an unsupervised manner utilizing GibbsCluster 1.1.289 Peptide yields for 
less frequent length variants were in some cases insufficient leading to contaminated clusters of the 
transfected HLA with peptides from the endogenously expressed HLA molecules. However, except 
for HLA-C*01:02 no changes in the preferred anchor residues emerged between the less frequent 
lengths and nonamers. Therefore, anchor residues were defined from the cluster of nonamers and 
assigned to the other length variants. This was helpful for the definition of ligands of all length 
variants. For HLA-C*01:02 additional anchor residues for longer length variants were included. 
A common feature of all allotypes is their preference for hydrophobic and/or aromatic residues at 
the C-terminal position similar to HLA-B, whereas some HLA-A allotypes accept basic amino acids as 
C-terminal anchors. The restricted repertoire of anchor residues at the C-terminal position could be a 
result of the proximity to the interaction side of KIRs with HLA-C. KIRs interact with residues α73 to 
α90 of the HLA molecule313,314 which are less polymorphic in HLA-C compared to HLA-A and -B. This 
region is also mainly involved in the C-terminal anchor contacts.29 The low polymorphism of the α2 
domain of HLA-C molecules restricts the binding repertoire of HLA-C alleles reducing the number of 
pote tial liga ds. This appea s at a gla e to e athe  u fa o a le fo  the od ’s defe se, si e i  
theory fewer pathogen-derived or tumor-associated antigens could be presented on HLA-C 
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molecules. This low polymorphism could be associated with the particular role of HLA-C in delivering 
inhibitory signals to NK cells to ensure self-tolerance. HLA-C alleles guarantee NK cell inhibition in 
every individual regardless of their HLA allele combination, since compared to HLA-A and -B (only few 
alleles show epitopes for KIR recognition) all HLA-C molecules have either the C1 or C2 epitope for 
KIR recognition.315,316 Thereby, HLA-C allows combinatorial diversity of HLA-A and -B molecules and a 
still sufficient broad binding repertoire within the population without the disadvantage of a loss of 
self-tolerance due to missing-self signals. 
The anchors in position 2 or 3, respectively, display high variability and thus contribute most to the 
peptide repertoire of HLA-C alleles. Based on the motif variability five groups can be determined: 1) 
small residues in position 2 of HLA-C*02:02, -C*03:03, -C*03:04, -C*12:03, -C*15:02, -C*16:01 and -
C*17:01, 2) acidic residues in position 3 of HLA-C*04:01, -C*05:01 and -C*08:02, 3) basic residues in 
position 2 of HLA-C*06:02, -C*07:01 and -C*07:02, 4) proline in position 3 of HLA-C*01:02 and 5) 
aromatic residues in position 2 of HLA-C*14:02. Interestingly, small residues in position 2 are often 
attended by aromatic residues in position 1 or 3 which may stabilize the binding of the position 2 
anchor. A striking change in the peptide motif is seen for longer length variants of HLA-C*01:02 
where the auxiliary anchor in position 2 almost reaches the importance of the anchor at position 3. 
The predominating length variant in HLA-C is 9 aa. However, a higher rate of shorter HLA ligands 
were obtained for HLA-C*04:01, -C*05:01, -C*07:01, -C*07:02, -C*08:02, -C*14:02, -C*15:02 and -
C*17:01. Interestingly, 6 of 8 listed allotypes prefer charged or aromatic anchor residues leading to 
the assumption that stronger interaction with the HLA molecule by charged or aromatic anchor 
residues may stabilize shorter peptides in the binding pocket. 
Peptide overlap was generally low among the HLA alleles ranging from 0% in allotypes with non-
overlapping motifs (Note: C-terminal anchor has low variance throughout the HLA-C alleles) to 
10.86% in allotypes with similar motifs (HLA-C*02:02 and HLA-C*12:03). This underlines the distinct 
peptide repertoire of allotypes with similar binding specificities, a feature that has also been 
reported for members of the HLA-B*44 supertype.305 However, high overlap is observed between 
HLA-C*05:01 and HLA-C*08:02 displaying peptide motifs which are virtually indistinguishable from 
each other. On the other hand, HLA subtypes usually demonstrate a high degree of binding similarity 
(41.24% peptide overlap between HLA-C*03:03 and HLA-C*03:04). Exceptional is the lower 
promiscuity (8.12%) in the HLA-C*07 subtypes HLA-C*07:01 and -C*07:02 caused primarily by distinct 
differences in the favored anchor residues in position 2 and differences in position 1 (basic auxiliary 
anchor in HLA-C*07:01 or uncharged residues in HLA-C*07:02, respectively). 
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The source proteome overlap of the top 500 ligands of each allotype was particularly increased by 
overlapping ligands. A limitation is the consideration of only the source proteome of the top 500 
ligands which will underestimate the source proteome overlap since the probability for further 
included ligands (up to 3463 ligands were detected for one HLA molecule [Table 10]) to derive from 
already included source proteins is higher. However, this was necessary due to high variations in the 
ligand yields. Including the source proteins of all ligands the source proteome overlap of 
non-overlapping ligands would increase from 5.42% to approximately 10%. This percentage still 
illustrates the high diversification added by a second allotype, including subtypes. 
The SYFPEITHI matrices resulting of this work reveal high TP prediction rates for HLA-C ligands in 
combination with a low FP prediction rate, whereas NetMHCpan-3.0 generally gains slightly higher TP 
rates which are often accompanied by a high FP rate. This high FP rate is problematic in that 
HLA-C*04:01 and HLA-B*35:03 peptides used for this comparison (endogenously expressed by C1R) 
exhibit distinguishable anchor residues. In general, SYFPEITHI prediction is more conservative (lower 
TP rates but outperforming low FP rates) than binding prediction with NetMHCpan-3.0 coming along 
with a higher precision. 
The importance of HLA-C becomes apparent in that several peptides of tumor associated antigens 
are known to be presented by HLA-C and are recognized by CD8+ T cells. HLA-C ligands which are 
known to be recognized by CD8+ T cells arise from the shared tumor specific antigens MAGE317-320, 
BAGE321, GAGE322 and NY-ESO1323, the differentiation antigens DCT, PMEL324 and SLC45A3325, the 
overexpressed antigen TPBG326, and the antigen PARP12327. Indeed, SAFPTTINF (MAGEA1) and 
VYPEYVIQY (PARP12) were also found within our dataset. Furthermore, neoepitopes are known 
arising from KRAS328 or MUM2329. Within our dataset further peptides of tumor associated antigens 
(according to 330) were found to be presented by HLA-C alleles which may be targets of CD8+ T cells 
and NK cells [Table 14].  
3.4.2. HLA-E 
C1R cells transfected with HLA-E*01:01 exhibit no increase in cell surface expression, although 
successful transfection was demonstrated by sequencing. This is in line with results of Braud et al.298 
revealing a correlation of HLA-E surface expression with the presence of HLA molecules. In fact, the 
presentation of the HLA-C*04:01 signal peptide VMAPRTLIL was higher in C1R transfected with an 
HLA allele harboring the same signal peptide (HLA-C*01:01, -C*03:03, -C*03:04, -C*05:01, -C*06:02, -
C*08:02, -C*12:03, -C*14:02 and -C*16:01) compared to HLA-E*01:01 transfected cells (not shown). 
In accordance to Braud et al.298 only HLA signal peptides, in total five, could be found to be presented 
by HLA-E looking for recurring sequence similarities throughout the transfectants after the exclusion 
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of HLA-B*35:03 and HLA-C*04:01 ligands (Clustering did also not work). However, some conventional 
peptides from pathogens331-334 and a prostate cancer-associated antigen335 were reported to elicit 
HLA-E-dependent T cell responses. Furthermore, a broader binding repertoire of HLA-E was reported 
with similarities to the HLA-A*02 binding motif in TAP-deficient K562 cells.336 
3.4.3. HLA-G 
In contrast to HLA-E*01:01, HLA-G*01:01 displayed a much larger peptide repertoire with over 2200 
detected HLA ligands including peptides of tumor associated antigens such as PSA, Cyclin B1, Sperm 
protein 17 and LCK [Table 14] which may elicit inhibitory effects on T and NK cells. The peptide motif 
displays unusual and highly specialized binding preferences. In contrast to the conclusion made by  
Table 14: HLA-C and HLA-G ligands of tumor associated antigens according to Cheever et al.
330
 and the allotype by which 
the ligand is presented. Proteins in brackets may be also the source of the HLA ligand. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein Uniprot ID Ligand HLA 
MAGEA3 P43357 FQAALSRKV C*02:02 
MAGEA3 P43357 FVQENYLEY C*02:02 
MAGEA3 P43357 TFPDLESEF C*14:02 
MAGEA3 P43357 NYPLWSQSY C*14:02 
TP53 P04637 TAKSVTCTY C*02:02 
PSMA Q04609 FTEIASKF C*12:03 
gp100/PMEL P40967 HFLRNQPL C*14:02 
PSA P55786 ISTVEVLKV C*15:02 
PSA (PSAL) P55786 VVPKDRVAL G*01:01 
PSA P55786 RSPVYLTVL G*01:01 
Cyclin B1 P14635 VQDLAKAV C*05:01/C*08:02 
Cyclin B1 P14635 FRLLQETMY C*07:02 
Cyclin B1 P14635 VQVQMKFRL G*01:01 
RhoC (RhoA) P08134 FSIDSPDSL C*03:03 
RhoC P08134 MATRAGLQV C*15:02 
RhoC (RhoB) P08134 KTKEGVREV C*15:02/C*16:01 
SART3 Q15020 YIDFEMKI C*05:01 
SART3 Q15020 IGDPARIQL C*05:01 
SART3 Q15020 NADFAKLFL C*08:02 
SART3 Q15020 IFSNRGDF C*14:02 
SART3 Q15020 VAAATYKTM C*16:01 
SART3 Q15020 AAFTRALEY C*16:01 
Sperm protein 17 Q15506 RIPQGFGNLL G*01:01 
LCK P06239 ITFPGLHEL C*07:01/C*12:03/C*15:02 
LCK P06239 FYISPRITF C*14:02 
LCK P06239 KTPSGIKL G*01:01 
B7H3 Q5ZPR3 FSPEPGFSL C*01:02 
B7H3 Q5ZPR3 LFDVHSVL C*04:01 
B7H3 Q5ZPR3 VAAPYSKPSM C*16:01 
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Diehl et al.280 assuming three anchor residues (I/L in position 2, P in position 3 and L in position 9), 
our results indicate that position 2 seems to be less important for peptide binding. The preferred 
length of HLA-G*01:01 ligands is 9 aa with a sparse peptide overlap to the analyzed HLA-C alleles. 
The SYFPEITHI matrix for nonameric HLA-G*01:01 reveals a strong performance with a TP rate of 
0.91 and a FP rate of 0.05 using the C1R-HLA-G*01:01 peptide dataset, whereas NetMHCpan-3.0 
exhibits a random prediction with a TP rate of 0.67 and a FP rate of 0.65. In summary, the peptide 
motif of HLA-G*01:01 was uncovered making use of over 2200 HLA-G*01:01 ligands. The SYFPEITHI 
matrix for nonamers outperforms prediction by NetMHCpan-3.0. 
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Supplementary Figure 2: HLA expression of transfected C1R cells. A) Gating strategy. C1R cells were gated for single and 
viable cells (7-AAD-negative). B) HLA expression of transfected C1R cells (blue) and C1R control (red). Cells were stained 
with pan-HLA class I-specific mAb W6/32. 500,000 cells were counted. C) Cell surface and intracellular staining of C1R-HLA-
E*01:01 with W6/32 and HLA-E specific Ab 3D-12. 
 
 
Supplementary Figure 3: Method overview. Clustering of nonameric peptides was performed using GibbsCluster1.1 (30). 
Cluster of transfected HLA could be distinguished from the previously described motifs of endogenously expressed 
HLA-B*35:03 and HLA-C*04:01 (39, 40). Anchor positions and residues were defined using frequencies of amino acids at 
each position of peptides in the transfected HLA cluster. Peptides harboring both anchor residues were defined as ligands in 
length variants 8-11. SYFPEITHI matrices were established using the defined ligands. 
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Supplementary Figure 4: ROC analysis of SYFPEITHI matrices of nonamers. Each point represents the true and false 
positive predicted ligands applying SYFPEITHI thresholds in 5% steps from 0-100% of the maximal score. 
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4. Summary 
Current therapy of ccRCC is commonly constrained by low response rates and frequent resistance 
against administered drugs. In recent years, drug discovery is focusing on the positive modulation of 
the immune system. The lately approved checkpoint ab nivolumab for treatment of ccRCC is the first 
drug in the upcoming era of immunotherapy. Being an immunogenic tumor entity, specific 
immunotherapies have the potential to increase the anti-cancer response with lower side effects. 
To identify suitable targets for a specific immunotherapy a comprehensive analysis on the HLA 
ligandome of 58 ccRCC samples and corresponding adjacent benign tissues was conducted by LC-
MS/MS and compared to an additional in-house database of benign immunopeptidomes. TUMAPs 
were selected according to several evaluations focusing on tumor-exclusivity, quantitative expression 
and HLA restriction as well as the biological role of the source antigens. Overall, 26 peptides from six 
HLA alleles were selected and screened for their immunogenicity in CD8+ T cell priming experiments, 
with 19 peptides exhibiting immune recognition. This set of peptides can be considered for future 
specific immunotherapeutic approaches. 
HLA-C as well as HLA-E and HLA-G molecules possess important roles in both the innate and adaptive 
immunity with different immunomodulatory functions. However, the uncovering of the peptide 
motifs received insufficient attention until recent data from in vitro binding experiments for HLA-C 
allotypes.  
For this purpose, the characterization of the binding specificities of the most frequent HLA-C 
allotypes as well as HLA-E and HLA-G were accomplished by LC-MS/MS-based identification of 
naturally processed and presented HLA ligands from monoallelic C1R transfectants. HLA-C allotypes 
display anchors in the B or C pocket (position 2 or 3 within the peptide) and a less variable anchor in 
pocket F (C-terminal position within the peptide). Overall, 20,156 HLA-C ligands were identified. For 
HLA-E the previously reported small ligand repertoire could be confirmed with five identified ligands, 
whereas a large ligand repertoire for HLA-G (2258 ligands) could be unveiled with anchor positions 3 
and 9 and an auxiliary anchor at position 1. The data was utilized to establish SYFPEITHI matrices for 
epitope prediction and for peptide assignment to the correct HLA. Especially for HLA-G the number 
of HLA ligands could be tremendously increased from three prior known HLA ligands within the IEDB 
database to more than 2000 HLA ligands. 
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5. Zusammenfassung 
Die gegenwärtige Therapie vom klarzelligem Nierenzellkarzinom ist, sowohl durch eine niedrige 
Ansprechrate als auch durch die häufig auftretenden Resistenzen gegenüber der angewandten 
Medikation begrenzt. Dies ist ein Grund weshalb der Fokus immer weiter in Richtung Modulation des 
Immunsystems gesetzt wird. Der kürzlich für ccRCC zugelassene Checkpoint-Inhibitor-Antikörper 
Nivolumab ist das erste Medikament der bevorstehenden Ära der Immuntherapie. Spezifische 
Immuntherapien haben aufgrund der Immunogenität von ccRCC das Potential höherer 
Anspruchsraten als auch geringerer Nebenwirkungen. 
Um geeignete Angriffsziele für eine spezifische Immuntherapie zu identifizieren wurde eine 
umfangreiche Analyse des HLA Ligandoms von 58 ccRCC Proben und entsprechendem benachbarten 
Normalgewebe mittels LC-MS/MS durchgeführt und zusätzlich mit einer internen Immunpeptidom-
Datenbank von diversen gesunden Organen verglichen. TUMAPs wurden durch Anwendung 
unterschiedlicher Auswertungen ausgewählt, die sowohl deren Tumorexklusivität, quantitative 
Expression und HLA-Restriktion als auch die Funktion des Quellantigens berücksichtigten. Insgesamt 
wurden 26 Peptide von sechs HLA-Allotypen ausgewählt und auf deren Immunogenität in CD8+ 
T-Zell-Priming-Experimenten überprüft. 19 von 26 Peptiden konnten im Komplex mit HLA durch CD8+ 
T-Zellen gesunder Spender erkannt werden. Dieses Set an Peptiden kann für zukünftige spezifische 
immuntherapeutische Ansätze in Betracht gezogen werden. 
HLA-C- als auch HLA-E- und HLA-G-Moleküle nehmen sowohl in der angeborenen als auch in der 
adaptiven Immunität diverse immunmodulatorische Funktionen ein. Nichtsdestotrotz wurden viele 
HLA-C-Bindemotive erst kürzlich über in vitro Bindungsexperimenten angegangen. 
Aus diesem Grund wurden die Bindungsspezifitäten der häufigsten HLA-C-Allotypen als auch die 
Bindungsspezifitäten von HLA-E und HLA-G charakterisiert. Hierfür wurden natürlich prozessierte und 
präsentierte HLA-Liganden aus monoallelischen C1R-Transfektanten mittels LC-MS/MS identifiziert. 
HLA-C-Allotypen zeigen Ankerpositionen in der B- oder C-Tasche (Interaktion mit Position 2 bzw. 3 im 
Peptid) und einen wenig variablen Anker in der F-Tasche (Interaktion mit C-terminaler Position im 
Peptid). Insgesamt wurden 20.156 HLA-C-Liganden identifiziert. Für HLA-E wurde das bekannte kleine 
Ligandenrepertoire (5 identifizierte Liganden) bestätigt, wohingegen das breite Repertoire von HLA-G 
(2258 Liganden) aufgedeckt werden konnte. Position 3 und der C-Terminus des Liganden bilden 
hierbei die Ankerpositionen und Position 1 einen Hilfsanker. Die Daten wurden verwendet um 
SYFPEITHI-Matrizen für die Epitopvorhersage als auch für die Peptidzuordnung zum entsprechenden 
HLA Molekül zu etablieren. Insbesondere für HLA-G konnte die Anzahl der HLA-Liganden massiv von 
bisher drei bekannten Liganden IEDB Datenbank) auf über 2000 Liganden gesteigert werden. 
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6. Abbreviations 
aa amino acid 
ab antibody 
ACT adoptive T cell transfer  
APC antigen presenting cell 
AUC area under the curve  
ccRCC clear cell renal cell carcinoma  
chRCC chromophobe renal cell carcinoma  
CTA cancer-testis antigen 
CTL cytotoxic T lymphocyte 
CTLA-4 cytotoxic T lymphocyte-associated protein 4  
DC dendritic cell 
DRiP defective ribosomal product 
ER endoplasmic reticulum  
FDR false discovery rate  
FP false positive  
HIF hypoxia-inducible factor 
HLA human leukocyte antigen  
HRE hypoxia-response element 
ICS intracellular cytokine staining  
IDO indoleamine-2,3-dioxygenase  
IGF insulin growth factor  
IL interleukin 
IFN interferon 
KIR killer cell immunoglobulin-like receptor 
LC liquid chromatography 
LC-MS/MS liquid chromatographic tandem mass spectrometry  
MDSC myeloid-derived suppressor cell 
MHC major histocompatibility complex  
mRCC metastatic renal cell carcinoma  
MS mass spectrometry 
mTOR mammalian target of rapamycin  
NK cell natural killer cell 
PBMC peripheral blood mononuclear cell 
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PD-1 programmed cell death protein 1  
PD-L1 programmed cell death 1 ligand 1 
pHLA HLA-peptide complex  
pMHC MHC-peptide complex  
pRCC papillary renal cell carcinoma  
RCC Renal cell carcinoma  
ROC receiver operating characteristic  
RT room temperature  
TAA tumor-associated antigen 
TAM tumor-associated macrophage 
TAP transporter associated with antigen processing 
TCGA The Cancer Genome Atlas  
TCR T-cell receptor 
TGF-β transforming growth factor-β 
TH cell T helper cell 
TIL tumor-infiltrating lymphocyte 
TLR Toll-like receptor  
TP true positive  
Treg cell regulatory T cell 
TSA tumor-specific antigen 
TUMAP tumor-associated peptide 
VEGF vascular endothelial growth factor  
VHL Von-Hippel Lindau  
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8. Appendix 
8.1. Lists of TUMAPs of selected target candidates 
Supplementary Table 5: Class I TUMAPs of selected target candidates. All TUMAPs of the 112 filtered antigens are listed 
with number of ccRCC positive samples, Ensembl ID of the corresponding gene, Uniprot ID of the corresponding protein, 
fold change gene expression within the TCGA dataset and its statistical significance. Gene expression data was downloaded 
on 12/9/16 from the Genomic Data Commons Portal (https://gdc-portal.nci.nih.gov/, HTSeq – FPKM-UQ normalized data). 
Gene 
     TUMAP 
Found on n 
ccRCC 
patients 
Ensembl_ID Uniprot_ID FC 
expression 
(Tum/Ben) 
p-Value 
ABCA1 6 ENSG00000165029 O95477 3.17 1.73E-34 
QEMDLVRML 1     
RLSDLGISSY 3     
SAGLLVVILK 2     
ACAD11 16 ENSG00000240303 Q709F0 2.84 3.55E-14 
AEVLPQHKF 7     
DLAHFSLFY 1     
FPVPKPILY 2     
IYVATVETL 1     
RTQNTSLSR 1     
RVPATNLIL 2     
SVIGTEFYV 2     
ACLY 25 ENSG00000131473 P53396 2.85 5.45E-37 
ATADYICKV 1     
ATVGKATGFLK 1     
ETMNYAQIR 3     
EVEKITTSK 1     
EVPPPTVPMDY 1     
FHHEGGVDV 1     
FISGLFNFY 2     
GEIIQSVYEDL 1     
GVAIGGDRY 2     
HFPATPLLDY 2     
KEILIPVF 2     
LPKYSCQFI 1     
SRHTKAIVW 1     
TAVAKNQAL 1     
TMFSSEVQF 1     
VSSLTSGLLTI 1     
YPFTGDHKQKF 2     
YVLPEHMSM 1     
ADM 5 ENSG00000148926 P35318 8.87 6.75E-38 
KLVSVALMY 1     
LPEAGPGRTL 4     
ADSSL1 16 ENSG00000185100 Q8N142 6.14 1.08E-25 
AVKWVGVGK 1     
FPTEQINEI 5     
GEVKVGVSY 1     
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Supplementary Table 5 (continued) 
KEYDFHLLP 2     
QHQSMFPTL 1     
VENHVGVAVKW 1     
VLGEVKVGV 4     
WLDLMILRY 1     
AHNAK2 14 ENSG00000185567 Q8IVF2 24.43 7.59E-37 
DALKILQY 1     
GRLEGDLSL 1     
IPEPHTQARVY 1     
KLMVPRFSF 1     
KLPEGHMPEV 1     
MPKFKIPSL 2     
MPKFKMPSF 1     
RPQVHIPSL 1     
RRKFLNLRF 1     
SLDVSAPKV 3     
SVDVSPPKV 1     
ALDOA 19 ENSG00000149925 P04075 2.32 9.69E-32 
DGRPFPQVI 1     
GRALQASALK 1     
PLLKPWAL 1     
QEEYVKRAL 2     
RALQASALK 2     
RRFYRQLLL 1     
RTVPPAVTGITF 4     
SEEEASINL 4     
SIAKRLQSI 1     
TENTEENRRF 2     
ALPK2 18 ENSG00000198796 Q86TB3 4.64 4.63E-33 
AEAQPLEGF 1     
DELIQRNY 2     
DPIDEISVIEY 4     
DTIDSLVGR 2     
FPWEKPTTL 4     
KELSVTDSL 1     
NPKKPNANL 2     
SENNPLVQF 1     
YVFPVSQKR 1     
ANGPTL4 13 ENSG00000167772 Q9BY76 79.23 3.21E-39 
AQNSRIQQL 3     
AQNSRIQQLF 4     
DEMNVLAH 1     
LPRDCQELF 1     
RPWEAYKAGF 1     
RTRSQLSALER 2     
SRIQQLFHK 1     
APOB 30 ENSG00000084674 P04114 4.78 2.99E-13 
AEARSEILAHW 1     
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Supplementary Table 5 (continued) 
AEAVLKTLQEL 1     
AFTDLHLRY 1     
FELPTGAGL 1     
FTDLHLRY 1     
GEATLQRIY 2     
GRFREHNAKF 1     
HSTKNHLQL 1     
IFMENAFEL 1     
IRWKNEVRI 1     
KLRLEPLKL 1     
KLVELAHQY 1     
KPQEFTIVAF 1     
LPDFRLPEI 1     
QRANLFNKL 1     
SEPINIIDAL 1     
SLDGKAALTEL 1     
SPAKLLLQM 1     
SSASLAHMK 2     
SSPITLQAL 1     
TAYGSTVSKR 1     
TLLDSPIKV 1     
VASHIANIL 1     
VLMDKLVEL 3     
VPDGVSKVL 1     
YQMDIQQEL 1     
APOL1 11 ENSG00000100342 O14791 2.62 8.41E-27 
DVAPVSFFL 3     
IGKDIRALR 1     
KEKVSTQNL 1     
KLTDVAPVSF 1     
QELEEKLNIL 1     
RGIGKDIRALR 2     
SVPHASASR 2     
ARHGAP42 5 ENSG00000165895 A6NI28 2.51 1.27E-25 
AEPLMTYKL 1     
DEISIAQSL 3     
VQKLMNTTF 1     
ARSE 9 ENSG00000157399 P51690 2.12 1.13E-12 
DVFPTVVRL 2     
HSDHEFLMHY 4     
LTHLIPVSW 2     
SSIGYRVLQW 1     
ATP11A 5 ENSG00000068650 P98196 2.82 5.17E-27 
ALINTVLKY 1     
EVALVEGVQR 1     
VLFELSKTV 3     
BCO1 3 ENSG00000135697 Q9HAY6 3.02 3.51E-25 
IVSTDPQKL 3     
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Supplementary Table 5 (continued) 
BNIP3 6 ENSG00000176171 Q12983 3.18 1.53E-33 
LAIGLGIYI 1     
LAIGLGIYIGR 3     
RRKEVESILKK 1     
TLSMRNTSV 1     
C1QB 7 ENSG00000173369 P02746 7.86 2.6E-36 
IAFSATRTI 6     
LEQGENVFL 1     
C3 35 ENSG00000125730 P01024 40.66 8.94E-34 
AEDLVGKSLY 3     
FTIPANREF 1     
HRIHWESASLL 1     
HRIHWESASLLR 1     
IPIEDGSGEVVL 2     
IPSFRLVAY 1     
KIWDVVEKA 3     
LSSEKTVL 1     
QEVEVKAAVY 1     
SEFPESWLW 3     
SPAYRVPVA 1     
TESETRILL 4     
VEIRAVLY 1     
VEKVVLVSL 7     
VTITARFLY 4     
YSIITPNILRL 1     
CA9 10 ENSG00000107159 Q16790 1072.87 2.9E-39 
APLCPSPWLPL 1     
EHTVEGHRF 1     
GTKGGVSYR 1     
SPRAAEPVQL 4     
SPVDIRPQL 2     
SVAFLVQMR 1     
CCND1 19 ENSG00000110092 P24385 4.97 1.54E-37 
ALLESSLRQA 5     
IEALLESSL 2     
KHAQTFVAL 1     
MELLLVNKL 1     
RAYPDANLL 1     
RSPNNFLSY 1     
SPNNFLSYY 2     
TPHDFIEHF 6     
CD180 3 ENSG00000134061 Q99467 6.32 5.23E-28 
QELDLTATHL 3     
CDK18 13 ENSG00000117266 Q07002 6.30 6.24E-38 
AEAALSHSY 6     
AEAALSHSYF 1     
EELHLIFRL 2     
SEFRTYSF 4     
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Supplementary Table 5 (continued) 
CEBPA 4 ENSG00000245848 P49715 2.36 3.08E-21 
YLDGRLEPLY 4     
CENPF 4 ENSG00000117724 P49454 4.51 3.41E-32 
KNKEIQEL 1     
LEKLKLAV 3     
COL1A1 4 ENSG00000108821 P02452 9.18 5.38E-24 
FSFVDLRLL 3     
TGNLKKAL 1     
COL4A2 4 ENSG00000134871 P08572 3.40 5.56E-30 
HPIIAPTGVTF 4     
COL6A2 15 ENSG00000142173 P12110 4.69 3.89E-30 
ALCDRDVTV 2     
DSLHESAHSMR 1     
DTINRIIKV 1     
FLLDGSERL 3     
HEKHESENL 1     
NEFYLDQVAL 1     
RPVDIVFLL 2     
RRFVEQVAR 1     
TAIGIGDMF 1     
TPSALKFAY 1     
TWTPSALKF 1     
CP 35 ENSG00000047457 P00450 24.92 5.17E-29 
AEDRVKWYL 1     
AEVGDTIRVTF 3     
DSTFRVPVER 1     
DVGDKVKIIFK 1     
ETFRTTIEK 1     
FLDKGEFY 1     
GTTRIGGSY 1     
HFHGHSFQY 1     
IEKPVWLGF 1     
NAFLDKGEFY 2     
NEIDLHTVHF 3     
NEVDVHAAF 3     
NEVDVHAAFF 3     
RLYKKALYL 1     
RQSEDSTFY 1     
RTTIEKPVW 1     
SHVAPTETF 3     
SIEPIGVRF 1     
STFRVPVERK 2     
TDSTFRVPVER 1     
TFYLGERTYY 1     
YLGERTYYI 1     
YTDASFTNR 1     
CSPG4 9 ENSG00000173546 Q6UVK1 8.44 2.87E-36 
GRLGLEVGR 1     
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Supplementary Table 5 (continued) 
GRLQVRLVL 1     
LSTDPQHHAY 1     
QAEVYAGNILY 3     
STDPQHHAY 2     
TLAPPLLRV 1     
CYP2J2 25 ENSG00000134716 P51589 48.52 9.5E-36 
ARTELFIFF 2     
DHFLENGQF 1     
ETRDFIDAY 1     
GTETTSTTLRW 1     
ITISPVSHR 1     
REVTVDTTL 5     
RPPNNEKLSL 2     
TALHRDPTEW 1     
TETTSTTLRW 1     
TTLRWALLY 5     
VLITGLPLI 2     
VPREVTVDTTL 2     
VVHPRTLLL 1     
CYP3A5 7 ENSG00000106258 P20815 5.96 5.82E-24 
RLFPVAIRL 7     
DDIT4 6 ENSG00000168209 Q9NX09 5.87 1.28E-33 
FSSANSPFL 1     
LALDPSLVPTF 1     
REEGFDRSTSL 3     
RLWPKIQGL 1     
DIRAS2 10 ENSG00000165023 Q96HU8 9.61 1.08E-33 
AEALARTW 1     
EAEALARTW 1     
SEAEALARTW 8     
DNAH11 11 ENSG00000105877 Q96DT5 34.34 6.71E-31 
GLVDIMVHL 8     
HYSTLVHMF 1     
NLDLLVQGY 1     
TPARVIVLL 1     
EGLN3 34 ENSG00000129521 Q9H6Z9 25.50 1.99E-39 
AEERAEAKKKF 1     
EAKKKFRNL 1     
FLLSLIDRL 9     
GSRLGKYYVK 2     
LSLIDRLVL 1     
LSLIDRLVLY 1     
MPLGHIMRL 8     
SLIDRLVLY 3     
SRLGKYYVK 2     
VPCLHEVGF 2     
VQPSYATRY 3     
YVKERSKAM 1     
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Supplementary Table 5 (continued) 
EHD2 11 ENSG00000024422 Q9NZN4 6.51 2.11E-36 
AERVDLIIL 1     
DEMLTHDI 2     
ERVDLIILL 1     
GTHMGPFVER 2     
SVLGRIWKL 4     
TEVGVQGGAF 1     
ENPP3 12 ENSG00000154269 O14638 47.97 1.9E-38 
GETRLEASL 2     
HAGGPVSAR 4     
KEQNNPAWW 1     
KTCGIHSKY 1     
RAMYPTKTF 1     
TLMPNINKL 2     
YQGLKAATY 1     
ESM1 3 ENSG00000164283 Q9NQ30 14.25 6.67E-38 
KSVLLLTTL 3     
FABP7 6 ENSG00000164434 O15540 2038.46 6.1E-38 
EYMKALGVGF 1     
LTFGDVVAVR 3     
YMKALGVGF 2     
FGG 16 ENSG00000171557 P02679 5.56 7.33E-07 
FLSTYQTKV 1     
GVYYQGGTYSK 1     
KMLEEIMKY 2     
KQSGLYFIK 2     
KRLDGSVDF 1     
KSRKMLEEI 1     
KVGPEADKY 1     
PYALRVEL 1     
SAIPYALRV 1     
SLEDILHQV 3     
THDSSIRYL 1     
TPNGYDNGIIW 1     
FSCN1 6 ENSG00000075618 Q16658 2.77 5.14E-30 
ASASSLKKK 3     
HDDGRWSL 1     
SVQTADHRFLR 1     
TLDANRSSY 1     
GABRD 5 ENSG00000187730 O14764 83.47 4.56E-39 
AAVPARVSL 1     
AFAHFNADY 1     
VTQELAISR 3     
GAL3ST1 4 ENSG00000128242 Q99999 7.98 4.94E-37 
RLFESSFHY 1     
SLDPSSPQV 3     
GALNT14 9 ENSG00000158089 Q96FL9 2.16 6.77E-31 
GEDAKSQVW 1     
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Supplementary Table 5 (continued) 
RPFGNVESRL 1     
SIPKESSIQK 5     
SRLDLRKNL 1     
TYIESASEL 1     
GAS2L3 7 ENSG00000139354 Q86XJ1 10.56 3.33E-38 
SVSPVKATQK 7     
GJA4 3 ENSG00000187513 P35212 2.51 1.11E-25 
NLLELVHLL 3     
GRIA4 11 ENSG00000152578 P48058 5.48 6.84E-08 
APFNLVPHV 1     
DTDRGYSIL 1     
NILEQIVSV 7     
RIISRQIVL 2     
HAVCR1 9 ENSG00000113249 Q96D42 6.13 1.47E-20 
GVIIAKKYFFK 4     
HPQVVILSL 1     
IIAKKYFFK 3     
VILSLILHL 1     
HHLA2 4 ENSG00000114455 Q9UM44 13.50 7.77E-29 
VYPRPIITW 4     
HILPDA 4 ENSG00000135245 Q9Y5L2 45.21 5.29E-39 
LPDHPSRSM 3     
TLLSIFVRV 1     
HLA-DMA 3 ENSG00000204257 P28067 2.80 5.4E-35 
FPIAEVFTL 3     
HLA-DOA 7 ENSG00000204252 P06340 2.27 1.16E-18 
HEFDEEQLF 1     
LPKSRVEL 1     
VTEGVAQTSFY 5     
HLA-DQB2 6 ENSG00000232629 P05538 8.55 4.22E-26 
FPKDFLVQF 2     
VMLSTPVAEA 4     
HLA-G 5 ENSG00000204632 P17693 10.21 2.28E-32 
SEASSHTLQW 1     
TGAAVAAVLW 1     
YPAEIILTW 3     
HMOX1 16 ENSG00000100292 P09601 5.25 1.81E-36 
AALEQDLAFW 1     
ATKFKQLYR 1     
EVIPYTPAMQRY 1     
IEEAKTAFL 4     
KAALEQDLAFW 1     
KESPVFAPVYF 1     
KIAQKALDL 4     
QVLKKIAQK 1     
RTEPELLVAHAY 1     
TEPELLVAHAY 1     
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Supplementary Table 5 (continued) 
HSD3B7 11 ENSG00000099377 Q9H2F3 4.43 1.81E-36 
AALNALLQW 3     
IPASVEHGRVY 1     
NTKGHPFYR 2     
QWLLRPLVL 1     
RHFGYEPLF 2     
TTFTVSTDKAQR 2     
HSF4 21 ENSG00000102878 Q9ULV5 50.40 1.12E-39 
ILWREVVTL 15     
RLLGEVQAL 1     
SPSPGKDPTL 4     
VPERGEPEL 1     
HSPB8 4 ENSG00000152137 Q9UJY1 5.08 9.16E-37 
KQQEGGIVSK 1     
WPDWALPRL 3     
IFI27 7 ENSG00000165949 P40305 2.48 3.37E-23 
AGIASSSIAAK 2     
GIASSSIAAK 3     
IASSSIAAK 1     
SGLTKFIL 1     
IGF2BP3 4 ENSG00000136231 O00425 3.65 2.49E-17 
IMKKIRESY 1     
KIQEILTQV 3     
IGFBP3 5 ENSG00000146674 P17936 15.47 7.98E-38 
NASAVSRLR 1     
NHLKFLNVL 1     
RPTLWAAA 3     
IL4R 3 ENSG00000077238 P24394 3.14 3.41E-38 
VLWPESISV 3     
IRX3 11 ENSG00000177508 P78415 3.25 1.11E-26 
AELPIFPQL 6     
FPQLGAQYEL 1     
LPIFPQLGAQY 2     
RTDEEGNAY 2     
KCNAB1 3 ENSG00000169282 Q14722 3.39 2.14E-24 
VEVQLPELY 3     
KCNMA1 3 ENSG00000156113 Q12791 6.96 5.37E-27 
VPPVFVSVY 3     
KCNN1 8 ENSG00000105642 Q92952 10.13 7.79E-30 
RVFLISLEL 8     
KISS1R 11 ENSG00000116014 Q969F8 201.06 5.94E-35 
EAFPSRALER 1     
RLSPGPRAY 1     
RPAPADSAL 6     
SEAFPSRAL 3     
LECT2 3 ENSG00000145826 O14960 2.14 0.00025002 
GTLLPLQK 3     
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Supplementary Table 5 (continued) 
LOX 7 ENSG00000113083 P28300 11.63 8.04E-34 
DVKPGNYILK 1     
GAWRQQIQW 2     
IQWENNGQVF 1     
IRYTGHHAY 3     
LOXL2 7 ENSG00000134013 Q9Y4K0 9.19 3.34E-34 
FGFPGERTY 4     
GMFGFPGERTY 1     
KSWTASSSY 2     
LPCAT1 8 ENSG00000153395 Q8NF37 5.51 2.5E-39 
ALAEGQLRL 1     
EEEKRNPAL 1     
GRNPFVHEL 1     
LEVPVSDLL 3     
YPNKLDTITW 2     
LRRK2 18 ENSG00000188906 Q5S007 2.15 5.76E-19 
DGKKRHTL 1     
DIIRFLQQR 1     
ESSPKLVEL 1     
GEEHQKILL 4     
HETSLPVQL 2     
HHSFDLVIF 2     
KIMAQILTV 1     
KLPDPVKEY 1     
KPWLFNIKA 1     
MHSSSKEVF 1     
QTILAILKL 1     
TLLKKWAL 1     
VELEKIIL 1     
MET 11 ENSG00000105976 P08581 2.17 4.12E-25 
APLEGGTRL 1     
FPIKYVNDFF 1     
HYVHVNATY 1     
KPFEKPVMI 1     
RISAIFSTF 4     
SYREDPIVY 1     
YVDPVITSI 2     
MS4A6A 3 ENSG00000110077 Q9H2W1 7.12 8.39E-34 
MLICTLLEF 3     
NDRG1 26 ENSG00000104419 Q92597 2.64 4.93E-32 
ALPDMVVSH 2     
FALNNPEM 1     
FPAGYMYPSM 5     
LPDMVVSHLF 1     
MPGTHTVTL 1     
MPSASMTRLM 1     
NPEMVEGLVL 1     
NVEVVHTYR 1     
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Supplementary Table 5 (continued) 
PSASMTRL 1     
QPAKLAEAF 3     
RPMPGTHTVTL 1     
SAGPKSMEV 1     
SHTSEGAHL 1     
SNVEVVHTYR 2     
YFVQGMGY 3     
YILTRFAL 1     
NDUFA4L2 22 ENSG00000185633 Q9NRX3 153.58 1.7E-38 
AGASLGARFYR 1     
ASLGARFYR 2     
AVSTDYKKLKK 1     
DQYKFLAV 3     
GASLGARFY 3     
GSAALYLLR 9     
KRHPGIIPM 1     
RLSPNDQYK 1     
SLGARFYR 1     
NNMT 20 ENSG00000166741 P40261 35.86 1.8E-37 
AESQILKHL 2     
AESQILKHLL 4     
GLFSLVARK 1     
KEIVVTDY 3     
LPLGREAVEA 1     
LVARKLSRPL 1     
RVKGPEKEEK 1     
SQILKHLL 4     
VEAAVKEAGY 2     
YTIEWFEVI 1     
NPTX2 15 ENSG00000106236 P47972 194.64 4.61E-38 
ALLAASVALA 2     
ALLQRVTEL 2     
LLAASVALA 5     
PGDFREVL 1     
SPDAFKVSL 3     
VSLPLRTNY 2     
P4HA2 8 ENSG00000072682 O15460 3.21 3.03E-27 
AEKELVQSL 5     
FHERGQEFL 1     
GEEATTTKSQVL 1     
WPALEDLVL 1     
PFKP 15 ENSG00000067057 Q01813 5.18 1.47E-36 
GQIDKEAVQK 2     
GQLEHVQPWSV 1     
ILGTKRVL 1     
KEWSGLLEEL 3     
KVYFIYEGY 1     
LGYDTRVTI 1     
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Supplementary Table 5 (continued) 
MEWITAKL 1     
RRFQDAVRL 1     
RSFAGNLNTY 4     
PGF 5 ENSG00000119630 P49763 16.65 1.07E-36 
YPSEVEHMF 5     
PLIN2 61 ENSG00000147872 Q99541 11.95 1.66E-36 
AVDPQPSVV 1     
AVTTTVTGAK 2     
ESRTLAIAR 1     
EVSDSLLTSSK 1     
GAVTGSVEK 5     
GVMAGDIYSV 2     
HIESRTLAI 1     
IEERLPIL 1     
IEFARKNVY 3     
IQDAQDKLYL 3     
KEAKKVEGF 1     
LVGPFYPQL 1     
MAGDIYSVF 1     
RTLAIARNL 1     
SALPIIQKL 1     
SELLVEQY 3     
SINTVLGSR 5     
SLSTKLHSR 3     
SRVKEAKQK 1     
STKDQYPYLK 1     
STVHLIEFAR 3     
STVHLIEFARK 1     
SVASTITGVMDK 3     
SVFRNAASF 4     
TSSKGQLQK 4     
TVHLIEFAR 3     
VTTTVTGAK 3     
YPYLKSVC 1     
YQQALSRV 1     
PLOD1 6 ENSG00000083444 Q02809 2.62 1.62E-34 
DVFMFLTNR 2     
KRFLGSGGF 1     
QLFYTKIFL 3     
PLOD2 24 ENSG00000152952 O00469 2.89 1.3E-30 
AEARNMGMDF 1     
ALLNFVVKY 1     
GRLLSTANY 2     
IPTDKLLVI 5     
KESDGFHRF 1     
KIIAPLVTR 4     
LMKEVMEHY 1     
NPVDWKEKY 2     
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Supplementary Table 5 (continued) 
REFIAPVTL 2     
RPHHDASTF 2     
RYLNSGGFIGY 2     
YSKIFTENI 1     
PLOD3 8 ENSG00000106397 O60568 2.75 1.07E-37 
AETEGYLRF 1     
HHDSSTFTL 1     
NPVDWKEQY 2     
SPRKGWAL 3     
YTVRTLGL 1     
PLXNA3 6 ENSG00000130827 P51805 2.53 1.27E-30 
FPIDKPPSF 6     
PRAME 12 ENSG00000185686 P78395 3.88 0.0000177 
GQHLHLETF 3     
KMILKMVQL 1     
MPMQDIKMIL 1     
QLLALLPSL 1     
SLLQHLIGL 4     
SPSVSQLSVL 1     
TVWSGNRASL 1     
PRUNE2 38 ENSG00000106772 Q8WUY3 2.63 3.23E-20 
DEGKLSITL 4     
DEINLHQL 4     
DNSERNLSL 1     
ETRFILEEL 1     
FHSNITSDL 1     
IESPFEREL 1     
ITDSEQREL 1     
KVYEKVDSW 1     
LEEDSLKQSL 2     
NPSSDLDHTW 2     
NRLPGSQL 1     
REDPESVYL 2     
REFVPSNAEL 1     
SEAAFDHSF 4     
SEINTTHNL 9     
TEQLAHRL 1     
THNLDENEL 1     
YVMENLFLY 1     
RASSF4 4 ENSG00000107551 Q9H2L5 3.52 1.95E-34 
EVPHEVAQY 3     
YHEGKSFQL 1     
RGS5 36 ENSG00000143248 O15539 5.54 4.78E-32 
ALMEKDSL 1     
EIKIKLGI 7     
HALMEKDSL 5     
ILLQKPDSV 5     
KAKQIYEEF 1     
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Supplementary Table 5 (continued) 
KEIKIKLGI 1     
KEIKIKLGILL 1     
KIKSPAKMAEK 6     
KLLQNNYGL 5     
PAKTQKTSL 2     
VRSEFYQEL 2     
RNF145 4 ENSG00000145860 Q96MT1 2.09 3.86E-32 
EAVLNVALR 3     
LEIADPIVL 1     
RPLP0 4 ENSG00000089157 P05388 2.04 3.1E-30 
IEILSDVQL 3     
RGNVGFVF 1     
RPS19 4 ENSG00000105372 P39019 2.66 3.04E-34 
ASTARHLYL 1     
TARHLYLR 3     
RRAD 14 ENSG00000166592 P55042 3.45 1.53E-20 
ALFEGVVRQI 5     
EAAGHTYDR 2     
MPVDERDL 1     
MPVDERDLQA 4     
TSAALHHNV 1     
WPEDSEDSL 1     
SAP30 6 ENSG00000164105 O75446 6.28 1.04E-39 
IPVNEKDTL 5     
RPGLNKAQL 1     
SCARB1 9 ENSG00000073060 Q8WTV0 20.59 1.55E-38 
DVMNPSEILK 1     
GVFEGIPTYR 2     
HPNQEAHSL 3     
IVMPNILVL 1     
KEIPIPFYL 1     
VLMPKVMHY 1     
SCD 18 ENSG00000099194 O00767 13.09 1.44E-36 
AVGEGFHNY 1     
ETHADPHNSRR 1     
FPYDYSASEY 1     
ITAGAHRL 1     
ITAGAHRLW 3     
LPLRLFLI 1     
RRYYKPGLLM 1     
RYAVVLNATW 2     
SEYRWHINF 1     
SLLHLGALY 4     
VVLNATWLV 1     
YAVVLNATW 1     
SHMT2 4 ENSG00000182199 P34897 4.43 6.27E-39 
ALLERGYSL 4     
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Supplementary Table 5 (continued) 
SLC16A3 12 ENSG00000141526 O15427 11.29 1.86E-38 
DTAWISSILL 1     
FVAGLGKVR 1     
KLLDATHVY 4     
KLLDATHVYM 1     
VPPVFVVSY 3     
VVHTPETSV 2     
SLC17A3 29 ENSG00000124564 O00476 5.61 1.03E-13 
ALIVSLPYL 8     
APRYSSFL 2     
ARYGIALVL 1     
FLMGASRGF 2     
GYITATALL 2     
IPRKVPSL 2     
ITATALLTL 1     
KEYIISSL 1     
LPSSALIVSL 3     
MVVYIPTYI 2     
SALPFIVAW 3     
SEKEYIISSL 1     
SEVLPVDSF 1     
SLC6A13 6 ENSG00000010379 Q9NSD5 3.05 2.66E-11 
SLYRLGTLK 1     
VMLPFSPLW 1     
YLYPNLTRL 4     
SLC6A8 9 ENSG00000130821 P48029 2.95 3.91E-25 
IAYPRAVTL 7     
LPASYYFRF 1     
VVYYEPLVY 1     
SNX10 5 ENSG00000086300 Q9Y5X0 2.08 1.38E-28 
ALLVQLPEL 3     
KVLQNALLL 1     
RQRLQSNAL 1     
STBD1 5 ENSG00000118804 O95210 2.07 4.71E-26 
AEKLPSSNLL 1     
GRWNTYIPLHY 1     
VENGGVTRW 3     
TLR3 14 ENSG00000164342 O15455 3.31 1.88E-32 
INTSILLIF 4     
LPMLKVLNL 4     
LSYNKYLQL 1     
RLFGLFLNNV 1     
TRYSQLTSL 1     
VPSLQRLML 2     
YAAYIIHAY 1     
TLR7 5 ENSG00000196664 Q9NYK1 5.14 2.46E-27 
DTKDPAVTEW 2     
VLAELVAKL 3     
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Supplementary Table 5 (continued) 
TMEM176A 7 ENSG00000002933 Q96HP8 2.77 1.06E-28 
GSSRLLVASW 1     
HQESALAKLLL 1     
QESALAKLLL 3     
QHTHIDVHI 1     
SSRLLVASW 1     
TMEM91 5 ENSG00000142046 Q6ZNR0 12.81 1.4E-38 
AESLRGLQF 1     
FLSPPLPSV 4     
TRIB3 5 ENSG00000101255 Q96RU7 7.56 1.5E-35 
ASYSGKAADVW 1     
YPFQDSEPVL 4     
USH1C 17 ENSG00000006611 Q9Y6N9 2.37 1.81E-18 
AEAALQKAW 2     
AEAALQKAWNQ 1     
AEAEAALQKAW 5     
DEIVRINGY 1     
EEQGEQDFRKY 2     
KSSPDEPLTW 1     
SPIGKVVVSA 1     
TAEVHPVPL 1     
THEEVINLI 3     
VCAM1 5 ENSG00000162692 P19320 3.97 7.19E-29 
AQIGDSVSL 1     
SPKNTVISV 1     
YPFDRLEIDL 3     
VEGFA 10 ENSG00000112715 P15692 12.30 2.58E-39 
GQHIGEMSF 1     
HPIETLVDIF 9     
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Supplementary Table 6: Class I candidates from quantitative analysis. All HLA class I ligands with a mean log(2) fold change 
e p essio  of  i  RCC sa ples o pa ed to adja e t e ig  sa ples. 
Gene 
     HLA ligand 
Uniprot_ID 
Quantified 
samples 
Mean 
area 
(log2) 
Found on 
n benign 
samples 
[n=158] 
Found on 
n adjacent 
benign 
samples 
[n=58] 
Found on n 
malignant 
samples 
[n=58] 
Malignant/ 
Total [%] 
AATF Q9NY61       
PQPDVFPLF  3 2.00 20 3 5 17.86 
ABCA1 O95477       
ALFEEQGIGV  4 2.72 4 1 7 58.33 
DAFLNKNSI  5 2.94 4 1 7 58.33 
DGYTIVVRI  5 2.47 5 7 8 40.00 
MLRADVIL  3 2.05 1 0 1 50.00 
NVINNAILR  3 2.06 5 1 3 33.33 
ABCC1 P33527       
QILKLLIKF  3 4.42 0 0 2 100.00 
ABCC3 O15438       
AYLHTTTTF  6 2.48 20 2 9 29.03 
VILPLAVLY  3 3.68 1 0 3 75.00 
ABCF3 Q9NUQ8       
VLLDAPIQL  7 2.97 7 1 11 57.89 
ABI1 Q8IZP0       
NYIEKVVAI  3 2.40 23 2 4 13.79 
ABLIM3 O94929       
FPIGDKVTF  4 4.71 15 0 6 28.57 
ACLY P53396       
FMDHVLRY  3 2.19 0 2 3 60.00 
KLYRPGSVAY  3 2.09 13 1 5 26.32 
NFTNVAATF  4 2.68 9 1 7 41.18 
THMTAIVGM  3 2.19 2 3 4 44.44 
ACO1 P21399       
TYIKSPPFF  5 2.99 17 3 8 28.57 
ACTN1 P12814       
ETIDQLYLEY  3 2.64 2 2 3 42.86 
VSKIVQTY  3 2.32 32 1 1 2.94 
ACTR2 P61160       
LPDGRIIKV  3 2.68 9 2 4 26.67 
STMYPGLPSRL  6 3.59 23 0 7 23.33 
ADCK2 Q7Z695       
SLLSSVFKL  3 2.20 4 0 6 60.00 
ADGRE2 Q9UHX3       
TIINSLQGV  3 2.13 0 1 5 83.33 
ADPGK Q9BRR6       
DEFHLILEY  5 3.03 4 2 6 50.00 
RLLEVVTSI  3 2.63 3 0 6 66.67 
SEFPGAQHY  3 2.14 7 2 7 43.75 
ADSSL1 Q8N142       
FPTEQINEI  4 5.08 0 0 5 100.00 
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AFF1 P51825       
EAFPEKIPLF  3 3.09 1 0 3 75.00 
AFF4 Q9UHB7       
MPSPVSPKL  10 2.31 24 6 14 31.82 
AGAP1 Q9UPQ3       
DEISFQTVY  4 2.17 1 2 4 57.14 
AGR2 O95994       
KIPVSAFLL  3 3.36 18 0 2 10.00 
AGRN O00468       
APDVARALL  4 2.76 0 0 5 100.00 
AHNAK Q09666       
FEGPDAKL  3 2.32 0 1 4 80.00 
AHR P35869       
AIMDPLPLRTK  7 2.60 24 3 7 20.59 
AIM1 Q9Y4K1       
SLSPVILIK  8 2.30 24 4 10 26.32 
AKR1C3 P42330       
HPNYPYSDEY  5 3.03 14 3 5 22.73 
ALDOA P04075       
ALSDHHIYL  14 3.16 23 9 20 38.46 
ASINLNAINK  5 3.37 1 0 6 85.71 
ESTGSIAKRL  3 3.98 0 1 2 66.67 
HHIYLEGTLL  4 3.59 0 1 4 80.00 
LFVSNHAY  5 3.62 7 0 1 12.50 
LSDHHIYL  9 3.94 1 2 12 80.00 
RTVPPAVTGITF  3 4.34 0 0 4 100.00 
SEEEASINL  3 3.91 0 0 4 100.00 
SESLFVSNHAY  10 2.07 21 8 14 32.56 
SLFVSNHAY  5 2.53 23 6 9 23.68 
ALDOB P05062       
TEKVLAAVY  7 2.50 3 5 7 46.67 
ALDOC P09972       
ESVGSMAKR  3 2.71 2 0 4 66.67 
ALKBH6 Q3KRA9       
EEYLLRQVF  3 3.67 8 1 3 25.00 
ALOX5 P09917       
KIVPIAIQL  11 3.46 1 0 11 91.67 
QVVEEDPEL  3 3.33 0 0 2 100.00 
ALPK2 Q86TB3       
DPIDEISVIEY  3 4.07 0 0 4 100.00 
FPWEKPTTL  3 4.35 0 0 4 100.00 
AMN Q9BXJ7       
READTEIQVVL  3 3.44 0 1 4 80.00 
ANKRD13A Q8IZ07       
TSWVPLVSR  3 3.46 2 0 5 71.43 
ANKRD18B A2A2Z9       
MQAIEKLEEI  3 4.00 0 0 1 100.00 
ANXA2 P07355       
LIDQDARDLY  3 3.71 0 0 5 100.00 
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ANXA4 P09525       
DEVKFLTV  3 2.66 0 1 4 80.00 
DEVKFLTVL  5 4.54 1 1 5 71.43 
IRSDTSFMF  3 4.81 1 0 3 75.00 
NAMEDAQTL  5 3.56 5 2 6 46.15 
SAYFAEKLYK  6 3.97 4 0 7 63.64 
ANXA5 P08758       
DAYELKHAL  4 2.10 22 6 7 20.00 
AOC1 P19801       
KAVHSFLW  3 4.70 0 0 3 100.00 
AP2S1 P53680       
VYTVVDEMFL  3 2.93 10 0 4 28.57 
AP3D1 O14617       
MPNHSASIQL  3 3.83 1 0 3 75.00 
APLP2 Q06481       
SLLYKVPYV  3 2.91 2 1 3 50.00 
APOL1 O14791       
FLVLDVVYL  3 2.16 0 2 8 80.00 
IFIEDAIKY  3 3.06 0 1 4 80.00 
SLAGNTYQL  5 2.01 3 2 6 54.55 
AQP2 P41181       
GQAVTVELFL  3 2.32 0 0 1 100.00 
AQP3 Q92482       
LYYDAIWHF  5 2.74 12 4 6 27.27 
ARCN1 P48444       
ETTFLVDKY  5 2.42 2 1 8 72.73 
FVETESVRY  5 2.65 0 1 7 87.50 
IQVTKVTQV  5 2.38 5 1 2 25.00 
ARHGAP42 A6NI28       
DEISIAQSL  3 2.61 0 0 3 100.00 
ARHGEF2 Q92974       
KYPLLISRI  4 2.41 10 1 5 31.25 
ARL2BP Q9Y2Y0       
IYTPIFNEY  3 2.13 6 1 3 30.00 
ARL4C P56559       
KLYEMILKR  4 4.46 17 2 5 20.83 
ARL6IP1 Q15041       
NQHGIILKY  3 3.73 1 0 3 75.00 
ARPC3 O15145       
FPIPGEPGF  10 2.24 22 3 12 32.43 
ARRDC3 Q96B67       
KVKSLTISF  3 3.26 4 0 5 55.56 
ARSB P15848       
VPLDEKLLPQL  4 2.71 4 1 2 28.57 
ASPA P45381       
VYLIEHPSL  4 4.15 0 0 6 100.00 
ATF4 P18848       
YLKDLIEEV  4 2.54 8 1 9 50.00 
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ATL2 Q8NHH9       
HEDDHNFEL  3 2.28 0 0 4 100.00 
ATM Q13315       
SVYDALPLTR  6 2.33 22 2 6 20.00 
SVYDALPLTRL  3 3.40 6 0 1 14.29 
ATP1B1 P05026       
AYVLNIVRF  9 2.53 3 10 10 43.48 
KAYGENIGY  3 2.79 3 3 6 50.00 
YPYYGKLL  5 2.74 0 4 6 60.00 
ATP5G1 P05496       
SPVNSSKQPSY  5 2.10 4 2 6 50.00 
ATP6V1E1 P36543       
MPEVRGALF  3 2.18 4 2 6 50.00 
BAK1 Q16611       
NAYEYFTKI  3 2.25 6 3 5 35.71 
BARX2 Q9UMQ3       
RLSSPGQLK  4 3.09 1 0 5 83.33 
BAZ2A Q9UIF9       
GEVQDLLVRL  3 2.04 2 1 3 50.00 
BBS4 Q96RK4       
IYQKAFEHL  5 2.55 13 2 8 34.78 
QYASAFHFL  4 3.22 16 3 6 24.00 
BCAS2 O75934       
VYNENLVHMI  7 2.49 21 3 9 27.27 
BHLHE41 Q9C0J9       
GQKLEPLAY  3 4.17 24 0 5 17.24 
BHMT2 Q9H2M3       
DEARIKKLF  3 4.93 0 0 4 100.00 
YPFGLESRV  6 3.86 0 2 8 80.00 
BICC1 Q9H694       
MPAETIKEL  10 2.98 1 5 11 64.71 
BIRC2 Q13490       
KLGDSPIQK  3 2.73 5 0 4 44.44 
BPIFB4 P59827       
LLGGIKVKL  5 2.31 0 1 7 87.50 
BTBD9 Q96Q07       
GEIDHVHIL  3 2.57 6 1 5 41.67 
BTNL9 Q6UXG8       
APHRVALTL  4 2.41 5 1 6 50.00 
BZW2 Q9Y6E2       
FLDSTGSRLDY  3 2.81 8 1 5 35.71 
C11orf52 Q96A22       
MSEDSNLHY  4 2.23 6 3 8 47.06 
C12orf4 Q9NQ89       
EVVQQVVLY  3 3.00 0 0 3 100.00 
C14orf166 Q9Y224       
TEFRNFIVW  5 2.70 9 1 5 33.33 
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C16orf58 Q96GQ5       
NLAKCIVSV  3 4.25 1 0 4 80.00 
C16orf87 Q6PH81       
KIINQRLIL  4 5.14 0 0 4 100.00 
C1QB P02746       
FLLFPDMEA  9 2.54 61 0 9 12.86 
IAFSATRTI  3 4.51 0 0 6 100.00 
RFDHVITNM  7 4.00 4 2 10 62.50 
VTTGGMVLK  3 4.28 11 0 4 26.67 
C1S P09871       
TLFGSVIRY  3 2.81 9 0 3 25.00 
C2 P06681       
DHIREILNI  3 3.17 0 2 3 60.00 
C3 P01024       
ATFGTQVVEK  4 4.16 29 0 5 14.71 
TEFEVKEY  4 3.63 0 1 4 80.00 
TESETRILL  3 2.80 0 0 4 100.00 
TPTVIAVHY  3 4.70 2 0 3 60.00 
VEKVVLVSL  6 4.13 0 0 7 100.00 
C3orf70 A6NLC5       
ISDLFIDNY  3 2.29 1 1 5 71.43 
C6orf106 Q9H6K1       
SEFQRLLGF  4 2.27 4 2 4 40.00 
CA9 Q16790       
SPRAAEPVQL  3 5.41 0 0 4 100.00 
CABIN1 Q9Y6J0       
SVLPWIILH  4 2.71 22 1 6 20.69 
CAD P27708       
HPQPGAVEL  4 2.28 4 2 5 45.45 
CALML4 Q96GE6       
DEFIHKITL  3 2.82 1 2 3 50.00 
CARD11 Q9BXL7       
FLMNEVIKL  4 2.20 11 2 10 43.48 
CASD1 Q96PB1       
TSIAPLLEK  7 5.44 9 0 8 47.06 
CCND1 P24385       
ETIPLTAEK  4 4.57 5 0 4 44.44 
ETIPLTAEKL  4 2.45 18 3 6 22.22 
TPHDFIEHF  4 3.68 0 0 6 100.00 
CCND2 P30279       
ALTELLAKI  9 2.44 7 4 18 62.07 
ATDFKFAMY  12 2.71 18 4 18 45.00 
CCT5 P48643       
HVIETLIGK  9 2.24 33 4 10 21.28 
CCT6A P40227       
HPRIITEGF  3 2.62 2 1 5 62.50 
CCT8 P50990       
AEELLRIGL  6 2.33 6 5 7 38.89 
FLAKLIAQA  3 3.84 8 1 6 40.00 
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CD24 P25063       
ARLGLGLLL  3 5.22 2 1 5 62.50 
RAMVARLGL  3 4.10 2 0 6 75.00 
CDC42SE2 Q9NRR3       
AHVGSGDLF  3 3.00 0 1 3 75.00 
CDH2 P19022       
EEIVFPRQF  3 3.64 1 0 4 80.00 
CDH5 P33151       
GSDPREELLY  3 3.66 1 0 5 83.33 
CDK18 Q07002       
DTASIFSLK  7 4.33 4 0 7 63.64 
CDKL1 Q00532       
FTETSKLQY  3 3.05 2 1 3 50.00 
CDKN2A P42771       
LPVDLAEEL  3 3.08 1 0 6 85.71 
CDKN2AIPNL Q96HQ2       
IEVEDLPQF  3 3.45 0 0 5 100.00 
CECR1 Q9NZK5       
APVFRDYVF  6 3.41 12 1 7 35.00 
CFI P05156       
AEGKFSVSL  4 2.72 0 0 5 100.00 
CFL1 P23528       
ILEEGKEILV  4 2.54 6 2 5 38.46 
CHD4 Q14839       
RIPPVAVRL  4 5.16 1 0 6 85.71 
CIB1 Q99828       
AEYQDLTFL  6 2.57 3 3 7 53.85 
FASSFKIVL  3 3.80 11 0 3 21.43 
FLTKQEILL  15 2.10 17 16 24 42.11 
CIITA P33076       
GVSSIFIYH  8 2.06 3 5 9 52.94 
CIT O14578       
YLDIPNPRY  8 3.39 1 0 11 91.67 
CLASP1 Q7Z460       
AEYDNFFQHL  3 2.72 17 1 3 14.29 
CLNS1A P54105       
YPTISLHAL  3 3.38 10 1 5 31.25 
CLTC Q00610       
KMYDAAKLLY  3 4.47 8 0 7 46.67 
MFTELAILY  3 2.27 0 3 3 50.00 
CMBL Q96DG6       
SEFRAGVSVY  3 2.13 0 1 4 80.00 
VEYQIKTF  5 3.71 0 1 5 83.33 
CMTR1 Q8N1G2       
GEELLHSVL  4 2.39 5 0 5 50.00 
CNDP2 Q96KP4       
QEIPVNVRF  8 2.10 8 6 9 39.13 
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CNOT1 A5YKK6       
YHDINVYSL  3 2.16 2 2 4 50.00 
COL6A2 P12110       
EVISPDTTER  3 3.36 12 1 3 18.75 
FVIDSSESIGY  4 3.87 4 1 4 44.44 
COPB1 P53618       
FEWENKVTV  4 2.37 15 2 8 32.00 
COPB2 P35606       
GELKIAYQL  3 3.01 2 1 4 57.14 
COPG1 Q9Y678       
ALVSSLHLL  9 2.06 3 3 13 68.42 
DTVTMQVTAR  3 2.13 9 2 4 26.67 
COX8A P10176       
SVLTPLLLR  3 2.51 1 0 3 75.00 
CP P00450       
AEVGDTIRVTF  3 3.33 0 0 3 100.00 
FLDKGEFYI  6 3.80 0 1 8 88.89 
KVYPGEQYTY  3 5.64 4 0 4 50.00 
NEADVHGIYF  8 2.73 2 3 8 61.54 
SHVAPTETF  3 2.50 0 0 3 100.00 
TVDQVKDLY  13 2.55 15 10 17 40.48 
VVDENFSWY  3 2.95 0 1 7 87.50 
CPE P16870       
ASAPGYLAITK  3 5.20 13 0 4 23.53 
CREB3L2 Q70SY1       
VLLELQQHL  3 3.10 3 2 7 58.33 
CRIP1 P50238       
GGAESHTFK  5 2.27 7 0 5 41.67 
CRYAB P02511       
DEHGFISREF  3 2.72 0 1 4 80.00 
CRYL1 Q9Y2S2       
KLFAGLVHV  6 2.64 18 3 10 32.26 
CSPG4 Q6UVK1       
TMLARLASA  18 3.28 2 7 24 72.73 
CTNNA1 P35221       
SEFKAMDSI  4 2.24 19 2 7 25.00 
CTNNB1 P35222       
HAIMRSPQM  3 2.63 4 1 6 54.55 
CTSL P07711       
KVFQEPLFY  10 4.23 11 3 14 50.00 
CUBN O60494       
PYSQVWIHF  3 4.79 1 3 7 63.64 
CXCL13 O43927       
KFISTSLLL  3 2.38 5 0 4 44.44 
CYP2J2 P51589       
ITFGERFEY  5 4.84 2 0 6 75.00 
KLLDEVTYL  12 6.01 2 0 16 88.89 
REVTVDTTL  4 4.86 0 0 5 100.00 
TTLRWALLY  4 4.47 0 0 5 100.00 
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CYP7B1 O75881       
KLLEKAFSI  4 2.09 14 2 9 36.00 
DARS P14868       
AEPRLPLQL  3 3.61 1 0 6 85.71 
TSTSQAVFR  3 2.44 2 0 3 60.00 
DBR1 Q9UK59       
RIGGISGIFK  3 2.22 25 2 3 10.00 
DCLK1 O15075       
IPATITERY  3 2.78 6 0 3 33.33 
DCPS Q96C86       
ATEKHLQKY  3 3.04 10 0 6 37.50 
DDOST P39656       
DSFFNSAVQK  3 2.17 5 1 3 33.33 
FPDKPITQY  6 2.06 39 6 9 16.67 
VQFKLPDVY  3 2.16 21 2 3 11.54 
YSSTQVSVR  3 2.43 6 1 3 30.00 
DDRGK1 Q96HY6       
REHEEYLKL  3 2.05 3 2 5 50.00 
DDX27 Q96GQ7       
LPVLERLIY  5 3.05 5 0 6 54.55 
DDX42 Q86XP3       
GSVLLFVTK  6 2.50 8 2 6 37.50 
DDX60 Q8IY21       
YLWNTVSKL  3 2.75 0 1 4 80.00 
DEGS1 O15121       
EVINTVAQV  5 2.09 14 3 6 26.09 
FPNIPGKSL  18 2.07 48 16 22 25.58 
LPIGIPYSISF  3 2.76 3 2 4 44.44 
SMTLAIHEI  9 2.03 7 8 17 53.13 
DEPP Q9NTK1       
RPSSVLRTL  5 3.82 9 1 9 47.37 
SHLPVIHEL  3 2.81 0 3 3 50.00 
DERA Q9Y315       
DEWLKPELF  3 3.15 2 1 3 50.00 
DERL1 Q9BUN8       
TVAVPLVGKL  12 2.30 14 2 8 33.33 
DHX15 O43143       
RIFEPPPPK  8 2.82 52 2 8 12.90 
DHX32 Q7L7V1       
SEFPLDPQL  3 2.01 1 0 3 75.00 
DHX40 Q8IX18       
VPISKSEAL  3 3.79 5 1 4 40.00 
DIRAS2 Q96HU8       
SEAEALARTW  5 3.99 0 0 8 100.00 
DNAJA2 O60884       
KEISFAYEVL  3 3.15 1 0 3 75.00 
DNAJB12 Q9NXW2       
EAFKAIGTAY  3 2.48 9 0 5 35.71 
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DNAJB14 Q8TBM8       
FPSGSVHSF  5 2.94 4 1 5 50.00 
DNAJB9 Q9UBS3       
REIAEAYETL  3 2.72 2 0 4 66.67 
DNPEP Q9ULA0       
PSLSHNLLVD  7 2.57 32 0 2 5.88 
DOCK2 Q92608       
AYTLLLHTW  7 2.12 21 3 10 29.41 
KMWEEAISL  6 2.59 14 2 12 42.86 
DOCK8 Q8NF50       
AEIPADPKLY  3 2.57 8 1 4 30.77 
DOK3 Q7L591       
TPIKDGILY  4 2.48 16 1 5 22.73 
DPP9 Q86TI2       
MPYGSRENSL  3 3.13 3 0 5 62.50 
DPYSL3 Q14195       
MPYKGMTTV  3 2.63 2 2 7 63.64 
DST Q03001       
LPSDKALVL  4 2.35 8 2 4 28.57 
DTX3L Q8TDB6       
NVIEVDSAHY  4 2.99 2 3 4 44.44 
DUSP1 P28562       
KLDEAFEFV  3 3.93 2 1 4 57.14 
EDNRA P25101       
NHVDDFTTF  3 2.78 0 3 3 50.00 
EEF1G P26641       
FPAGKVPAF  3 2.97 10 1 6 35.29 
EEF2 P13639       
GLKEGIPAL  7 2.26 8 4 13 52.00 
KSTAISLFY  4 3.50 13 0 4 23.53 
LEPEELYQTF  3 2.31 4 1 3 37.50 
LPSPVTAQKY  5 2.31 21 5 7 21.21 
RVFSGLVSTGLK  13 2.92 28 7 16 31.37 
TAISLFYEL  4 2.35 17 1 5 21.74 
EEF2K O00418       
VVDIQGVGDLY  6 2.01 9 3 10 45.45 
EGLN1 Q9GZT9       
NPHEVQPAY  4 2.74 1 1 4 66.67 
EGLN3 Q9H6Z9       
AEERAEAKKKF  3 2.91 0 0 1 100.00 
EVQPSYATR  5 3.97 2 0 8 80.00 
MPLGHIMRL  4 5.18 0 0 8 100.00 
NPHEVQPSY  5 6.18 1 1 5 71.43 
EHD2 Q9NZN4       
ALASHLIEA  13 2.36 11 6 20 54.05 
FGAFHSPAL  4 3.15 8 2 10 50.00 
KLPNSVLGR  3 3.85 1 0 3 75.00 
LPVIFAKI  3 2.33 1 3 5 55.56 
RVHAYIISY  13 3.50 25 4 17 36.96 
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EHHADH Q08426       
APRTFGLTL  3 3.60 10 1 7 38.89 
EIF3K Q9UBQ5       
LPHTDFTL  3 2.37 0 2 4 66.67 
TVTAQILLK  8 2.12 9 4 8 38.10 
EIF4A1 P60842       
MPLNVADLI  4 3.50 2 1 6 66.67 
EIF4G1 Q04637       
FVAEQKVEY  7 2.11 22 3 7 21.88 
EIF6 P56537       
TVADQVLVGSY  5 3.16 0 5 6 54.55 
ELAC2 Q9BQ52       
RYQQWMERF  3 2.11 17 0 4 19.05 
EMC1 Q8N766       
IPPEVQRI  4 3.19 3 3 5 45.45 
YPSKQFDVL  5 2.98 4 3 6 46.15 
EML2 O95834       
IHTDGNEQI  3 2.75 0 0 3 100.00 
EML4 Q9HC35       
SHDNFIYLY  3 2.36 0 0 3 100.00 
ENC1 O14682       
YLPELLQTV  4 2.26 5 1 5 45.45 
ENGASE Q8NFI3       
SPDPLPVRY  3 2.68 10 0 3 23.08 
ENO1 P06733       
KTIAPALVSK  4 2.70 2 0 5 71.43 
ENPP2 Q13822       
STEERHLLY  10 3.46 6 2 13 61.90 
VRPPLIIF  4 3.50 1 1 6 75.00 
YSEQPDFSGHKY  6 4.37 1 0 9 90.00 
EPPK1 P58107       
YPDPYGGEKL  3 3.37 2 1 4 57.14 
YPDPYSRASL  5 5.39 8 0 7 46.67 
EPRS P07814       
FTDVNSILRY  14 2.24 39 12 18 26.09 
KEDFEKVIL  3 2.75 0 0 5 100.00 
EPSTI1 Q96J88       
EAFREHQQY  3 2.13 6 0 3 33.33 
QELANLEKW  3 4.28 3 0 3 50.00 
ERBB3 P21860       
LPLPNLRVV  5 2.61 0 5 5 50.00 
VYDGKFAIF  4 3.10 4 1 4 44.44 
ERCC2 P18074       
YPLEVTKLIY  4 2.48 3 1 5 55.56 
ERGIC1 Q969X5       
YILKIVPTV  3 4.77 3 0 5 62.50 
EVL Q9UI08       
VVINYSIVK  4 3.52 35 0 6 14.63 
149 
 
Supplementary Table 6 (continued) 
EXD2 Q9NVH0       
FPLDKSLLL  3 3.49 9 2 7 38.89 
EXOC3 O60645       
EAVATAVQR  3 2.52 12 0 4 25.00 
EZR P15311       
AEYTAKIAL  6 3.34 8 4 8 40.00 
EYTAKIALL  3 2.79 2 2 5 55.56 
YPEDVAEEL  4 3.45 2 2 6 60.00 
FAM109A Q8N4B1       
EEFAFAVRF  3 2.16 5 1 3 33.33 
FAM120A Q9NZB2       
MYPYIFHVL  5 2.47 22 2 8 25.00 
FAM120B Q96EK7       
FVYPGNPLRH  6 2.20 14 0 1 6.67 
FAM129A Q9BZQ8       
VLFEKEVNEV  4 2.21 2 2 5 55.56 
FAM149A A5PLN7       
AVLDLGSLLAK  13 3.80 6 2 14 63.64 
FAM32A Q9Y421       
TEHYDIPKVSW  3 3.37 4 0 3 42.86 
FAM65B Q9Y4F9       
IEVNGKQSW  3 2.60 13 3 4 20.00 
FANCI Q9NVI1       
KLQEFLQTL  3 3.26 10 0 5 33.33 
FAR1 Q8WVX9       
VFMHVSTAY  3 2.33 10 1 5 31.25 
FASN P49327       
HPLGDIVAF  4 3.94 17 0 4 19.05 
FAU P35544       
APLEDEATL  3 3.66 1 0 4 80.00 
FBXL17 Q9UF56       
VQQYPHITF  3 2.00 30 1 4 11.43 
FBXO28 Q9NVF7       
ILAAVETRL  3 2.25 3 1 8 66.67 
FBXO3 Q9UK99       
KIFNVAIPRF  4 2.12 10 3 7 35.00 
FBXW5 Q969U6       
DEFLWREQF  5 2.21 2 4 5 45.45 
FCGR3A P08637       
RVLEKDSVTLK  5 4.17 14 1 7 31.82 
FCHO2 Q0JRZ9       
FPSGIIKVF  6 2.21 10 4 10 41.67 
KTFALPGIIK  5 3.46 7 1 6 42.86 
KTFALPGIIKK  6 2.32 18 6 9 27.27 
FEM1B Q9UK73       
FPNALVTKL  5 2.66 15 2 6 26.09 
FGA P02671       
GDSTFESKSYK  4 3.11 20 0 7 25.93 
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FGG P02679       
IPYALRVEL  3 3.42 1 1 4 66.67 
FIBP O43427       
VTDAVALRV  8 2.06 3 5 10 55.56 
FLII Q13045       
FARLPEEEF  3 3.46 3 0 3 50.00 
VLNGNPLLH  3 2.73 10 1 5 31.25 
FLNB O75369       
SPFKADIEM  6 2.84 7 3 7 41.18 
FLOT1 O75955       
GEVLDILTRL  4 2.42 1 2 6 66.67 
FMR1 Q06787       
VLLDYHLNYL  5 2.02 9 5 13 48.15 
FNDC3B Q53EP0       
ILWETVPSM  13 2.22 5 10 20 57.14 
FXYD2 P54710       
YETVRNGGL  5 2.26 1 3 6 60.00 
GALK2 Q01415       
TQDVLIFKL  3 2.27 0 3 3 50.00 
GANAB Q14697       
FLDDGHTFNY  6 2.27 16 2 13 41.94 
GAS2L3 Q86XJ1       
SVSPVKATQK  4 2.15 0 0 7 100.00 
GBA P04062       
LTDPEAAKY  9 2.20 19 3 15 40.54 
YFVKFLDAY  3 2.33 0 0 3 100.00 
GBA3 Q9H227       
YHFDLPQTL  3 4.60 0 2 4 66.67 
YPSSRLPEF  3 5.85 0 0 3 100.00 
GBP1 P32455       
QEQLLKEGF  3 3.93 6 0 4 40.00 
GBP2 P32456       
AQIENSAAVEK  7 2.36 17 2 8 29.63 
GBP5 Q96PP8       
RLKNLVLTY  5 2.80 12 0 5 29.41 
SLLSELQHA  8 2.88 12 3 14 48.28 
GFPT1 Q06210       
ETADTLMGLRY  4 2.08 3 4 5 41.67 
GMPPA Q96IJ6       
ALYASRLYL  9 3.40 5 1 13 68.42 
QEFNLPVRY  3 2.07 2 0 5 71.43 
GNL3 Q9BVP2       
VPLDKQITI  5 2.32 9 6 8 34.78 
GPAA1 O43292       
LHQSFFLYL  3 2.35 0 0 4 100.00 
GPNMB Q14956       
KGLSVFLNR  5 3.06 2 4 4 40.00 
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GRB7 Q14451       
WPVGGDSRFVF  6 2.83 1 2 8 72.73 
GSN P06396       
WSVDPLDR  8 4.11 53 0 1 1.85 
WSVDPLDRAM  7 3.73 42 1 10 18.87 
GUCY1A3 Q02108       
KFSNVTMLF  5 3.55 7 0 7 50.00 
GUCY1B3 Q02153       
DLYTRFDTL  4 2.43 5 2 6 46.15 
MYGFVNHAL  3 2.39 6 0 3 33.33 
RYDNVTILF  3 4.76 14 0 5 26.32 
GZMK P49863       
VLIDPQWVL  6 2.21 3 0 8 72.73 
HADHA P40939       
SPNSKVNTL  4 2.53 17 2 8 29.63 
HAVCR1 Q96D42       
ALLGVIIAK  12 4.33 0 2 16 88.89 
GVIIAKKYFFK  4 4.65 0 0 4 100.00 
HBA1 P69905       
ALTNAVAHV  3 2.16 13 0 3 18.75 
ASVSTVLTSKYR  8 2.07 57 2 0 0.00 
HCFC1R1 Q9NWW0       
SLIPEALRL  4 4.23 2 0 3 60.00 
HDLBP Q00341       
IPAKLHNSL  6 2.10 17 5 9 29.03 
HEATR1 Q9H583       
FLFDTQHFI  3 2.35 9 2 6 35.29 
HEYL Q9NQ87       
ATGIILPAR  6 2.19 12 1 5 27.78 
HIF1A Q16665       
ELNPKILAL  3 2.17 6 2 7 46.67 
HLA-DPA1 P20036       
WEAQEPIQM  3 2.12 0 3 5 62.50 
HLA-DQA1 P01909       
VVGTVFIIR  4 4.11 2 1 4 57.14 
HLA-DQB1 P01920       
SPEDFVYQF  6 2.26 6 3 7 43.75 
HLA-DRA P01903       
IIGTIFIIK  8 4.00 25 3 8 22.22 
LPFLPSTEDVY  5 2.99 18 1 7 26.92 
HM13 Q8TCT9       
FPASFPNRQY  5 2.61 7 5 6 33.33 
HMOX1 P09601       
AENAEFMRNF  3 4.67 4 1 4 44.44 
APLLRWVL  13 3.48 19 9 21 42.86 
DSAPVETPR  4 3.91 14 1 5 25.00 
EVIPYTPAM  8 3.89 9 4 9 40.91 
FPNIASATKF  4 4.67 3 0 6 66.67 
KIAQKALDL  3 4.91 0 0 4 100.00 
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Supplementary Table 6 (continued) 
RVIEEAKTAF  3 5.30 18 0 6 25.00 
SLYHIYVAL  4 4.09 1 2 4 57.14 
HNRNPA2B1 P22626       
FGPGPGSNF  4 3.26 13 2 3 16.67 
HNRNPA3 P51991       
DTVDKIVVQKY  3 2.31 0 1 2 66.67 
HNRNPU Q00839       
AENPGKYNIL  3 2.82 2 0 3 60.00 
HPS3 Q969F9       
IYPWVHVVI  3 4.69 11 0 5 31.25 
HPS4 Q9NQG7       
SLNGLEVHL  4 2.65 13 0 5 27.78 
HSD3B7 Q9H2F3       
RVYVGNVAW  4 4.62 1 1 5 71.43 
HSF2 Q03933       
LVQNNQLVSL  6 5.33 5 0 6 54.55 
HSF4 Q9ULV5       
ILWREVVTL  12 3.87 0 0 15 100.00 
SPSPGKDPTL  3 3.84 0 0 4 100.00 
HSP90AB1 P08238       
IPNPQERTLTL  4 2.96 0 1 4 80.00 
RRLSELLRY  4 2.05 13 4 5 22.73 
HSP90B1 P14625       
HPTDITSLDQY  3 3.76 1 0 4 80.00 
HSPA5 P11021       
AEAYLGKKV  3 2.27 10 1 4 26.67 
KVYEGERPLTK  4 2.77 11 0 4 26.67 
QARIEIESF  5 3.80 8 1 3 25.00 
QPTVTIKVY  4 4.32 1 0 5 83.33 
HSPA7 P48741       
TVFDAKRLIGR  8 2.99 28 3 8 20.51 
HSPA8 P11142       
ILNVSAVDK  5 2.12 9 2 6 35.29 
NAVVTVPAY  3 2.59 2 0 3 60.00 
HSPB8 Q9UJY1       
AEVDPVTVF  3 2.40 2 1 7 70.00 
SWPDWALPRL  5 2.22 1 3 6 60.00 
WPDWALPRL  3 2.92 0 0 3 100.00 
HSPD1 P10809       
DGVAVLKV  3 2.26 10 4 7 33.33 
RTVIIEQSW  4 2.28 11 3 6 30.00 
HSPG2 P98160       
DASPPPVKI  5 2.06 0 3 5 62.50 
EVAQPGPSNR  4 2.19 1 2 4 57.14 
GLNLHTLLY  4 3.90 4 2 5 45.45 
ID2 Q02363       
TPVDDPMSLLY  3 3.65 2 0 4 66.67 
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IDE P14735       
FPIPDLQKY  3 2.26 18 1 6 24.00 
IDO1 P14902       
NPKAFFSVL  3 2.67 7 1 6 42.86 
NPSVREFVL  4 3.22 0 2 5 71.43 
RSYHLQIVTK  12 3.10 28 4 13 28.89 
IFI16 Q16666       
EVPNKIINR  3 3.44 25 2 3 10.00 
IFI27 P40305       
GIASSSIAAK  3 2.49 0 0 3 100.00 
IFT57 Q9NWB7       
RPFEQPQEY  5 2.42 4 2 5 45.45 
IFT81 Q8WYA0       
RQQASIISR  3 2.46 0 0 3 100.00 
IGFBP3 P17936       
RPTLWAAAL  10 4.82 5 2 11 61.11 
IGKV2-30 P06310       
LPAQLLGLLM  4 2.81 3 2 4 44.44 
IKBIP Q70UQ0       
EPLVNDLTL  3 2.43 0 1 4 80.00 
IL1B P01584       
SVDPKNYPK  5 3.03 41 0 10 19.61 
IL32 P24001       
YLETVAAYY  6 2.35 3 1 7 63.64 
IPO9 Q96P70       
RLIPTLVSI  3 2.85 4 0 5 55.56 
IQCB1 Q15051       
ELQLSMLEI  4 2.46 0 4 4 50.00 
IQGAP1 P46940       
DEIGLPKIFY  4 3.24 3 1 5 55.56 
DPLQKEEL  4 2.11 2 3 6 54.55 
IRAK1 P51617       
SVLWPWINR  4 3.20 8 1 4 30.77 
IRF7 Q92985       
SEADARIFKAW  4 2.41 2 1 4 57.14 
IRX3 P78415       
AELPIFPQL  5 3.11 0 0 6 100.00 
IST1 P53990       
AELKIVADQL  3 2.18 2 1 6 66.67 
ITGA3 P26006       
FPAHPSLLL  3 3.70 1 0 5 83.33 
ITGA4 P13612       
SVINPGAIYR  10 2.42 35 3 10 20.83 
ITGA5 P08648       
IEDKAQILL  6 2.83 1 1 6 75.00 
ITGA7 Q13683       
EAVGIKSFGY  3 3.69 0 1 3 75.00 
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ITGAV P06756       
KSLLWTETF  5 2.11 17 6 9 28.13 
NPMKAGTQL  4 2.45 12 6 6 25.00 
ITGB2 P05107       
AENNIQPIF  3 2.97 6 1 5 41.67 
IVNS1ABP Q9Y6Y0       
DAYIQEHLL  5 3.64 4 0 6 60.00 
SPRSNAGIATV  3 3.76 1 0 5 83.33 
VEVLLNYAY  3 2.77 3 0 4 57.14 
JAK1 P23458       
KYLATLETL  3 2.01 7 2 6 40.00 
JKAMP Q9P055       
ALFQHITAL  9 2.66 8 3 15 57.69 
KANSL1L A0AUZ9       
LPSDVPLHF  6 2.54 0 0 6 100.00 
KARS Q15046       
LTDFIQKY  4 2.54 2 2 8 66.67 
KBTBD7 Q8WVZ9       
NHDQKLLLI  3 2.01 0 2 3 60.00 
KCNMA1 Q12791       
VPPVFVSVY  3 4.65 0 0 3 100.00 
KDSR Q06136       
YPSRAVITTM  3 3.23 7 0 3 30.00 
KHK P50053       
DVISLVDKY  4 3.81 0 2 3 60.00 
RSVQEALRF  3 5.74 0 0 3 100.00 
KIF11 P52732       
RVITALVER  3 3.40 3 0 3 50.00 
KIFAP3 Q92845       
NEVEQLLYY  6 2.11 3 3 8 57.14 
KISS1R Q969F8       
RPAPADSAL  3 4.68 0 0 6 100.00 
KLHL12 Q53G59       
SPIDVVEKY  5 2.44 22 5 8 22.86 
KLHL22 Q53GT1       
LPLEKVYSL  3 3.78 8 1 4 30.77 
KMO O15229       
MPFEEFEKL  3 4.95 1 0 6 85.71 
KRR1 Q13601       
HPIYNIKSL  4 3.31 17 2 5 20.83 
KRT18 P05783       
ALLNIKVKL  10 2.80 7 6 19 59.38 
ILLHLESEL  9 3.39 0 3 16 84.21 
IMADIRAQY  5 4.81 2 0 7 77.78 
KVKLEAEIATY  4 2.42 2 0 2 50.00 
LLNIKVKL  6 3.08 1 1 5 71.43 
REVEARYAL  5 4.04 1 1 6 75.00 
RLESKIREH  4 3.86 0 0 4 100.00 
RVKYETELAMR  4 3.28 0 0 4 100.00 
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RVRSLETENR  3 3.01 0 0 3 100.00 
RYALQMEQL  8 2.28 4 4 8 50.00 
SETNDTKVL  4 3.44 0 0 6 100.00 
YEALLNIKV  5 2.62 10 3 6 31.58 
KRT19 P08727       
ALISGIEAQL  3 5.12 0 1 7 87.50 
KRT8 P05787       
AESMYQIKY  6 3.10 0 2 8 80.00 
KLSELEAAL  10 3.28 1 6 17 70.83 
NMDNMFESY  5 4.02 2 0 12 85.71 
LAMB1 P07942       
AEYIEKVVY  5 2.66 0 3 6 66.67 
LAMB3 Q13751       
HINGRVLYY  7 4.05 6 2 9 52.94 
LAMP2 P13473       
FPVPGSGLVL  4 2.36 10 1 6 35.29 
LCP2 Q13094       
KVYNIQIRY  7 3.38 27 5 8 20.00 
TAKLPAPSI  5 2.15 12 3 6 28.57 
LDHA P00338       
SVADLAESIMK  4 3.23 3 0 5 62.50 
LDOC1L Q6ICC9       
FPGEAERVAF  7 2.65 10 2 8 40.00 
LEMD3 Q9Y2U8       
IENPFGETF  6 2.10 4 2 6 50.00 
LGALS2 P05162       
SEVKFTVTF  9 4.06 4 0 11 73.33 
LGALS3 P17931       
KPNANRIAL  10 2.20 20 5 9 26.47 
LIN7A O14910       
TAIREVYQY  4 3.95 2 0 5 71.43 
LITAF Q99732       
VYVQHPITF  8 2.21 26 5 10 24.39 
LMTK2 Q8IWU2       
EIYTGTSVAR  4 2.08 6 1 4 36.36 
LONRF1 Q17RB8       
LKERLTKI  3 2.38 5 0 1 16.67 
LOXL3 P58215       
LPYTGAETRI  3 3.56 13 4 4 19.05 
LPCAT1 Q8NF37       
IQYIRPVFV  3 2.17 6 0 4 40.00 
KEPEQPPALW  4 3.93 4 1 5 50.00 
TLFPVRLLV  11 4.28 12 0 14 53.85 
LPCAT3 Q6P1A2       
RLIQESPTL  9 2.25 18 5 16 41.03 
LRP2 P98164       
IPHPFGVSL  3 3.84 2 0 6 75.00 
LRRC20 Q8TCA0       
LVSFPIGIYK  3 3.54 11 0 4 26.67 
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VSFPIGIYK  7 2.10 15 3 7 28.00 
LRRC42 Q9Y546       
RYLVISEKL  5 2.04 10 4 7 33.33 
LRRK2 Q5S007       
EEIVLHVL  3 4.37 1 0 3 75.00 
FLDLNTEGY  8 3.32 2 4 15 71.43 
NESGVLLHF  13 3.31 14 4 14 43.75 
SLIGYLITK  4 3.12 5 0 6 54.55 
SLIGYLITKK  4 3.82 7 2 7 43.75 
MALT1 Q9UDY8       
LTDPIQGTEY  4 2.12 4 0 7 63.64 
MAOB P27338       
AIMGFILAH  6 2.27 7 1 10 55.56 
MAP1B P46821       
SESPIEKVL  5 2.75 3 4 8 53.33 
MAP4 P27816       
SVPADLSRPK  4 2.60 2 1 4 57.14 
TVKEVGLLK  3 3.07 0 1 2 66.67 
MAPK1 P28482       
APFKFDMEL  3 2.44 17 2 8 29.63 
MAT2A P31153       
FPWEVPKKLKY  4 3.07 5 3 6 42.86 
RRNGTLPWLR  3 6.17 9 1 4 28.57 
MCM3 P25205       
ALKDFVASI  3 2.02 5 1 4 40.00 
MCTP2 Q6DN12       
IFDLQKTSL  3 2.60 22 1 6 20.69 
MDM2 Q00987       
DEVYQVTVY  3 3.06 1 1 4 66.67 
YTMKEVLFY  4 3.40 13 0 11 45.83 
MET P08581       
TEGIIMKDF  3 3.42 1 0 5 83.33 
MGEA5 O60502       
LPIDGANDLF  6 2.59 3 1 9 69.23 
MGLL Q99685       
KPTGTPKAL  3 2.75 6 1 4 36.36 
MGMT P16455       
HPVFQQESF  4 2.15 6 2 6 42.86 
MITF O75030       
LPVSGNLIDLY  4 2.86 4 2 6 50.00 
MKL1 Q969V6       
GLAPAEVVVATV  4 2.27 6 1 5 41.67 
MLF2 Q15773       
AEGPPRLAI  4 2.70 7 2 8 47.06 
MMP24 Q9Y5R2       
LPARIDAAY  4 3.53 1 0 4 80.00 
MOGS Q13724       
FLWDEGFHQL  4 3.91 9 2 10 47.62 
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MPI P34949       
RPVEEIVTF  4 2.44 3 1 4 50.00 
MSANTD4 Q8NCY6       
ERDPQSPEF  3 2.49 0 1 3 75.00 
MSH6 P52701       
KISEVVELL  5 2.50 4 1 6 54.55 
MTDH Q86UE4       
WVDEERASL  5 2.05 12 4 7 30.43 
MYH11 P35749       
KEIENLTQQY  3 3.11 4 2 6 50.00 
SVLQLGNIVFK  7 3.01 28 4 8 20.00 
TEFSIIHY  4 2.09 0 1 5 83.33 
MYH9 P35579       
KTDLLLEPYNKY  11 2.04 21 7 14 33.33 
MYO10 Q9HD67       
NSDVVEQIY  4 2.30 0 1 6 85.71 
MYO1F O00160       
FTDREIDLY  12 2.73 27 4 16 34.04 
MYOF Q9NZM1       
DDLLVVEKY  5 2.36 0 3 5 62.50 
MPPLVIKV  4 2.41 2 3 6 54.55 
NAA15 Q9BXJ9       
TPLEEAIKF  3 2.15 5 2 4 36.36 
NAA20 P61599       
VYRTVIEYY  3 3.54 13 0 6 31.58 
NAMPT P43490       
VPVSVVSDSY  4 3.21 0 0 4 100.00 
NAP1L1 P55209       
AVLYQPLFDK  8 2.47 46 5 9 15.00 
NARS O43776       
FPVEIKSFYM  5 3.66 9 0 7 43.75 
NAT10 Q9H0A0       
KEIELPSGQL  3 3.15 2 0 4 66.67 
NCEH1 Q6PIU2       
KYFLKPEVL  3 4.15 7 1 4 33.33 
NCKAP1L P55160       
HVYELLNTI  3 3.45 3 1 3 42.86 
NCLN Q969V3       
RLPAFTLSHL  3 3.31 7 0 4 36.36 
NDRG1 Q92597       
AEMLPGVLQQF  10 2.78 20 8 12 30.00 
KLDPTKTTL  16 2.11 12 15 23 46.00 
MPSASMTRL  12 4.39 14 2 16 50.00 
NDUFA3 O95167       
VILPPLSPYFK  4 2.83 5 1 4 40.00 
NDUFA4L2 Q9NRX3       
DQYKFLAV  6 6.99 0 0 3 100.00 
GASLGARFY  4 3.78 0 0 3 100.00 
GSAALYLLR  7 5.94 0 0 9 100.00 
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NDUFB4 O95168       
IENPALLRW  4 2.24 5 2 5 41.67 
NEK6 Q9HC98       
SLADFQIEK  9 2.59 24 2 12 31.58 
NFKBIE O00221       
VLDIQNNLY  11 3.09 2 5 14 66.67 
NHP2 Q9NX24       
EEVQSLPLPL  13 2.13 47 0 8 14.55 
NIFK Q9BYG3       
DETQIFSYF  4 2.76 5 1 5 45.45 
NLRC5 Q86WI3       
ATLTNILEH  5 2.53 35 3 5 11.63 
NMB P08949       
RLLVQILQK  4 5.54 4 0 5 55.56 
NMI Q13287       
VSPYTEIHL  3 2.17 5 1 3 33.33 
NNMT P40261       
AESQILKHLL  3 2.63 0 0 4 100.00 
DYLEKYYKF  3 4.00 17 2 6 24.00 
WFEVISQSY  3 4.52 1 0 3 75.00 
YYMIGEQKF  9 4.09 7 2 10 52.63 
NOP56 O00567       
YPASTVQIL  4 2.14 3 1 4 50.00 
NPM1 P06748       
TPPVVLRL  3 3.67 8 1 5 35.71 
NPTX2 P47972       
LLAASVALA  3 3.18 0 0 5 100.00 
NRIP1 P48552       
SVIESPSTNR  4 2.11 1 0 4 80.00 
NRP1 O14786       
DTIKIESPGY  4 2.27 0 3 4 57.14 
NUP153 P49790       
SPFYPGKTTY  5 2.55 8 2 5 33.33 
NUP160 Q12769       
YVDAVLGKGHQY  3 2.63 2 0 5 71.43 
NUSAP1 Q9BXS6       
SVASTPISQR  3 3.31 6 1 3 30.00 
OASL Q15646       
EEFLRQEHF  4 2.59 9 2 5 31.25 
ODC1 P11926       
NIIAKKIVL  12 4.92 12 0 14 53.85 
OGFOD3 Q6PK18       
GVTDVVITR  3 2.76 6 1 3 30.00 
OGT O15294       
EAIRISPTF  4 3.22 9 1 4 28.57 
OPN3 Q9H1Y3       
VYNPVIYVF  4 2.83 22 1 7 23.33 
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OR8G1 Q15617       
MYLQPSSISSM  4 4.30 0 0 3 100.00 
ORC4 O43929       
SENVLQVHL  3 2.29 1 1 6 75.00 
OS9 Q13438       
DVVIVSSKY  3 2.80 0 1 3 75.00 
OSGIN2 Q9Y236       
TYITSVSRL  3 2.43 4 1 6 54.55 
P3H4 Q92791       
FYPAIADLF  3 2.09 11 0 4 26.67 
P4HA1 P13674       
AEIEIVKDL  5 2.46 4 1 7 58.33 
P4HA2 O15460       
AEKELVQSL  3 3.90 0 0 5 100.00 
PAICS P22234       
FYPPKVELF  4 2.17 15 1 6 27.27 
PAM P19021       
YPVGHPVDVSF  3 3.26 1 0 5 83.33 
PARD6B Q9BYG5       
YPQQIEPSF  3 3.60 0 1 5 83.33 
PARG Q86W56       
YPDINFNRL  3 4.05 8 1 4 30.77 
PARP12 Q9H0J9       
DEFGSWQEY  4 2.22 1 2 5 62.50 
PARP14 Q460N5       
GVFGFPLGR  11 2.84 12 5 13 43.33 
SPDSGVYEM  4 2.85 10 1 4 26.67 
PARP4 Q9UKK3       
FIFSDTHEL  5 2.11 15 3 11 37.93 
PATJ Q8NI35       
SHADVVNLL  3 2.65 0 0 4 100.00 
PATL1 Q86TB9       
YYQNYFEKL  4 2.63 21 4 9 26.47 
PBK Q96KB5       
SYQKVIELF  4 3.64 17 0 8 32.00 
PCBP2 Q15366       
FPMTHGNTGF  8 2.21 23 5 9 24.32 
PDCD11 Q14690       
KVFERAVQY  3 3.46 15 0 4 21.05 
RLKDGVLAY  3 4.34 9 0 4 30.77 
PDGFD Q9GZP0       
HRLIFVYTL  8 2.41 4 4 8 50.00 
PDIA3 P30101       
LALFPGVAL  3 2.35 10 0 5 33.33 
PDK4 Q16654       
KEIDILPTQL  3 2.40 2 0 4 66.67 
PDZK1IP1 Q13113       
IAFAVNHFW  3 3.73 3 2 5 50.00 
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PER2 O15055       
EEQSFLQKF  3 2.18 8 2 5 33.33 
VPVDLQHQF  4 3.45 0 1 5 83.33 
PFDN5 Q99471       
FLSTSIAQL  4 2.03 5 1 9 60.00 
KTAEDAKDFFK  4 2.55 18 1 5 20.83 
PFKL P17858       
TTEFLYNLY  5 2.86 6 0 11 64.71 
PFKP Q01813       
TTDFIYQLY  10 4.70 12 2 14 50.00 
PGF P49763       
YPSEVEHMF  4 4.98 0 0 5 100.00 
PHKA2 P46019       
EIISKLQGR  4 3.61 4 1 4 44.44 
PI4KAP1 Q8N8J0       
IYSTAFDYF  3 2.17 21 1 3 12.00 
PIGP P57054       
IPALRDISI  7 2.02 7 1 8 50.00 
PIK3AP1 Q6ZUJ8       
NEPYIFKVF  3 3.87 11 1 5 29.41 
PKM P14618       
YPLEAVRM  3 3.98 0 0 3 100.00 
PKP2 Q99959       
SQNIYIQNR  4 2.25 6 2 4 33.33 
PLCB1 Q9NQ66       
RTDPQGFFFY  7 3.19 8 1 11 55.00 
PLIN2 Q99541       
AEHIESRTL  8 2.17 5 1 12 66.67 
DQYPYLKSV  5 3.77 1 3 7 63.64 
GAVTGSVEK  4 2.85 0 0 5 100.00 
HSTVHLIEF  4 4.78 1 0 4 80.00 
IQDAQDKLYL  3 4.73 0 0 3 100.00 
KSELLVEQY  12 3.88 2 1 15 83.33 
LTSSKGQLQK  5 3.84 0 1 6 85.71 
LVNNTPLNW  3 5.60 2 1 4 57.14 
MAGDIYSVFR  3 3.31 15 2 3 15.00 
MTSALPIIQK  8 4.30 8 3 9 45.00 
RAYQQALSR  8 3.88 1 3 12 75.00 
SELLVEQY  3 4.45 0 0 3 100.00 
SINTVLGSR  3 3.58 0 0 5 100.00 
SLLTSSKGQLQK  12 3.04 11 11 13 37.14 
STQIVANAK  5 3.06 5 0 6 54.55 
TLLSNIQGV  6 2.82 4 3 10 58.82 
TSALPIIQK  16 3.18 68 13 19 19.00 
TSSKGQLQK  4 2.58 0 0 4 100.00 
VQKPSYYVR  4 5.21 1 2 4 57.14 
VRLGSLSTK  3 6.22 2 0 4 66.67 
PLOD2 O00469       
KIIAPLVTR  3 3.95 0 0 4 100.00 
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KVFAGYYTK  5 3.52 9 1 7 41.18 
PLOD3 O60568       
AVMNFVVRY  3 3.19 11 0 5 31.25 
PLXNA2 O75051       
NKVFLLTFI  3 3.48 0 0 1 100.00 
PLXNA3 P51805       
FPIDKPPSF  4 3.49 0 0 6 100.00 
TQDPTVTRL  3 2.66 0 1 4 80.00 
PLXNB2 O15031       
TYTDRVFFL  8 2.12 26 9 11 23.91 
PLXNC1 O60486       
FLVTVIHTL  4 2.58 11 0 8 42.11 
POLR1C O15160       
DEILAHRL  3 2.15 2 0 3 60.00 
TTDFPGNYSGY  3 2.88 2 0 6 75.00 
POLR2H P52434       
YPVDLGDKF  10 3.18 5 4 9 50.00 
POP7 O75817       
SEIYIHGLGL  4 2.40 0 0 4 100.00 
PPARGC1A Q9UBK2       
LPVDEDGLPSF  4 3.66 2 0 7 77.78 
PPM1G O15355       
EVIKELAQI  4 2.00 13 2 6 28.57 
PPP1R15A O75807       
VPRGQGSQF  4 2.64 18 1 6 24.00 
PPP1R3C Q9UQK1       
GRMENLASYR  3 3.51 6 1 4 36.36 
MPVDVAMRL  5 4.43 7 1 9 52.94 
PPP1R7 Q15435       
NPLQKDPQY  4 2.14 3 1 4 50.00 
PPP4R4 Q6NUP7       
VISSDQIYY  3 2.29 0 2 1 33.33 
PQBP1 O60828       
LPVALQTRL  4 3.04 8 1 4 30.77 
PRELID1 Q9Y255       
QRYPNPYSK  3 3.15 3 0 3 50.00 
PRF1 P14222       
TSNVHVSV  3 2.15 1 1 3 60.00 
PRKDC P78527       
AEVLGLILRY  4 2.62 9 1 5 33.33 
PRMT5 O14744       
FPVEVNTVL  3 3.50 1 0 5 83.33 
PRMT7 Q9NVM4       
FPIHVQTSL  7 3.44 13 1 9 39.13 
PROS1 P07225       
LPLNLDTKY  3 3.14 9 0 3 25.00 
PRPF8 Q6P2Q9       
VYTTTVHWL  3 2.76 18 2 3 13.04 
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Supplementary Table 6 (continued) 
PRRC2C Q9Y520       
FYMDTSHLF  4 2.19 25 2 9 25.00 
PRUNE2 Q8WUY3       
DEGKLSITL  4 3.42 0 0 4 100.00 
DEINLHQL  3 2.95 0 0 4 100.00 
SEINTTHNL  7 2.66 0 0 9 100.00 
PSMA2 P25787       
RVASVMQEY  6 2.12 18 2 10 33.33 
PSMA6 P60900       
AEIDAHLVAL  3 2.02 9 1 5 33.33 
PSMB10 P40306       
GVDLTGPQLY  4 2.63 1 0 7 87.50 
PSMB2 P49721       
RFILNLPTF  3 2.14 17 1 5 21.74 
PSMB5 P28074       
GVMDRGYSY  3 2.79 1 3 3 42.86 
PSMB8 P28062       
STDVSDLLHQY  11 2.75 9 2 14 56.00 
PSMC6 P62333       
GEIDYEAIVKL  3 2.17 3 1 3 42.86 
PSMD14 O00487       
AMLDTVVFK  5 2.18 18 3 9 30.00 
VVVDPIQSVK  3 3.66 12 0 4 25.00 
PSMD7 P51665       
KLLDIRSYL  4 2.44 6 2 9 52.94 
LPINHQIIY  4 2.68 6 0 5 45.45 
PSMD8 P48556       
RILFFNTPK  7 2.62 29 2 9 22.50 
PSME2 Q9UL46       
KVLERVNAV  5 2.14 7 2 12 57.14 
PSME4 Q14997       
FLQPELVKL  6 2.30 12 4 14 46.67 
PTGS1 P23219       
EEAPVLMHY  5 2.36 9 6 5 25.00 
HPTWGDEQL  4 5.20 5 1 5 45.45 
PTP4A1 Q93096       
RPAPVEVTY  5 2.58 26 3 6 17.14 
PTP4A3 O75365       
RPAPVEVSY  3 3.77 9 0 3 25.00 
PTPN11 Q06124       
LPFDHTRVV  3 2.69 9 3 6 33.33 
PTPRU Q92729       
GLDDILLLSY  3 3.47 1 0 4 80.00 
PTRF Q6NZI2       
KSFTPDHVVYAR  9 3.82 2 1 11 78.57 
SFTPDHVVY  3 4.27 0 0 3 100.00 
PYGL P06737       
WPVDLVEKL  6 2.79 1 3 11 73.33 
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Supplementary Table 6 (continued) 
QPRT Q15274       
VEAARGAGW  3 2.40 1 0 3 75.00 
RAD50 Q92878       
EYVEKFYRI  4 2.85 22 1 6 20.69 
RARRES2 Q99969       
FPAGIFVRL  6 3.30 7 0 8 53.33 
RRLLIPLAL  3 3.07 2 0 5 71.43 
RASSF2 P50749       
ATDYPLIAR  3 4.69 20 0 4 16.67 
RBBP7 Q16576       
KDEIFQVHW  3 2.17 4 2 3 33.33 
RBM47 A0AV96       
FPAAPAPKM  7 3.60 7 0 10 58.82 
TEDTIKKSF  4 2.96 0 2 7 77.78 
REXO4 Q9GZR2       
ARVSIVNQY  3 2.50 10 0 4 28.57 
RFC4 P35249       
RIIEPLTSR  3 3.30 17 0 5 22.73 
RGS5 O15539       
EIKIKLGI  4 5.55 0 0 7 100.00 
GLASFKSFL  12 4.22 1 2 18 85.71 
HALMEKDSL  4 4.80 0 0 5 100.00 
ILLQKPDSV  4 3.42 0 0 5 100.00 
KLLQNNYGL  4 4.06 0 0 5 100.00 
KPAKTQKTSL  8 3.23 11 7 10 35.71 
KTSLDEALQW  3 2.28 0 2 3 60.00 
MAQKRIHAL  5 2.79 5 0 13 72.22 
PAKTQKTSL  3 2.49 0 0 2 100.00 
SSFDMAQKR  5 2.73 13 2 6 28.57 
RHPN2 Q8IUC4       
HYAALAHYF  5 3.32 0 1 7 87.50 
RIC1 Q4ADV7       
ETLLLSVFQ  5 2.12 1 0 1 50.00 
RIOK2 Q9BVS4       
FPVPKPIDY  3 4.01 9 0 3 25.00 
RIPK4 P57078       
QENIVRILL  6 3.02 0 0 8 100.00 
RNF20 Q5VTR2       
HLAEVLERV  3 2.61 1 2 7 70.00 
RNF213 Q63HN8       
EPLSQITAY  3 2.19 2 0 3 60.00 
FPIPLINRL  8 2.13 11 2 9 40.91 
IYPQVLHSL  3 3.29 8 0 7 46.67 
NAFLSKSSV  3 2.01 5 4 5 35.71 
RNFT1 Q5M7Z0       
DVHIQINSI  3 4.47 2 0 1 33.33 
RNLS Q5VYX0       
MPVPEILQL  4 2.58 2 0 5 71.43 
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Supplementary Table 6 (continued) 
RPA1 P27694       
TEFPNFKY  4 2.79 2 1 5 62.50 
RPF2 Q9H7B2       
RPFEDQTSL  6 3.59 9 2 7 38.89 
RPL34 P49207       
RLSYNTASNK  3 2.24 6 0 4 40.00 
RPL35 P42766       
QLDDLKVEL  8 3.02 12 1 11 45.83 
RPL7A P62424       
KVVNPLFEK  5 2.43 30 3 6 15.38 
RPL9 P32969       
AHFPINVVI  3 2.12 2 1 3 50.00 
IPENVDITL  3 2.32 0 1 4 80.00 
RPN2 P04844       
ALSALTARL  7 2.22 3 3 11 64.71 
RMLAQQAVK  7 2.14 12 2 10 41.67 
RPS10 P46783       
YLTNEGIQYL  4 2.08 15 1 6 27.27 
RPS19 P39019       
STARHLYLR  3 3.40 4 1 4 44.44 
RRAD P55042       
ALFEGVVRQI  3 3.93 0 0 5 100.00 
MPVDERDLQA  3 4.84 0 0 4 100.00 
RRAGA Q7L523       
LLFERATFL  3 2.26 0 0 6 100.00 
RRAGC Q9HB90       
LENLLNIFI  3 2.93 1 0 3 75.00 
RRBP1 Q9P2E9       
ATQKGDPVAILK  3 2.02 15 2 5 22.73 
RRM1 P23921       
SPVSKGILQY  4 3.41 3 2 5 50.00 
RRN3 Q9NYV6       
ITNKYQLVF  8 2.15 12 5 15 46.88 
RRP12 Q5JTH9       
RPTDVAISF  3 4.58 6 0 4 40.00 
RTKN Q9BST9       
APRKPPQAL  3 2.27 9 2 6 35.29 
RTN4 Q9NQC3       
ISEELVQKY  4 3.30 0 4 3 42.86 
RUNX1 Q01196       
DVPDGTLVTVM  3 2.46 3 2 4 44.44 
S100A10 P60903       
EHAMETMMF  3 2.00 0 1 3 75.00 
S100A11 P31949       
FLSFMNTEL  8 2.34 4 6 17 62.96 
S100A9 P06702       
LDTNADKQL  3 2.24 2 0 1 33.33 
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Supplementary Table 6 (continued) 
SAP30 O75446       
IPVNEKDTL  4 5.07 0 0 5 100.00 
SARAF Q96BY9       
KGWDGYDVQW  3 3.61 1 1 4 66.67 
YSEYPPFSHRY  14 2.70 22 10 18 36.00 
SCD O00767       
ITAPPSRVL  5 4.33 10 0 9 47.37 
LPLRLFLII  5 2.52 0 3 8 72.73 
SLLHLGALY  3 3.84 0 0 4 100.00 
VFVATFLRY  4 2.51 3 4 4 36.36 
SEC14L1 Q92503       
TRWPGFYIL  6 2.06 8 2 9 47.37 
SEC16A O15027       
GLWGHALLL  5 2.34 6 1 8 53.33 
SEC23B Q15437       
MPQFSTIEY  3 3.78 9 0 3 25.00 
SEC24A O95486       
FLLHIQQQV  13 3.07 22 8 17 36.17 
SEC24B O95487       
LPVVSSLADVY  4 2.32 11 1 5 29.41 
SEC24C P53992       
SVLPVLDNPLSK  5 3.39 9 0 5 35.71 
SEC31A O94979       
MPRVQTQQY  4 2.60 5 1 4 40.00 
SEL1L3 Q68CR1       
SVSEIGGKIFEK  5 4.32 14 0 6 30.00 
YYITGNLETF  5 2.96 16 0 7 30.43 
SELL P14151       
STQRDLWNIFK  3 3.99 15 0 5 25.00 
SEMA5A Q13591       
FTDLNNYDEY  3 2.47 2 0 3 60.00 
SERINC2 Q96SA4       
SIAAVLPKV  4 4.11 0 0 6 100.00 
SERPINA1 P01009       
SVLGQLGITK  6 2.35 22 2 7 22.58 
SETD3 Q86TU7       
PSEYDTPLY  3 2.50 3 0 4 57.14 
SF3B3 Q15393       
MVTEIRLKY  3 2.65 2 1 3 50.00 
SF3B4 Q15427       
RPITVSYAF  3 3.11 13 0 4 23.53 
SGPL1 O95470       
TELLVKAY  3 2.19 0 0 3 100.00 
SH3BP1 Q9Y3L3       
YLADLYHFV  5 2.11 10 2 8 40.00 
SHANK2 Q9UPX8       
KLWGDVTEI  7 2.18 1 2 11 78.57 
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Supplementary Table 6 (continued) 
SHTN1 A0MZ66       
EVIEEVNKV  4 2.61 5 2 5 41.67 
SLC11A1 P49279       
IIMPHNIYL  5 2.12 21 2 11 32.35 
SLC15A4 Q8N697       
VSIKAIGW  3 2.88 1 1 3 60.00 
SLC16A3 O15427       
KLLDATHVY  3 4.08 0 0 4 100.00 
VPPVFVVSY  3 4.77 0 0 3 100.00 
YAFPKAVSV  9 3.56 16 0 16 50.00 
YAFPKAVSVF  6 3.44 7 1 8 50.00 
SLC17A3 O00476       
ALIVSLPYL  6 2.57 0 0 8 100.00 
SLC22A18 Q96BI1       
APEERPAAL  10 2.28 14 6 13 39.39 
RSSVILLTY  3 3.45 3 1 3 42.86 
SLC28A1 O00337       
SYILRPVAF  7 3.16 2 7 8 47.06 
SLC2A1 P11166       
FHPLGADSQV  3 5.35 7 0 2 22.22 
SLC35B3 Q9H1N7       
FICVAGVFVF  3 3.69 0 0 2 100.00 
SLC38A1 Q9H2H9       
LPSSLYLKI  4 4.24 3 1 6 60.00 
SLC3A1 Q07837       
EEIKEILRF  10 2.74 2 8 11 52.38 
MPKEVLFQF  4 4.52 0 1 6 85.71 
NELLLNRGW  8 2.03 0 2 8 80.00 
QEADFPFNNY  3 3.11 0 0 4 100.00 
TALNIKTVW  4 3.79 0 1 6 85.71 
YHDFTTTQV  3 3.72 0 2 4 66.67 
YRFMGTEAY  4 5.47 0 0 6 100.00 
YSSVLNILY  4 4.63 0 1 10 90.91 
SLC4A4 Q9Y6R1       
DEVFHDIAY  3 2.21 0 1 2 66.67 
SLC6A17 Q9H1V8       
GFSVGLGNIW  3 3.73 0 0 1 100.00 
SLC6A8 P48029       
IAYPRAVTL  3 3.80 0 0 7 100.00 
SLC6A9 P48067       
AFVAYPEALTL  5 2.41 3 1 3 42.86 
SLU7 O95391       
DPTKLELLY  3 2.35 5 0 3 37.50 
SMAD2 Q15796       
LTELPPLDDY  6 2.01 7 2 9 50.00 
SMPD4 Q9NXE4       
TQKPLPVSL  3 2.05 12 0 5 29.41 
SMPDL3A Q92484       
NPNLRIISL  4 3.98 2 0 9 81.82 
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Supplementary Table 6 (continued) 
SNAPC1 Q16533       
RVGALYLLY  3 2.12 6 1 5 41.67 
SND1 Q7KZF4       
ITDDLHFYV  5 3.09 2 0 7 77.78 
NADAIVVKL  5 2.05 6 3 5 35.71 
SNRNP200 O75643       
LYQDKFPFF  5 2.17 22 2 8 25.00 
RPVPLEQTY  4 2.12 4 2 5 45.45 
SYLKQLPHF  5 2.09 19 3 7 24.14 
SOAT1 P35610       
DSYPRNPTV  5 3.53 6 1 6 46.15 
SORBS1 Q9BX66       
IVNPTIVLL  4 2.40 11 0 4 26.67 
SPATS2L Q9NUQ6       
NVKEKIYAV  4 2.24 2 3 8 61.54 
SPCS2 Q15005       
KYVENFGLI  4 2.38 3 1 6 60.00 
SRC P12931       
FYITSRTQF  4 2.88 12 1 5 27.78 
STAMBPL1 Q96FJ0       
MPDHTDVSL  4 5.57 4 0 5 55.56 
STAT1 P42224       
FLEQVHQLY  11 3.04 10 5 15 50.00 
FPMEIRQY  5 3.03 4 2 5 45.45 
FPMEIRQYL  5 2.22 19 2 8 27.59 
IELLNVTEL  4 2.25 1 1 6 75.00 
REGAITFTW  4 3.39 7 1 5 38.46 
SEVLSWQF  5 2.84 3 3 6 50.00 
VLWDRTFSLF  3 2.57 4 1 7 58.33 
VTFPDIIRNYK  3 5.00 6 0 3 33.33 
STAT2 P52630       
IELLLPKL  3 3.16 4 0 4 50.00 
STAT3 P40763       
KFPELNYQL  5 4.00 13 0 6 31.58 
SFAEIIMGY  4 2.31 0 1 4 80.00 
STK39 Q9UEW8       
SEIPDEVKL  3 2.32 4 0 4 50.00 
STMN3 Q9NZ72       
TQPHPNTVY  3 3.60 19 0 6 24.00 
STOML1 Q9UBI4       
AEADLRALL  3 2.46 3 1 7 63.64 
STXBP2 Q15833       
ILSGVIRSV  3 2.39 12 1 4 23.53 
SWT1 Q5T5J6       
KLWGQSIQL  5 2.43 13 3 12 42.86 
TAGLN Q01995       
HVIGLQMGSNR  3 2.63 4 0 2 33.33 
TAGLN2 P37802       
NVIGLQMGTNR  4 2.26 15 2 3 15.00 
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Supplementary Table 6 (continued) 
TAP1 Q03518       
HPTAFVVSY  4 5.12 18 0 4 18.18 
LLYESPERY  14 3.05 16 4 17 45.95 
TALPRIFSL  3 2.20 5 1 5 45.45 
VLLSIYPRV  4 2.94 4 0 5 55.56 
VLRQETEFF  3 2.67 11 0 3 21.43 
TAPBP O15533       
MPAAQEGAVAF  5 4.53 8 1 5 35.71 
SAFLLLGLFK  6 2.04 20 3 6 20.69 
TAPT1 Q6NXT6       
TLLPLRVFL  7 2.01 10 5 13 46.43 
TBC1D14 Q9P2M4       
EEFLFRTAL  7 2.01 12 3 8 34.78 
TBL1XR1 Q9BZK7       
DEVNFLVY  4 2.35 1 1 4 66.67 
TBL3 Q12788       
HPDPTRLLLF  3 3.27 1 1 4 66.67 
TBX2 Q13207       
VEDDPKVTL  4 2.18 0 1 5 83.33 
TBXAS1 P24557       
IPRPILVLL  4 2.24 17 3 7 25.93 
TCEA3 O75764       
IEDHIYQEL  5 2.06 0 3 6 66.67 
TCN2 P20062       
MRHLGAFLF  4 2.79 7 3 5 33.33 
TCP1 P17987       
HPTSVISGY  3 2.79 12 1 3 18.75 
TEP1 Q99973       
RYPSNLQLF  4 2.16 25 2 7 20.59 
TFG Q92734       
IPIHNEDITY  4 2.89 3 0 4 57.14 
TFIP11 Q9UBB9       
APVNFISAGL  7 3.07 0 0 7 100.00 
VYPLMKEYF  3 2.75 23 1 6 20.00 
TFRC P02786       
ELIERIPEL  3 3.46 1 1 4 66.67 
TGFBI Q15582       
ALFVRLLALA  10 2.66 3 8 13 54.17 
LPAEVLDSL  5 4.30 2 0 7 77.78 
THEMIS2 Q5TEJ8       
HPTDPLTSF  4 3.19 14 1 4 21.05 
TIMP1 P01033       
APFEPLASGIL  6 2.90 17 3 9 31.03 
DAADIRFVY  4 4.14 9 0 4 30.77 
TIPARP Q7Z3E1       
HYILHNSFF  4 2.68 16 2 6 25.00 
TLN1 Q9Y490       
AVASAAAALVLK  6 2.30 11 4 6 28.57 
RELETVRELL  4 3.09 3 0 5 62.50 
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Supplementary Table 6 (continued) 
TLR3 O15455       
EYNNIQHLF  4 3.70 11 0 6 35.29 
TLR7 Q9NYK1       
ILISKLLGA  4 2.63 2 3 11 68.75 
TMED3 Q9Y3Q3       
TVIDSQTHY  3 2.66 13 0 6 31.58 
TMED4 Q7Z7H5       
QLLDQVEQI  10 2.25 6 5 15 57.69 
TMED9 Q9BVK6       
QLVEQVEQI  5 2.78 0 1 4 80.00 
TMEM189 A5PLL7       
GSVELPIVGK  8 2.00 17 3 9 31.03 
TMEM37 Q8WXS4       
AEDRLFGLW  5 3.02 4 0 6 60.00 
TMEM38B Q9NVV0       
FPFFDIAHY  5 2.29 11 3 10 41.67 
TMEM86A Q8N2M4       
VPYSRALIM  3 2.07 1 2 5 62.50 
TMTC3 Q6ZXV5       
LSELKPMSY  3 3.58 10 0 7 41.18 
TMX2 Q9Y320       
PLYMGPEYI  3 3.64 1 0 2 66.67 
TNR Q92752       
ITAKVATHL  3 5.20 2 0 4 66.67 
TNS1 Q9HBL0       
HYPLNTVTF  8 2.22 3 4 10 58.82 
ITIEPGLLLK  4 3.10 18 2 5 20.00 
TNS3 Q68CZ2       
HTQGPVDGSLY  8 2.71 2 3 13 72.22 
TOMM70 O94826       
NRAAAFEQL  3 2.62 4 2 4 40.00 
TOP6BL Q8N6T0       
VYTLLTTHL  4 2.78 4 0 5 55.56 
TPMT P51580       
TEIPGTKVF  6 2.13 5 1 8 57.14 
TPX2 Q9ULW0       
KILEDVVGV  6 2.69 9 0 9 50.00 
LPLPHFDTI  4 4.16 2 0 5 71.43 
TRAFD1 O14545       
EEPDVIFQNF  3 4.71 8 1 5 35.71 
TRAM1 Q15629       
IIHAVIQEY  4 2.31 8 2 5 33.33 
TRAPPC2L Q9UL33       
DVVDEKISAM  4 2.66 2 0 5 71.43 
YPTEDYKVY  3 4.33 4 0 4 50.00 
TRAPPC6A O75865       
EELDVLKFL  4 2.47 11 3 6 30.00 
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Supplementary Table 6 (continued) 
TRBC1 P01850       
YEILLGKATLY  3 2.77 6 0 3 33.33 
TRIM23 P36406       
TEVADHIQL  4 3.23 1 0 5 83.33 
TSC22D1 Q15714       
KELIEKNSQL  4 2.40 0 1 5 83.33 
TSEN34 Q9BSV6       
SPQPDGKVVY  4 2.45 1 0 5 83.33 
TTC17 Q96AE7       
AKVPLGDLDLY  6 2.81 2 0 1 33.33 
HLDATKLLL  8 2.02 12 3 16 51.61 
TTC39B Q5VTQ0       
LPAPVKLIL  3 2.13 8 0 3 27.27 
TTI1 O43156       
QYILFPLRF  3 2.70 18 1 4 17.39 
TUBB P07437       
QLDRISVYY  3 3.59 2 1 5 62.50 
TUBGCP2 Q9BSJ2       
MPHDLITQL  5 3.34 3 2 7 58.33 
TUFT1 Q9NNX1       
HEEIIKVYL  4 2.44 0 1 5 83.33 
TUSC3 Q13454       
RPPNYSGTIAL  3 3.00 1 1 4 66.67 
TXNDC11 Q6PKC3       
IPAKPPVSF  6 2.72 16 2 9 33.33 
TYMS P04818       
DAHIYLNHI  6 3.15 10 5 8 34.78 
TYROBP O43914       
YSDLNTQRPY  8 2.47 20 2 15 40.54 
U2SURP O15042       
YPEPFLIKL  4 2.55 2 0 5 71.43 
UBA6 A0AVT1       
FPAAIEHTI  3 2.69 3 2 4 44.44 
UBD O15205       
DANPYDSVKKI  3 6.53 0 0 1 100.00 
KMMADYGIRK  4 3.16 3 0 5 62.50 
NPYDSVKKI  5 2.31 2 5 8 53.33 
UBE2V2 Q15819       
LPQPPEGQTY  3 3.28 1 0 3 75.00 
UBE2W Q96B02       
YPFDSPQVMF  3 3.60 2 0 3 60.00 
UBE2Z Q9H832       
NPYHNEPGF  5 2.26 2 0 6 75.00 
UBE3A Q05086       
NESPLKYLF  3 2.39 6 1 5 41.67 
UBL3 O95164       
SPNILRLIY  3 2.80 6 0 6 50.00 
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Supplementary Table 6 (continued) 
UBR4 Q5T4S7       
MPIYEAADKAL  7 4.74 0 0 7 100.00 
UBXN4 Q92575       
FPRREFTKEDY  4 4.96 2 0 4 66.67 
UGP2 Q16851       
LPVAKDVSY  3 2.73 12 0 4 25.00 
UGT2A3 Q6UWM9       
ATAIFLFTK  5 4.73 6 1 7 50.00 
LAVPFVLTL  9 2.95 1 0 11 91.67 
UHRF1 Q96T88       
TLFDYEVRL  10 3.92 13 2 18 54.55 
UHRF1BP1L A0JNW5       
YTDSSSILNY  4 2.65 12 0 8 40.00 
USH1C Q9Y6N9       
THEEVINLI  3 5.13 0 0 3 100.00 
USP10 Q14694       
FPAEAGRDTL  4 2.53 1 1 5 71.43 
USP7 Q93009       
VEGTIPKLF  3 2.37 6 1 5 41.67 
USP8 P40818       
KYVTVYNLI  3 2.02 16 0 6 27.27 
UXT Q9UBK9       
VPDTSRIYV  4 3.76 5 1 6 50.00 
VPDTSRIYVAL  6 2.77 21 2 8 25.81 
VASN Q6EMK4       
SRVPLLLPL  4 2.62 0 0 5 100.00 
VAV1 P15498       
FLLDKALLI  4 2.10 21 2 13 36.11 
VAV3 Q9UKW4       
GEVNGRVGW  3 2.40 2 2 4 50.00 
VCAM1 P19320       
FPRDPEIEM  10 4.64 12 3 13 46.43 
KSIDGAYTI  3 5.21 1 0 3 75.00 
QIDSPLNGK  5 3.53 2 1 5 62.50 
QIDSPLSGK  9 2.09 11 6 10 37.04 
VCAN P13611       
FPYSGDKILV  3 5.37 1 0 4 80.00 
VEGFA P15692       
HPIETLVDIF  6 4.40 0 0 9 100.00 
VIM P08670       
ALRPSTSRSLY  11 3.20 36 6 17 28.81 
LEQQNKILL  7 2.62 5 5 7 41.18 
LPLPNFSSL  12 2.98 26 5 16 34.04 
QAKQESTEY  3 3.01 23 1 9 27.27 
RISLPLPNF  11 2.02 40 10 14 21.88 
SLPLVDTHSK  7 3.72 24 1 8 24.24 
VN1R17P Q8TDU5       
PIDMTISHL  3 4.13 0 1 2 66.67 
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VPS13A Q96RL7       
IPMAKSYVL  3 2.57 4 1 3 37.50 
VPS13B Q7Z7G8       
YPEPRVLTL  3 3.28 7 1 5 38.46 
VPS25 Q9BRG1       
DEATLLRAL  4 2.02 1 4 5 50.00 
VPS29 Q9UBQ0       
KTLAGDVHIVR  3 2.02 2 0 3 60.00 
VPS35 Q96QK1       
DELHYLEVY  4 2.36 1 2 5 62.50 
VWA5A O00534       
KTFEDKVTF  3 2.23 13 2 3 16.67 
VWF P04275       
AVLSSPLSH  6 3.14 19 2 10 32.26 
AYGFVARI  5 2.95 8 2 7 41.18 
DALGFAVRY  6 3.88 10 2 8 40.00 
EAYGFVARI  8 2.02 13 8 9 30.00 
EVIASYAHL  6 3.79 6 3 4 30.77 
IPARFAGVL  11 4.11 31 5 14 28.00 
MPYASKGLYL  7 3.04 10 0 7 41.18 
VTASVRLSY  6 4.18 11 1 8 40.00 
WDFY4 Q6ZS81       
EEEGNLLRSW  3 3.59 6 0 3 33.33 
WDR43 Q15061       
KLILLITQV  4 2.01 7 1 6 42.86 
WDR72 Q3MJ13       
LSDVDSSSSFY  3 3.93 2 0 3 60.00 
WDR81 Q562E7       
TLMDILPRI  9 2.12 11 2 16 55.17 
WDR91 A4D1P6       
MPVPVILNF  7 2.45 4 1 10 66.67 
WTAP Q15007       
NELSAWKF  4 2.03 1 2 4 57.14 
WWC2 Q6AWC2       
SLIENQILL  7 2.45 6 2 12 60.00 
YBX3 P16989       
APAPAAHVA  3 2.07 9 1 5 33.33 
YIPF3 Q9GZM5       
FPQKIAGELY  3 2.54 2 0 4 66.67 
YTHDC2 Q9H6S0       
DEATIRAII  4 2.02 0 2 5 71.43 
ZCRB1 Q8TBF4       
LPFSLTNNDLY  3 2.71 2 1 4 57.14 
ZHX2 Q9Y6X8       
FPYPTQAEL  3 3.86 0 0 4 100.00 
ZKSCAN1 P17029       
DGIVIVKV  5 2.53 9 2 6 35.29 
ZWINT O95229       
LPAKILVEF  7 2.39 10 3 8 38.10 
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Supplementary Table 7: Class II TUMAPs of selected target candidates. All TUMAPs found in at least 3 ccRCC patients are 
listed. 
Gene 
    TUMAP 
Found on n ccRCC patients Uniprot_ID 
ADAM17 3 P78536 
VRIIKPFPAPQTPG 3  
ADAMDEC1 3 O15204 
KGNILNEKNSVAS 3  
AGRN 12 O00468 
GAPVPAFEGRSFLAFPTL 3  
LEFRALEPQGLLL 3  
TGDTRIFFVNPAPPYLWPA 6  
ALAD 3 P13716 
IQPITSLPGVARYG 3  
ALB 3 P02768 
GERAFKAWAVARLS 3  
ALCAM 3 Q13740 
TKKSVQYDDVPEYKDR 3  
ANG 3 P03950 
PVHLDQSIFRRP 3  
ANPEP 4 P15144 
STGTLSQEHFLLD 4  
ANXA4 10 P09525 
IGRDLIDDLKSELSG 3  
ISQTYQQQYGRSLED 7  
ANXA5 3 P08758 
IKQVYEEEYGSSLED 3  
APCS 8 P02743 
SKVIEKFPAPVH 4  
TSKVIEKFPAPVH 4  
APOA1 14 P02647 
RLAEYHAKATEHLST 7  
RLAEYHAKATEHLSTL 4  
RTHLAPYSDELRQR 3  
APOA4 13 P06727 
GDLQKKLVPFATELH 3  
LQQRLEPYADQLRTQ 3  
QQRLEPYADQLR 4  
RQRLAPLAEDVRG 3  
B2M 3 P61769 
FYLLYYTEFTPTEKDE 3  
BGN 5 P21810 
VPKEISPDTTLLDLQ 5  
BTF3 3 P20290 
AEALPKQSV 3  
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Supplementary Table 7 (continued) 
C1QA 3 P02745 
VSSSRGQVR 3  
C1QC 3 P02747 
APNSLIRFNAVLTNPQ 3  
C3 11 P01024 
GISTKLMNIFLKDSIT 4  
KVTIKPAPETEKRPQ 3  
VYHHFISDGVRKS 4  
CAGE1 3 Q8TC20 
ESMSESDTMNVSN 3  
CANX 8 P27824 
DDWDEDAPAKIPDE 5  
KTDAPQPDVK 3  
CD3G 4 P09693 
EDDQYSHLQGNQLR 4  
CD4 3 P01730 
RVTQDPKLQMGKK 3  
CD74 3 P04233 
GLGVTKQDLGPVPM 3  
CDV3 17 Q9UKY7 
KTPQGPPEIYSDTQFPSLQ 8  
RKTPQGPPEIYSDTQFPSLQ 3  
TPQGPPEIYSDTQFPSLQ 6  
CECR1 3 Q9NZK5 
HDEEWSVKTYQEVAQK 3  
CLU 3 P10909 
VAEKALQEYRKKHRE 3  
CNN1 4 P51911 
TNHTQVQSTL 4  
COL14A1 3 Q05707 
APGNVEKYRVVYYPTRGGKPDE 3  
COL18A1 3 P39060 
DPDKFQGVIAELKVR 3  
COL1A2 4 P08123 
GKTIIEYKTNKPS 4  
COL4A2 6 P08572 
AGIPQKIAVQPGTVGPQG 3  
IPQKIAVQPGTVGPQGR 3  
COL6A2 3 P12110 
INRIIKVMKHEAYG 3  
CPE 3 P16870 
APETKAVIHWIMDIPF 3  
CRP 3 P02741 
TSYVSLKAPLT 3  
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Supplementary Table 7 (continued) 
CTSA 3 P10619 
VARIVGNSGLNI 3  
CTSD 17 P07339 
FIGRYYTVFDRDNN 3  
LVRIPLHKFTSIRR 3  
RIPLHKFTSIRR 3  
VFIGRYYTVFDRDN 4  
YPRISVNNVLPV 4  
CUBN 3 O60494 
VIELKFSDFDVVPS 3  
CXCL14 4 O95715 
KMVIITTKSVSRYR 4  
CYB5R3 3 P00387 
SPDIKYPLR 3  
DNAH11 4 Q96DT5 
LKKQDIPDSALAIFK 4  
DSC2 3 Q02487 
TGSIKVFRSLDREA 3  
EDIL3 7 O43854 
GVITQGAKRIGSPE 4  
VTGVITQGAKRIGSPE 3  
ENPEP 15 Q07075 
DDAFALARAQLLDYK 3  
IDDAFALARAQLL 3  
IDDAFALARAQLLD 4  
IDDAFALARAQLLDY 5  
ENPP3 10 O14638 
VPFYEPSHAEEVSK 5  
YNNEFRSMEAIFLAHGPS 5  
EZR 3 P15311 
DRIQVWHAEHRG 3  
FAM162A 3 Q96A26 
EEAAMKAKTE 3  
FGA 10 P02671 
FPGFFSPMLG 3  
HPGIAEFPSRGK 4  
HPGIAEFPSRGKSSSY 3  
FGG 3 P02679 
YLQEIYNSNNQKIVNLK 3  
FLT1 3 P17948 
FPLDTLIPDGKRIIWD 3  
FN1 25 P02751 
DDTSIVVRWSRPQAPI 3  
DEPQYLDLPSTATS 4  
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Supplementary Table 7 (continued) 
DEPQYLDLPSTATSV 3  
GDEPQYLDLPSTATSVN 3  
KTYHVGEQWQKEYLG 3  
SSPVVIDASTAIDAPS 6  
TPPESAVTGYRVDVIPVNLPG 3  
FTL 3 P02792 
AAVNSLVNL 3  
GAA 4 P10253 
SLPSQYITGLAEHLSPL 4  
GAPDH 5 P04406 
AVGKVIPELNGKLTG 5  
GLRX 3 P35754 
EIQDYLQQLTGARTVPR 3  
GPC4 3 O75487 
LDRLVTDVKEKLKQAK 3  
GPNMB 6 Q14956 
DVYVVTDQIPVFVTMFQKN 3  
VPIAQVKDVYVVTDQIPVFVTM 3  
GSN 3 P06396 
KPMIIYKGGTSREG 3  
H2AFZ 3 P0C0S5 
IGKKGQQKTV 3  
HLA-DRA 4 P01903 
VDMAKKETVWRLEEF 4  
HMGB1 3 P09429 
KDIAAYRAKGKPD 3  
HNRNPA3 3 P51991 
GSGGYGSRRF 3  
HNRNPK 3 P61978 
LQLPSPTATSQLPLESD 3  
HP 12 P00738 
ATGILSFDKSCAVAE 3  
LPSKDYAEVGRVGYVS 3  
LPSKDYAEVGRVGYVSG 3  
YATGILSFDKSCAVAEYG 3  
HSP90AB1 3 P08238 
AEEPNAAVPDEIPPLEGDEDASRME 3  
HSPD1 10 P10809 
GIIDPTKVVR 4  
GSPKVTKDGVTVAK 3  
LKDKYKNIGAK 3  
HSPG2 25 P98160 
APPIRIEPSSSRVA 4  
GGSLRYNVRYELAR 3  
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Supplementary Table 7 (continued) 
GPGYVGNPSVQGGQ 3  
STQLQIDPSLHE 6  
STQLQIDPSLHEFQL 6  
VTPTVRIESSSSQVAEG 3  
HTRA1 4 Q92743 
KADIALIKIDHQGK 4  
IFI30 5 P13284 
SPLQALDFFGNGPPVNYKTG 5  
IGF2 3 P01344 
YPVGKFFQYDTWKQST 3  
IGFBP3 24 P17936 
HSKIIIIKKG 4  
HSKIIIIKKGHA 3  
IIIIKKGHAK 5  
IIIIKKGHAKD 5  
IIIKKGHAK 3  
IIKKGHAKD 4  
IGFBP5 3 P24593 
RPKHTRISELKAEAVKK 3  
IGHG1 6 P01857 
APIEKTISKAKGQPREPQ 6  
ITGAX 3 P20702 
RGAVYLFHGVLGPS 3  
ITGB2 3 P05107 
SNQFQTEVGKQLISG 3  
ITIH2 3 P19823 
LKKFYNQVSTPLLR 3  
ITIH4 6 Q14624 
RPSLVPASAENVNKA 3  
WRPSLVPASAENVN 3  
KNG1 4 P01042 
VHPISTQSPDLEP 4  
KRT2 3 P35908 
SGGGKHSSGGGSRGG 3  
KRT9 3 P35527 
GGGGLGSGGSIR 3  
LAMC1 4 P11047 
FGDEVFNDPKVLKSY 4  
LCP1 7 P13796 
IKIFHGLKSTDVAK 7  
LGALS1 3 P09382 
VRGEVAPDAKSFVLNL 3  
LGALS3BP 5 Q08380 
VPSELALLKAVDTWS 5  
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Supplementary Table 7 (continued) 
LRP1B 3 Q9NZR2 
IPHCKDKSDEKLL 3  
LRP2 13 P98164 
MPRHIVVDPKNRYLFW 3  
RRTVVQYLNNPR 3  
SSSVASDNAIRRIKPD 3  
VDREVIVNAAVHA 4  
MARCKS 3 P29966 
TPKKKKKRF 3  
MDH2 3 P40926 
LLKNSPLVSR 3  
NDUFA4L2 10 Q9NRX3 
AGASLGARF 3  
AVSTDYKKLKKDRPDF 7  
NID1 9 P14543 
LDGTQRRVLFETDLVNPR 3  
WESVAPYQGPSRDPD 3  
WESVAPYQGPSRDPDQ 3  
NPM1 6 P06748 
RSAPGGGSKVPQK 6  
NPTX2 8 P47972 
INDKVAQLPLFVSDG 4  
MPGNIIPWVDNNVDVF 4  
OLFML2B 3 Q68BL8 
IRSALQRDAAAAYAHPE 3  
OR2A5 6 Q96R48 
IQMLLSGLFSLL 6  
PCOLCE 3 Q15113 
VIALTFEKFDLEPDT 3  
PCSK9 6 Q8NBP7 
IEGRVMVTDFENVPEE 3  
VEVYLLDTSIQSDH 3  
PDGFD 3 Q9GZP0 
DLYRRDETIQVKGN 3  
PEA15 3 Q15121 
EEEIIKLAPPPKKA 3  
PLG 3 P00747 
HSIFTPETNPRA 3  
PLIN2 3 Q99541 
TKSELLVEQYLPLTEE 3  
PLXNC1 4 O60486 
DEPVWRSEQAIGAIA 4  
POSTN 4 Q15063 
IIHGNQIATNGVVHVIDR 4  
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Supplementary Table 7 (continued) 
PRSS23 15 O95084 
LPVVLPQSTLNLAK 4  
LPVVLPQSTLNLAKP 4  
LPVVLPQSTLNLAKPD 7  
PSAP 23 P07602 
APFMANIPLLLYP 4  
DPYQKQCDQFVAEYEPV 4  
EVVAPFMANIPLLLYPQ 6  
VAPFMANIPLLLYP 6  
VAPFMANIPLLLYPQDG 3  
PTMA 13 P06454 
AAVDTSSEITTKDLKEKK 3  
AVDTSSEITTKDL 4  
AVDTSSEITTKDLKEKK 3  
ITTKDLKEK 3  
PXDN 11 Q92626 
GKFHISPEGFLTINDV 11  
RPL13 3 P26373 
PRKPSAPKKGDSSAEEL 3  
RPL7A 3 P62424 
KVAPAPAVVK 3  
RPS11 4 P62280 
YQKQPTIFQNK 4  
RPS13 3 P62277 
RDSHGVAQVR 3  
RPS20 3 P60866 
KTPVEPEVAIHRIR 3  
RPS6 3 P62753 
IVKKGEKDIPGLTDTTVPR 3  
S100A9 3 P06702 
LGHPDTLNQGEFKEL 3  
SDCBP 3 O00560 
GKITSIVKDSSAARN 3  
SERPINF2 4 P08697 
GPDLKLVPPMEEDYPQF 4  
SIRPA 3 P78324 
LQVIQPDKSVLVAAG 3  
SLAMF7 9 Q9NQ25 
DSIVWTFNTTPLVTIQP 3  
EDVIYTWKALGQA 3  
SIVWTFNTTPLVTIQPE 3  
SLIT3 3 O75094 
KDSYVELASAKVRP 3  
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Supplementary Table 7 (continued) 
SPARC 3 P09486 
YERDEDNNLLTEKQKLRVKKIHENE 3  
STAB1 3 Q9NY15 
GHMIRNVEALASDLPN 3  
TEKT5 4 Q96M29 
MEFLGTTQTA 4  
TF 7 P02787 
IRAIAANEADAVT 4  
YEYVTAIRNLREGT 3  
TGFBI 9 Q15582 
IDKVISTITNNIQ 3  
VNIELLNALRYHMVG 3  
VSGGIGALVRLKSLQ 3  
TGS1 3 Q96RS0 
VTPEKIAEHIAG 3  
THBS1 7 P07996 
SSPAFRIEDANLIPPV 3  
SSPAFRIEDANLIPPVPD 4  
THBS2 6 P35442 
SRGTLLALEGPGLSQ 6  
TMEM57 3 Q8N5G2 
QKDKQNISQLEKKL 3  
TMSB10 3 P63313 
TQEKNTLPTKETIEQEKRSEIS 3  
TMSB4X 11 P62328 
LKKTETQEKNPLPSK 4  
TETQEKNPLPSK 3  
TQEKNPLPSK 4  
TOB2 3 Q14106 
FTTASFAATKFGS 3  
TTR 8 P02766 
DAVRGSPAINVAVHVFRK 3  
VRGSPAINVAVHVFRK 5  
USP34 3 Q70CQ2 
SRYIHDLFPSLIKN 3  
VCAM1 15 P19320 
DRLEIELLKGETILE 3  
GETILENIEFLEDTDMK 4  
STLTLSPVSFENEHSYL 3  
TPESRYLAQIGDSVS 5  
VWA1 3 Q6PCB0 
GPERIVISHARPRSL 3  
ZNF112 3 Q9UJU3 
VMLENFRNLLLV 3  
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8.2. SYFPEITHI matrices 
The following tables display the SYFPEITHI matrices for each length variant established from 
monoallelic transfectants of C1R cells. The first lines constitute the amino acid position within the 
peptide. The first row represents the amino acid. Scores were distributed according to predefined 
standards. First, anchor and auxiliary anchor positions are defined depending on the frequency of 
one or a group of similar amino acids representing at least 75% or 50%, respectively, of all residues at 
a specific position. For anchor positions scores of 4-10 are assigned depending on the impact of the 
residue. The amino acid with the highest impact receives 10 points. Every other residue receives 10 
points if not >3x less frequent than the amino acid with the highest impact, 8 points if >3x less 
frequent and 6 points if >5x less frequent. For residues representing less than 10%, 4 points are 
assigned if they have similar characteristics compared to the other anchor residues and if they are 
more frequent then their background frequency within the human proteome (residues appear on the 
positive axis of the sequence logos, see Figure 25). For auxiliary anchors scores of 4 or 6 are assigned. 
A percentage over 50% accounting for one residue is rewarded with 6 points. If auxiliary anchor 
definition is achieved by two (or more) residues, 4 points are distributed to each amino acid. An 
amino acid frequency of >30% in non-anchor and non-auxiliary anchor position is awarded with 3 
points, a frequency of >20% with 2 points and a frequency of >10% with 1 point. Amino acids which 
are completely absent at a specific position may be also penalized with -1 point in non-anchor 
positions. 
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HLA-C*01:02, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 3 0 0 1 0 1 0 
C 0 0 0 0 0 0 0 0 
D 0 0 0 0 0 0 0 0 
E 0 0 0 1 0 0 2 0 
F 1 0 0 0 0 0 0 4 
G 0 0 0 0 3 0 0 0 
H 0 0 0 0 2 1 0 0 
I 0 0 0 0 0 0 0 4 
K 0 0 0 0 0 1 0 0 
L 0 0 0 0 0 0 0 10 
M 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 
P 0 0 10 0 0 0 0 0 
Q 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 1 0 0 
S 1 3 0 0 1 1 1 0 
T 0 0 0 1 0 0 1 0 
V 1 1 0 1 0 0 1 4 
W 0 0 0 0 0 0 0 0 
Y 1 0 0 0 0 0 0 0 
 
 
HLA-C*01:02, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 3 0 0 1 1 1 2 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 0 0 0 0 0 0 0 
E 0 0 0 1 0 0 0 1 0 
F 1 0 0 0 0 0 0 0 4 
G 0 0 0 0 1 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 0 0 0 0 0 0 0 4 
K 0 0 0 0 0 0 0 0 0 
L 0 2 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 0 
P 0 0 10 0 1 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 1 0 0 
S 1 2 0 1 1 0 1 2 0 
T 0 0 0 0 0 1 0 0 0 
V 1 0 0 0 0 0 0 0 4 
W 0 0 0 0 0 0 0 0 0 
Y 0 0 0 0 0 0 0 0 0 
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HLA-C*01:02, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 1 2 0 0 0 1 0 0 2 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 0 
E 0 0 0 2 0 0 0 0 1 0 
F 1 0 0 0 0 0 0 0 0 4 
G 0 0 0 0 1 0 0 0 0 0 
H 0 0 6 0 0 0 0 0 0 0 
I 0 2 0 0 0 0 0 0 0 4 
K 0 0 0 0 0 0 0 0 0 0 
L 0 6 0 0 0 0 1 1 0 10 
M 0 0 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 0 0 
P 0 0 10 0 0 2 1 0 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 0 
S 1 0 6 0 1 0 0 2 2 0 
T 0 0 0 0 0 0 0 1 1 0 
V 0 0 0 0 0 0 0 0 0 4 
W 0 0 0 0 0 0 0 0 0 0 
Y 1 0 0 0 0 0 0 0 0 0 
 
HLA-C*02:02, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 10 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 2 0 0 0 0 0 
E 0 0 0 0 0 0 1 0 
F 2 0 0 0 0 0 0 10 
G 0 0 1 0 1 0 0 0 
H 0 0 0 0 0 0 0 0 
I 0 8 0 0 0 0 0 0 
K 0 0 0 0 0 0 1 0 
L 0 0 0 0 0 0 0 10 
M 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 0 0 0 
P 0 0 0 0 0 0 0 0 
Q 0 6 0 0 0 0 0 0 
R 0 0 0 0 0 1 0 0 
S 0 8 0 0 0 0 0 0 
T 0 8 0 0 0 0 0 0 
V 0 8 0 1 0 1 0 6 
W 0 0 0 0 0 0 0 0 
Y 2 0 0 0 0 0 0 8 
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HLA-C*02:02, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 10 1 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 
E 0 0 0 0 0 0 0 1 0 
F 2 0 1 0 0 0 0 0 10 
G 0 0 0 1 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 6 1 0 1 1 0 0 0 
K 0 0 1 0 0 0 0 0 0 
L 0 0 0 0 0 1 1 0 10 
M 0 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 0 0 0 0 
P 0 0 0 1 0 0 0 0 0 
Q 0 6 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 
S 1 6 0 1 0 0 1 0 0 
T 0 6 0 0 0 0 0 1 0 
V 0 6 0 0 0 1 1 0 8 
W 0 0 0 0 0 0 0 0 0 
Y 2 0 1 0 0 0 0 0 10 
 
 
HLA-C*02:02, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 10 1 0 0 1 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 0 
E 0 0 0 0 0 0 0 0 1 0 
F 4 0 1 0 1 0 0 0 0 10 
G 0 0 0 0 1 0 1 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 6 0 0 0 0 0 0 0 0 
K 0 0 1 0 0 0 0 0 0 0 
L 0 0 0 0 0 0 1 0 0 8 
M 0 0 0 0 0 0 0 0 0 8 
N 0 0 0 0 0 1 0 0 0 0 
P 0 0 0 2 1 0 1 0 0 0 
Q 0 6 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 0 
S 0 8 0 0 0 1 0 1 1 0 
T 0 6 0 0 0 0 0 1 0 0 
V 0 8 0 0 0 0 0 0 0 6 
W 0 0 0 0 0 0 0 0 0 0 
Y 4 0 0 0 0 0 0 0 1 10 
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HLA-C*03:03, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 10 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 2 0 0 0 0 0 
E 0 0 0 0 0 0 1 0 
F 4 0 0 0 0 0 0 6 
G 0 0 0 0 4 0 0 0 
H 0 0 1 0 0 0 0 0 
I 0 6 0 0 0 0 0 0 
K 0 0 0 0 0 0 0 0 
L 1 0 0 2 0 1 0 10 
M 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 
P 0 0 0 0 1 0 0 0 
Q 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 2 1 0 
S 0 10 0 0 0 0 0 0 
T 0 8 0 0 0 0 0 0 
V 0 6 0 1 0 0 0 0 
W 0 0 0 0 0 0 0 0 
Y 4 0 0 0 0 0 0 0 
 
 
HLA-C*03:03, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 10 0 0 0 0 0 1 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 1 1 0 0 0 0 0 
E 0 0 0 1 0 0 0 1 0 
F 4 0 0 0 0 1 0 0 6 
G 0 0 0 1 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 6 1 0 0 0 0 0 0 
K 0 0 0 0 0 0 0 0 0 
L 1 0 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 0 
P 0 0 0 2 1 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 1 0 0 
S 0 8 0 0 0 0 0 1 0 
T 0 6 0 0 0 0 0 1 0 
V 0 6 1 0 0 0 0 1 0 
W 0 0 0 0 0 0 0 0 0 
Y 4 0 0 0 0 0 0 0 0 
186 
 
HLA-C*03:03, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 10 0 0 0 0 0 0 1 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 0 
E 0 0 0 1 0 0 0 0 1 0 
F 4 0 1 0 0 0 0 0 0 6 
G 0 0 0 1 1 1 1 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 6 1 0 0 0 0 0 0 0 
K 0 0 0 0 0 0 0 0 0 0 
L 0 0 0 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 0 0 
P 0 0 0 2 1 1 1 0 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 0 
S 0 8 0 0 0 1 0 0 1 0 
T 0 6 0 0 0 0 0 0 0 0 
V 0 6 1 0 0 0 0 0 1 0 
W 0 0 0 0 0 0 0 0 0 0 
Y 4 0 1 0 0 0 0 0 0 0 
 
 
HLA-C*03:04, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 10 0 0 1 0 1 0 
C 0 0 0 0 0 0 0 0 
D 0 0 1 0 0 0 0 0 
E 0 0 0 1 0 0 2 0 
F 4 0 0 0 0 0 0 6 
G 0 0 0 0 4 0 0 0 
H 0 0 1 0 0 0 0 0 
I 0 6 0 0 0 0 0 0 
K 0 0 0 0 0 1 0 0 
L 4 0 0 1 0 1 0 10 
M 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 0 0 0 
P 0 0 0 0 1 0 0 0 
Q 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 1 0 0 
S 0 10 0 0 0 0 0 0 
T 0 10 0 0 0 0 0 0 
V 0 6 0 1 0 0 0 0 
W 0 0 0 0 0 0 0 0 
Y 4 0 0 0 0 0 0 0 
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HLA-C*03:04, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 10 0 0 0 0 0 1 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 1 1 0 0 0 0 0 
E 0 0 0 1 0 0 0 1 0 
F 4 0 0 0 0 0 0 0 6 
G 0 0 0 1 0 1 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 6 1 0 0 0 0 0 0 
K 0 0 0 0 0 0 0 0 0 
L 4 0 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 0 0 0 0 
P 0 0 0 1 1 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 1 0 0 
S 0 8 0 0 0 1 0 1 0 
T 0 6 0 0 0 0 0 1 0 
V 1 6 1 0 0 0 0 1 0 
W 0 0 0 0 0 0 0 0 0 
Y 4 0 0 0 0 0 0 0 0 
 
 
HLA-C*03:04, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 10 0 0 0 0 0 0 1 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 0 
E 0 0 0 1 0 0 0 0 0 0 
F 4 0 0 0 0 0 0 0 0 8 
G 0 0 0 1 1 0 1 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 6 1 0 0 0 0 0 0 0 
K 0 0 0 0 0 0 0 0 0 0 
L 0 0 0 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 0 0 0 0 0 
P 0 0 0 2 1 1 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 0 
S 0 6 0 0 0 1 0 0 1 0 
T 0 6 0 0 0 1 0 0 1 0 
V 1 6 1 0 0 0 0 0 1 0 
W 0 0 0 0 0 0 0 0 0 0 
Y 4 0 0 0 0 0 0 0 0 0 
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HLA-C*04:01, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 0 0 0 1 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 10 0 0 0 0 0 
E 0 0 4 1 0 0 1 0 
F 1 4 0 0 0 0 0 8 
G 0 0 0 0 0 1 0 0 
H 0 0 0 0 1 0 1 0 
I 1 0 0 0 0 0 0 8 
K 0 0 0 0 0 0 1 0 
L 0 0 0 0 0 0 0 10 
M 0 0 0 0 0 0 0 8 
N 0 0 0 0 0 0 0 0 
P 0 0 0 0 0 0 0 0 
Q 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 1 0 
S 0 0 0 0 0 0 0 0 
T 0 1 0 0 0 0 0 0 
V 1 0 0 1 0 2 0 8 
W 0 0 0 0 0 0 0 0 
Y 1 4 0 0 0 0 0 0 
 
 
HLA-C*04:01, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 0 0 0 1 0 1 0 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 10 0 0 0 0 0 0 
E 0 0 6 1 0 0 0 1 0 
F 1 4 0 0 0 0 0 0 10 
G 0 0 0 0 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 1 0 0 0 0 1 0 0 6 
K 0 0 0 0 0 0 0 0 0 
L 1 0 0 1 0 1 0 1 10 
M 0 0 0 0 0 0 0 0 8 
N 0 0 0 0 0 0 0 0 0 
P 0 0 0 1 0 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 
S 0 0 0 0 0 0 0 0 0 
T 0 0 0 0 0 0 0 0 0 
V 1 0 0 0 0 1 1 0 8 
W 0 4 0 0 0 0 0 0 0 
Y 0 4 0 0 0 0 0 0 0 
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HLA-C*04:01, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 0 0 0 1 1 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 10 1 0 0 0 0 0 0 
E 0 0 6 1 0 0 0 1 0 0 
F 2 4 0 0 0 0 0 0 1 10 
G 0 0 0 0 0 1 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 0 0 0 0 0 0 0 0 4 
K 0 0 0 0 0 0 0 0 0 0 
L 0 0 0 1 0 0 0 0 1 10 
M 0 0 0 0 0 0 0 0 0 8 
N 0 0 0 0 0 0 0 0 0 0 
P 0 0 0 1 0 0 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 0 
S 0 0 0 0 1 0 0 0 0 0 
T 0 0 0 0 1 0 0 1 0 0 
V 2 0 0 1 0 0 0 1 1 8 
W 0 4 0 0 0 0 0 0 0 0 
Y 0 4 0 0 0 0 0 0 1 0 
 
 
HLA-C*05:01, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 3 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 10 0 0 0 0 0 
E 0 0 6 1 0 0 1 0 
F 1 0 0 0 0 0 0 8 
G 0 0 0 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 
I 1 1 0 0 0 0 0 8 
K 0 0 0 1 0 0 2 0 
L 0 1 0 0 0 0 0 10 
M 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 0 0 0 
P 0 0 0 0 1 0 0 0 
Q 0 0 0 0 0 1 0 0 
R 0 0 0 0 0 0 1 0 
S 1 1 0 0 0 1 0 0 
T 0 0 0 0 0 1 0 0 
V 1 1 0 0 0 2 0 8 
W 0 0 0 0 0 0 0 0 
Y 0 0 0 0 0 0 0 0 
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HLA-C*05:01, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 3 0 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 10 1 0 0 0 0 0 
E 0 0 6 1 0 0 0 1 0 
F 1 0 0 0 0 0 0 0 8 
G 0 0 0 0 1 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 1 0 0 0 0 0 0 0 6 
K 0 0 0 0 0 0 0 1 0 
L 0 0 0 0 0 0 0 1 10 
M 0 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 0 0 0 0 
P 0 0 0 0 1 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 
S 1 1 0 0 0 0 1 0 0 
T 0 0 0 0 0 0 1 0 0 
V 1 1 0 0 0 1 2 0 8 
W 0 0 0 0 0 0 0 0 0 
Y 0 0 0 0 0 0 0 0 0 
 
 
HLA-C*05:01, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 3 0 0 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 10 1 0 0 0 0 0 0 
E 0 0 6 1 0 0 0 1 0 0 
F 2 0 0 0 0 0 0 0 1 10 
G 0 0 0 1 1 1 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 1 0 0 0 0 0 0 0 6 
K 0 0 0 0 0 0 0 0 0 0 
L 0 0 0 0 0 0 1 0 1 10 
M 0 0 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 0 0 0 0 0 
P 0 0 0 1 2 0 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 0 
S 0 1 0 0 0 1 0 0 1 0 
T 0 0 0 0 0 0 0 1 1 0 
V 1 1 0 0 0 0 0 1 0 8 
W 0 0 0 0 0 0 0 0 0 0 
Y 1 0 0 0 0 0 0 0 0 0 
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HLA-C*06:02, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 0 2 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 0 0 0 0 0 0 
E 0 0 0 0 2 0 0 0 
F 2 0 2 0 0 0 1 6 
G 0 0 2 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 
I 0 0 0 0 1 1 1 10 
K 0 6 0 0 0 0 0 0 
L 0 0 0 2 1 2 2 10 
M 0 0 0 0 0 0 0 0 
N 0 0 0 0 0 0 0 0 
P 0 0 0 4 1 0 0 0 
Q 0 0 0 0 0 2 0 0 
R 0 10 0 0 0 0 0 0 
S 1 0 0 0 0 0 0 0 
T 0 0 0 0 0 0 0 0 
V 0 0 0 0 0 0 0 8 
W 1 0 0 0 0 0 0 0 
Y 3 6 0 0 0 0 0 0 
 
 
HLA-C*06:02, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 0 1 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 
E 0 0 0 1 0 0 0 1 0 
F 1 0 1 0 1 0 0 0 6 
G 0 0 0 0 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 0 0 0 1 1 1 0 8 
K 0 6 0 0 0 0 0 0 0 
L 0 0 0 0 1 1 1 1 10 
M 0 0 0 0 0 0 0 0 0 
N 0 0 0 0 0 0 0 0 0 
P 0 0 1 2 0 1 0 0 0 
Q 0 0 0 0 0 0 1 0 0 
R 0 10 0 0 0 0 1 0 0 
S 1 0 0 0 0 0 0 0 0 
T 0 0 0 0 0 0 0 0 0 
V 0 0 0 0 0 1 1 0 10 
W 0 0 0 0 0 0 0 0 0 
Y 1 6 1 0 0 0 0 0 6 
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HLA-C*06:02, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 0 0 0 0 1 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 2 0 0 0 0 0 0 
E 0 0 0 1 0 0 0 0 0 0 
F 3 0 1 0 1 0 1 0 1 10 
G 0 0 0 0 1 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 0 0 0 0 0 2 1 0 10 
K 0 6 0 0 0 0 0 0 0 0 
L 0 0 0 0 1 1 0 1 3 10 
M 0 0 0 0 0 0 0 0 0 0 
N 0 0 0 0 1 0 0 0 0 0 
P 0 0 2 1 0 0 1 0 0 0 
Q 0 0 0 0 0 0 0 2 0 0 
R 0 10 0 0 0 0 0 0 0 0 
S 0 0 1 0 0 0 0 0 0 0 
T 0 0 0 0 0 0 0 0 0 0 
V 0 0 0 0 0 1 0 0 0 8 
W 0 0 0 0 0 0 0 0 0 0 
Y 2 6 1 0 0 0 0 0 0 0 
 
 
HLA-C*07:01, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 0 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 1 0 0 0 0 0 
E 0 0 0 0 0 0 1 0 
F 0 0 0 0 0 0 0 10 
G 0 0 4 0 1 0 0 0 
H 0 0 0 0 1 0 0 0 
I 1 0 0 0 1 1 1 0 
K 1 0 0 0 0 0 0 0 
L 0 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 6 
N 0 8 0 0 0 0 0 0 
P 0 0 0 1 1 0 0 0 
Q 0 0 0 0 0 0 0 0 
R 1 10 0 0 0 0 0 0 
S 0 0 0 0 0 0 1 0 
T 0 10 0 0 0 0 0 0 
V 0 0 0 2 1 0 1 0 
W 0 0 0 0 0 0 0 0 
Y 1 0 0 0 0 0 0 8 
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HLA-C*07:01, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 0 0 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 
E 0 0 0 1 0 0 0 2 0 
F 0 0 0 0 1 0 1 0 10 
G 0 0 0 0 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 0 0 0 0 2 0 0 0 
K 4 0 0 0 0 0 0 0 0 
L 0 0 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 0 6 
N 0 6 1 0 0 0 0 0 0 
P 0 0 0 1 0 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 4 10 0 0 0 0 1 0 0 
S 1 0 0 0 0 0 0 0 0 
T 0 8 0 0 0 0 0 0 0 
V 0 0 0 0 1 1 1 2 0 
W 0 0 0 0 0 0 0 0 0 
Y 0 0 0 0 1 0 1 0 10 
 
 
HLA-C*07:01, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 0 0 0 1 0 1 1 0 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 2 0 0 0 0 1 0 
E 0 0 1 0 1 1 0 0 1 0 
F 0 0 0 0 0 0 1 2 0 10 
G 0 0 1 2 2 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 1 0 
I 1 0 0 0 0 0 3 0 0 0 
K 1 0 0 0 1 1 0 0 1 0 
L 0 0 0 0 0 0 0 0 0 10 
M 0 0 0 0 0 0 0 0 0 0 
N 1 6 0 0 0 0 0 0 0 0 
P 1 0 0 1 0 2 1 0 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 1 10 0 0 0 0 0 0 0 0 
S 1 0 0 0 0 1 1 1 0 0 
T 0 6 0 0 1 0 0 1 2 0 
V 0 0 0 0 0 0 0 0 0 0 
W 0 0 0 0 0 0 0 1 0 0 
Y 0 0 0 0 0 1 0 0 0 8 
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HLA-C*07:02, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 0 2 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 0 0 0 0 0 0 
E 0 0 0 0 1 0 2 0 
F 2 0 0 0 0 0 0 10 
G 0 0 2 0 0 0 0 0 
H 0 0 0 0 1 0 0 0 
I 0 0 0 0 0 1 0 0 
K 0 8 0 0 0 0 0 0 
L 0 0 0 0 1 2 1 10 
M 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 0 0 0 
P 0 0 2 4 0 1 0 0 
Q 0 0 0 0 0 1 1 0 
R 0 10 0 0 0 0 0 0 
S 1 0 0 0 0 0 0 0 
T 0 0 0 0 0 0 0 0 
V 0 0 0 1 1 0 1 0 
W 0 0 0 0 0 0 0 0 
Y 3 8 0 0 0 0 0 10 
 
 
HLA-C*07:02, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 0 0 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 
E 0 0 0 1 0 0 0 1 0 
F 1 0 0 0 1 0 1 0 10 
G 0 0 0 0 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 0 0 0 0 1 1 1 0 
K 0 6 0 0 0 0 0 0 0 
L 0 0 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 0 6 
N 1 0 1 0 0 0 0 0 0 
P 0 0 2 2 0 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 0 10 0 0 0 0 0 0 0 
S 1 0 0 0 0 0 0 1 0 
T 0 0 0 0 0 1 0 1 0 
V 0 0 0 0 1 2 1 1 0 
W 0 0 0 0 0 0 0 0 0 
Y 1 10 0 0 1 0 1 0 10 
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HLA-C*07:02, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 0 1 0 0 0 0 1 0 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 3 0 0 0 0 0 0 
E 0 0 0 1 0 0 0 0 1 0 
F 1 0 0 0 0 0 0 0 0 10 
G 0 0 0 0 2 1 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 0 0 0 0 0 1 0 0 0 
K 0 6 0 0 0 0 0 0 0 0 
L 0 0 0 0 0 0 0 0 0 10 
M 0 0 0 0 0 0 0 0 0 6 
N 1 0 0 0 0 0 0 0 0 0 
P 0 0 1 0 0 1 0 0 0 0 
Q 0 0 0 0 1 0 0 2 0 0 
R 0 10 0 0 0 0 0 0 0 0 
S 1 0 0 0 0 0 0 0 0 0 
T 0 0 0 0 0 1 0 0 0 0 
V 0 0 1 0 1 0 1 0 3 0 
W 0 0 0 0 0 0 0 0 0 0 
Y 2 8 2 0 0 0 0 0 0 10 
 
 
HLA-C*08:02, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 2 0 0 1 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 10 0 0 0 0 0 
E 0 0 4 1 0 0 1 0 
F 1 0 0 0 0 0 0 4 
G 0 0 0 0 0 0 0 0 
H 0 0 0 0 1 0 0 0 
I 1 0 0 0 0 0 0 6 
K 0 0 0 1 0 0 1 0 
L 1 1 0 1 0 0 0 10 
M 0 0 0 0 0 0 0 4 
N 0 0 0 0 1 0 0 0 
P 0 0 0 0 0 0 0 0 
Q 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 
S 0 1 0 0 1 1 0 0 
T 0 0 0 0 0 1 0 0 
V 1 0 0 0 0 0 0 6 
W 0 0 0 0 0 0 0 0 
Y 0 0 0 0 0 0 0 0 
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HLA-C*08:02, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 2 0 0 0 0 0 1 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 10 1 0 0 0 0 0 
E 0 0 6 1 0 0 0 1 0 
F 1 0 0 0 0 0 0 0 6 
G 0 0 0 0 0 1 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 1 0 0 0 0 0 0 0 6 
K 0 0 0 0 0 0 0 0 0 
L 1 1 0 1 0 0 0 0 10 
M 0 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 1 0 0 0 
P 0 0 0 0 1 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 
S 1 1 0 0 1 1 1 1 0 
T 0 0 0 0 0 0 0 1 0 
V 1 1 0 0 0 0 0 0 6 
W 0 0 0 0 0 0 0 0 0 
Y 0 0 0 0 0 0 0 0 0 
 
 
HLA-C*08:02, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 3 0 0 0 0 0 0 1 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 10 1 0 0 0 0 0 0 
E 0 0 4 1 0 0 0 0 1 0 
F 1 0 0 0 0 0 0 0 0 6 
G 0 0 0 1 1 1 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 1 1 0 0 0 0 0 0 0 4 
K 0 0 0 0 0 0 0 0 0 0 
L 0 0 0 0 0 0 1 0 0 10 
M 0 0 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 0 0 
P 0 0 0 1 1 0 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 0 
S 0 1 0 0 1 1 0 1 2 0 
T 0 0 0 0 0 0 0 1 1 0 
V 1 1 0 0 0 0 0 0 0 4 
W 0 0 0 0 0 0 0 0 0 0 
Y 0 0 0 0 0 0 0 0 0 0 
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HLA-C*12:03, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 10 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 1 0 0 0 0 0 
E 0 0 0 0 0 0 2 0 
F 3 0 2 0 0 0 0 8 
G 0 0 1 0 0 0 0 0 
H 0 0 0 0 1 0 0 0 
I 0 0 0 1 1 0 1 8 
K 0 0 2 0 0 1 0 0 
L 1 0 0 1 0 0 0 10 
M 0 0 0 0 0 0 0 10 
N 0 0 1 0 1 0 0 0 
P 0 0 0 1 0 0 0 0 
Q 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 1 0 0 
S 0 8 0 0 0 1 0 0 
T 0 8 0 0 0 0 0 0 
V 1 0 0 1 0 0 1 10 
W 0 0 0 0 0 0 0 0 
Y 2 0 0 0 0 0 0 8 
 
 
HLA-C*12:03, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 1 10 1 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 
E 0 0 0 1 0 0 0 1 0 
F 1 0 1 0 0 0 0 0 8 
G 0 0 0 1 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 0 0 0 0 1 1 0 8 
K 0 0 0 0 0 0 1 0 0 
L 0 0 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 0 8 
N 0 0 0 0 0 0 0 0 0 
P 0 0 0 2 0 1 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 1 0 0 
S 0 8 1 1 0 0 0 0 0 
T 0 8 0 0 0 0 0 1 0 
V 1 0 0 0 0 1 1 1 10 
W 0 0 0 0 0 0 0 0 0 
Y 1 0 1 0 0 0 0 0 10 
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HLA-C*12:03, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 1 10 0 0 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 2 0 0 0 0 0 0 
E 0 0 0 0 0 0 0 0 0 0 
F 2 0 3 0 0 0 0 0 0 10 
G 0 0 0 1 2 0 1 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 0 0 0 0 0 0 0 0 4 
K 0 0 0 0 0 0 0 0 0 0 
L 0 0 0 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 0 0 8 
N 0 0 0 0 0 0 0 0 0 0 
P 0 0 0 1 2 0 2 0 0 0 
Q 0 0 0 0 0 0 0 1 0 0 
R 0 0 0 0 0 0 0 1 0 0 
S 0 8 0 0 0 0 0 0 1 0 
T 0 6 0 0 0 1 0 0 0 0 
V 0 0 0 0 0 0 0 0 2 8 
W 0 0 0 0 0 0 0 0 0 0 
Y 1 0 1 0 0 0 0 0 0 10 
 
 
HLA-C*14:02, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 0 0 0 1 0 1 0 
C 0 0 0 0 0 0 0 0 
D 0 0 0 0 0 0 0 0 
E 0 0 0 0 0 0 1 0 
F 1 10 0 0 0 0 0 10 
G 0 0 0 0 3 0 0 0 
H 0 0 0 0 1 0 0 0 
I 0 0 0 0 0 0 0 0 
K 0 0 0 0 0 1 0 0 
L 0 0 1 0 0 0 0 10 
M 0 0 0 0 0 0 0 6 
N 0 0 0 1 0 0 0 0 
P 0 0 0 0 0 0 0 0 
Q 0 0 1 0 0 0 0 0 
R 0 0 0 0 1 1 0 0 
S 0 0 0 0 0 1 1 0 
T 0 0 0 1 0 0 0 0 
V 1 0 0 1 0 0 1 0 
W 0 0 0 0 0 0 0 0 
Y 1 10 0 0 0 0 0 8 
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HLA-C*14:02, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 1 0 0 0 0 1 0 1 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 
E 0 0 0 1 0 0 0 1 0 
F 1 10 0 0 0 0 0 0 10 
G 0 0 0 0 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 0 1 0 0 0 0 0 0 
K 0 0 0 0 1 0 0 0 0 
L 0 0 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 0 0 0 0 
P 0 0 2 1 0 0 0 0 0 
Q 0 0 1 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 
S 1 0 0 0 1 0 1 1 0 
T 0 0 0 0 0 0 0 0 0 
V 1 0 0 0 0 1 0 0 0 
W 0 0 0 0 0 0 0 0 0 
Y 1 10 0 0 0 0 0 0 8 
 
 
HLA-C*14:02, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 1 0 0 0 0 0 0 0 1 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 2 0 0 0 0 0 0 
E 0 0 0 1 0 0 0 0 1 0 
F 1 10 1 0 0 0 0 0 0 10 
G 0 0 0 1 1 0 1 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 0 1 0 0 0 1 0 0 0 
K 0 0 0 0 0 0 0 0 0 0 
L 0 0 0 0 0 0 0 0 0 10 
M 0 0 0 0 0 0 0 0 0 6 
N 0 0 0 0 0 0 0 0 0 0 
P 0 0 2 0 0 1 1 0 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 0 
S 1 0 0 0 0 0 0 1 2 0 
T 0 0 0 0 0 0 1 1 1 0 
V 0 0 0 0 0 0 1 0 0 0 
W 0 0 0 0 0 0 0 0 0 0 
Y 1 10 1 0 0 0 0 0 0 8 
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HLA-C*15:02, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 10 1 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 0 0 0 0 0 0 
E 0 0 0 0 0 0 1 0 
F 1 0 0 0 0 0 0 0 
G 0 0 4 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 
I 1 8 0 0 1 2 0 8 
K 1 0 0 2 0 0 1 0 
L 0 0 0 0 0 6 1 10 
M 0 0 0 0 0 0 0 4 
N 0 8 0 0 0 0 0 0 
P 0 0 0 1 3 0 0 0 
Q 0 0 0 0 0 0 0 0 
R 1 0 0 1 0 0 0 0 
S 0 10 2 0 0 0 0 0 
T 0 10 0 0 0 0 0 0 
V 1 8 0 0 0 2 0 10 
W 0 0 0 0 0 0 0 0 
Y 1 0 0 0 0 0 0 0 
 
 
HLA-C*15:02, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 1 8 0 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 
E 0 0 0 1 0 0 0 1 0 
F 1 0 0 0 0 1 0 0 0 
G 0 0 0 1 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 8 1 0 0 1 0 0 6 
K 1 0 0 0 1 0 0 0 0 
L 0 0 0 0 0 1 4 1 10 
M 0 0 0 0 0 0 0 0 4 
N 0 8 1 0 0 0 0 0 0 
P 0 0 0 1 0 1 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 1 0 0 0 0 0 0 0 0 
S 0 10 0 1 0 0 0 0 0 
T 0 10 0 0 0 0 0 0 0 
V 0 8 0 0 1 1 0 0 10 
W 0 0 0 0 0 0 0 0 0 
Y 0 0 0 0 0 0 0 0 0 
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HLA-C*15:02, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 8 1 0 0 1 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 0 
E 0 0 0 1 0 0 0 0 0 0 
F 0 0 0 0 1 0 0 0 1 0 
G 0 0 0 0 1 1 1 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 8 2 0 1 0 1 0 1 6 
K 4 0 0 0 0 0 0 0 0 0 
L 0 0 0 1 0 1 1 3 1 10 
M 0 0 0 0 0 0 0 0 0 4 
N 0 8 0 0 0 0 0 0 0 0 
P 0 0 0 0 0 1 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 4 0 0 0 0 0 0 0 0 0 
S 0 10 0 0 0 0 0 0 0 0 
T 0 10 0 0 0 0 0 0 0 0 
V 0 8 0 0 0 0 0 0 1 10 
W 0 0 0 0 0 0 0 0 0 0 
Y 0 0 0 0 0 0 0 0 0 0 
 
 
HLA-C*16:01, 8mers 
 
1 2 3 4 5 6 7 8 
A 1 10 2 0 0 0 1 0 
C 0 0 0 0 0 0 0 0 
D 0 0 0 0 0 0 0 0 
E 0 0 0 1 0 0 2 0 
F 2 0 0 0 0 0 0 8 
G 0 0 1 0 1 0 0 0 
H 0 0 0 0 1 0 0 0 
I 0 0 0 0 0 0 0 0 
K 0 0 0 0 1 0 0 0 
L 0 0 0 1 0 1 0 10 
M 0 0 0 0 0 0 0 8 
N 0 0 0 0 0 0 0 0 
P 0 0 0 0 0 1 0 0 
Q 0 0 0 0 0 0 0 0 
R 0 0 0 0 3 2 0 0 
S 0 10 2 0 0 0 0 0 
T 0 8 1 0 0 0 0 0 
V 1 0 0 1 0 0 1 6 
W 0 0 0 0 0 0 0 0 
Y 1 0 0 0 0 0 0 10 
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HLA-C*16:01, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 1 10 1 0 0 0 0 1 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 0 1 0 0 0 0 0 
E 0 0 0 1 0 0 0 1 0 
F 1 0 0 0 0 0 0 0 10 
G 0 0 0 0 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 0 0 0 0 0 0 0 0 
K 0 0 0 0 1 0 1 0 0 
L 0 0 0 0 0 0 1 0 10 
M 0 0 0 0 0 0 0 0 8 
N 0 0 0 0 0 0 0 0 0 
P 0 0 0 1 0 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 2 1 2 0 0 
S 0 10 2 0 0 0 0 1 0 
T 0 8 1 0 0 0 0 1 0 
V 1 0 0 0 0 0 0 1 8 
W 0 0 0 0 0 0 0 0 0 
Y 1 0 0 0 0 0 0 0 10 
 
 
HLA-C*16:01, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 10 1 0 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 2 0 0 0 0 0 0 
E 0 0 0 1 0 0 0 0 0 0 
F 2 0 0 0 0 0 0 0 0 10 
G 0 0 0 0 1 0 1 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 0 0 0 0 0 0 0 0 0 
K 0 0 0 0 0 0 0 0 0 0 
L 0 0 0 0 0 0 1 0 0 10 
M 0 0 0 0 0 0 0 0 0 8 
N 0 0 0 0 0 0 0 0 0 0 
P 0 0 0 0 2 0 1 0 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 1 3 0 0 
S 0 8 1 0 0 0 0 0 0 0 
T 0 8 1 0 1 0 0 0 1 0 
V 1 0 0 0 0 0 0 0 1 6 
W 0 0 0 0 0 0 0 0 0 0 
Y 2 0 0 0 0 0 0 0 0 10 
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HLA-C*17:01, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 10 2 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 1 0 0 0 0 0 
E 0 0 0 0 1 0 0 0 
F 3 0 0 0 0 0 1 6 
G 0 0 1 0 0 0 0 0 
H 0 0 0 0 1 0 0 0 
I 0 8 0 0 0 2 0 4 
K 0 0 0 1 0 0 0 0 
L 0 8 0 0 0 2 2 10 
M 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 
P 0 0 0 1 2 0 0 0 
Q 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 
S 0 8 1 0 0 0 0 0 
T 0 0 0 0 0 0 0 0 
V 0 8 0 0 0 2 0 0 
W 0 0 0 0 0 0 0 0 
Y 1 0 0 0 0 0 1 0 
 
 
HLA-C*17:01, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 10 1 0 0 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 1 0 0 0 0 0 0 
E 0 0 0 0 0 0 0 0 0 
F 3 0 0 0 0 0 0 1 6 
G 0 0 0 1 1 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 6 1 0 0 1 1 0 4 
K 0 0 0 0 0 0 0 0 0 
L 0 8 0 0 0 1 1 1 10 
M 0 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 0 
P 0 0 0 1 0 1 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 0 
S 1 8 0 1 0 0 0 0 0 
T 0 0 0 0 0 0 1 0 0 
V 0 8 1 0 0 1 1 0 0 
W 0 0 0 0 0 0 0 0 0 
Y 1 0 1 0 0 0 0 1 0 
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HLA-C*17:01, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 1 10 0 0 0 1 0 0 0 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 0 0 0 0 0 0 0 
E 0 0 0 0 1 0 0 0 0 0 
F 1 0 0 0 0 0 0 0 0 10 
G 0 0 0 1 1 1 1 1 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 6 0 1 0 0 0 0 1 4 
K 0 0 0 0 0 0 1 0 0 0 
L 0 10 1 0 1 1 1 1 1 10 
M 0 0 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 0 0 
P 0 0 0 1 1 1 0 1 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 0 0 0 0 0 0 0 0 1 0 
S 0 10 0 0 0 0 1 0 0 0 
T 0 0 0 0 1 0 0 0 0 0 
V 1 10 0 0 0 0 1 0 0 0 
W 0 0 0 0 0 0 0 0 0 0 
Y 1 0 0 0 0 0 0 0 0 0 
 
 
HLA-G*01:01, 8mers 
 
1 2 3 4 5 6 7 8 
A 0 0 6 0 1 0 0 0 
C 0 0 0 0 0 0 0 0 
D 0 0 0 0 0 0 0 0 
E 0 0 0 1 0 0 0 0 
F 0 0 0 0 0 0 0 4 
G 0 0 0 0 1 0 0 0 
H 0 0 0 0 0 0 0 0 
I 0 3 6 0 0 4 0 4 
K 4 0 0 1 0 0 0 0 
L 0 3 6 0 0 4 2 10 
M 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 
P 0 0 10 1 3 0 0 0 
Q 0 0 0 0 0 0 0 0 
R 4 0 0 0 0 0 0 0 
S 0 0 0 0 0 0 0 0 
T 0 0 0 0 0 0 0 0 
V 0 0 6 0 0 4 0 0 
W 0 0 0 0 0 0 0 0 
Y 0 0 0 0 0 0 0 0 
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HLA-G*01:01, 9mers 
 
1 2 3 4 5 6 7 8 9 
A 0 0 6 0 0 1 0 0 0 
C 0 0 0 0 0 0 0 0 0 
D 0 0 0 0 0 0 0 0 0 
E 0 0 0 0 0 0 0 1 0 
F 0 0 0 0 0 0 0 0 4 
G 0 0 0 0 0 0 0 0 0 
H 0 0 0 0 0 0 0 0 0 
I 0 2 10 0 0 0 4 0 4 
K 4 0 0 1 0 1 0 0 0 
L 0 2 6 0 0 0 4 1 10 
M 0 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 0 
P 0 0 10 1 0 0 0 0 0 
Q 0 0 0 0 0 0 0 0 0 
R 4 0 0 0 0 0 0 0 0 
S 0 0 0 0 0 0 0 0 0 
T 0 0 0 0 0 0 0 0 0 
V 0 1 8 0 0 0 4 1 0 
W 0 0 0 0 0 0 0 0 0 
Y 0 0 0 0 0 0 0 0 0 
 
HLA-G*01:01, 10mers 
 
1 2 3 4 5 6 7 8 9 10 
A 0 0 6 0 0 0 1 0 0 0 
C 0 0 0 0 0 0 0 0 0 0 
D 0 0 0 0 0 0 0 0 0 0 
E 0 0 0 0 0 0 0 0 0 0 
F 0 2 0 0 0 0 0 0 0 4 
G 0 0 0 1 0 1 1 0 0 0 
H 0 0 0 0 0 0 0 0 0 0 
I 0 1 6 0 0 0 0 4 0 4 
K 4 0 0 1 0 0 0 0 0 0 
L 0 2 6 0 1 0 0 4 1 10 
M 0 0 0 0 0 0 0 0 0 4 
N 0 0 0 0 0 0 0 0 0 0 
P 0 0 10 1 1 1 2 1 0 0 
Q 0 0 0 0 0 0 0 0 0 0 
R 4 0 0 0 0 0 0 0 0 0 
S 0 0 0 1 0 0 0 0 0 0 
T 0 0 0 0 0 0 0 0 0 0 
V 0 0 8 0 0 0 0 4 1 0 
W 0 0 0 0 0 0 0 0 0 0 
Y 0 0 0 0 0 0 0 0 0 0 
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